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Summary
The research reported in this thesis focused on the potential o f neural progenitor cells to provide a 
suitable source o f neurones which can be used in cell replacement strategies for Parkinson’s disease. 
Specifically, the parameters affecting the differentiation o f  these cells into neuronal phenotypes were 
addressed and increasing the survival o f transplanted dopamine neurones was attempted. In addition, 
the in vitro capacity o f  adult neural progenitor cells to generate neurones was assessed and a mouse 
model o f Parkinson’s disease was established.
In Chapter Three an extensive study investigating the effects o f  donor age and periods o f in vitro 
proliferation on the neurogenic capacity o f foetal rat neural progenitor cells revealed that these two 
parameters had significant effects on neuronal differentiation. While ventral mesencephalic (VM) cells 
isolated at embryonic day 12 generated the most neurones, increased periods of in vitro cell expansion 
had detrimental effects on neuronal yield. Dopamine differentiation was also severely effected by in 
vitro proliferation with VM cells failing to generate any dopamine neurones even after short-term 
expansion.
In Chapter Four, in an attempt to increase the survival rate o f transplanted dopamine neurones, 
dopamine neurones were transplanted into the striatum of rat models of Parkinson’s disease in a 
solution containing the antioxidant, ascorbic acid. Dopamine neurones transplanted with ascorbic acid 
formed grafts containing more dopamine neurones compared to standard dopamine grafts, indicating a 
specific survival effect o f ascorbic acid.
The ability o f adult neural progenitor cells to generate neurones has generated great excitement over 
the past years, however, while these cells have shown the capacity to generate neurones, the ability o f  
these cells to differentiate into neurones o f dopaminergic phenotypes has not been demonstrated. This 
issue was addressed in Chapter Five, where both expanded and non-expanded adult progenitors were 
assessed for the expression o f the non-specific dopamine marker tyrosine hydroxylase (TH). Neither 
expanded nor non-expanded cells that differentiated into neurones were immunopositive for TH, thus 
indicating an inability o f these cells to spontaneously differentiate into dopamine neurones.
To efficiently assess the functional capacity o f mouse-derived embryonic stem cells, a mouse model o f  
Parkinson’s disease was established in Chapter Six. Rotational behaviour induced following 
amphetamine and apomorphine challenge in mice with either unilateral 6-OHDA lesions o f the medial 
forebrain bundle (MFB) or the striatum were compared. While both models showed rotational bias, 
MFB lesions were variable and unreliable, whereas more consistent dopamine loss was observed 
following striatal lesions. The striatal lesion therefore provided the better lesion in mice, and optimal 
rotational bias was elicited following lOmg/kg amphetamine challenge.
To confirm rotational behaviour in this mouse model reflected dopamine loss, in Chapter Seven, mice 
received intrastriatal transplants o f dopamine neurones. 4-6 weeks post-transplantation, significant 
attenuation o f amphetamine-induced rotational bias was observed. This behavioural recovery not only 
confirmed that rotations reflect dopamine loss, but also demonstrated the suitability o f  this model for 
measuring the functional capacity o f mouse-derived cell lines.
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Chapter One
Introduction
This thesis discusses the potential use of neural progenitor cells as an alternative to 
foetal tissue in neuronal replacement therapies for Parkinson’s disease. The research 
concentrates on generating sufficient numbers of dopamine neurones from progenitor 
cells by investigating the effect of donor age and prolonged proliferation on cells 
isolated from the developing rat ventral mesencephalon (VM). In addition, increasing 
the survival of dopamine neurones by the addition of the antioxidant ascorbic acid 
(Vitamin C) to the culture environment of primary VM neurones has been assessed, 
and a discussion on the use of adult neural stem cells as a potential donor source of 
cells for transplantation is also included. A 6-OHDA-lesion model of Parkinson’s 
disease has been established in mice, which displays appropriate rotational behaviour 
reflecting unilateral dopamine depletion, and the attenuation of rotational bias 
following reinnervation of the striatum by intrastriatal transplantation of dopamine 
neurones. This model allows the assessment of the in vivo potential o f mouse-derived 
embryonic stem (ES) cells, and other mouse cell lines without the complications 
associated with immunosuppression.
The following chapter describes the basic anatomy and function of the basal ganglia, 
the degeneration o f this structure with respect to Parkinson’s disease, current 
pharmacological and surgical treatments for this neurodegenerative disorder, and a 
detailed discussion on stem cells and their potential in providing a source of neurones 
for neurotransplantation.
1.1 The Basal Ganglia
The basal ganglia are a structure consisting o f a number o f subcortical nuclei that 
have numerous interconnections and pathways. The connectional anatomy of the 
nuclei is highly complex, with pathways having excitatory or inhibitory functions and 
utilising a variety of neurotransmitters. The following description of the basal ganglia
1
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outlines the main nuclei and the major pathways that collectively play an important 
role in the regulation o f motor and cognitive control.
1.1.1 Anatomy o f the basal ganglia
The striatum, globus pallidus, subthalamic nucleus and the substantia nigra are the 
main nuclei that form the basal ganglia (Fig. 1.1). The striatum is comprised o f two 
regions, namely the dorsal zone (neostriatum) and ventral zone (ventral striatum). The 
neostriatum is composed of the putamen and caudate nuclei while the ventral striatum 
is composed of the nucleus accumbens and the olfactory tubercle. The globus 
pallidus, also known as the pallidum, consists of external and internal segments (GPe 
& GPi respectively), with the GPe positioned adjacent to the putamen, and the GPi 
situated medial to the GPe. The combination o f the putamen and the globus pallidus is
referred to as the lenticular or lentiform nucleus. Like the pallidum, the substantia
.nigra is also divided into two parts, namely the pars reticulata (SNr) and pars 
compacta (SNc) (Fig. 1.1). The basal ganglia link the cortex to the thalamus and its 
main inputs are from excitatory glutamatergic cortical neurones that project to the 
striatum. Striatal efferents contain different neurotransmitters and project to various 
nuclei, but ultimately terminate at the basal ganglia output nuclei (the SNr and GPi). 
The output nuclei then send inhibitory GABAergic projections to the thalamus, which 
in turn projects back to the cortex (Fig. 1.2).
A Basal
Ganglia
Striatum + Globus
Pallidus
+ Substantia
Nigra
+ Subthalamic
Nucleus
B Striatum
Neostriatum
(Caudate/Putamen)
Ventral Striatum
(Nucleus accumbens/OIfactorv tubercle)
Globus Globus Pallidus
Pallidus — Internal +
segment (GPi)
Globus Pallidus 
External 
segment (GPe)
D
Substantia Substantia
Nigra — Nigra Pars +
Reticulata (SNr)
Substantia 
Nigra Pars 
Compacta (SNc)
Putamen + Globus Pallidus = Lentiform/Lenticular Nucleus
Figure 1.1 Diagram 
showing the main 
nuclei of the basal 
ganglia (A). The 
subdivisions of the 
Striatum (B),
Globus Pallidus (C) 
and the Substantia 
Nigra (D) are also 
shown.
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The basal ganglia connections are organised into a series of functional circuits, with 
each circuit segregating and relaying specific cortical information to distinct target 
zones in the thalamus and in turn to defined areas of the cortex (Alexander & 
Crutcher., 1990). The motor circuit receives input from the sensorimotor cortex and 
projects to the putamen and then to the output nuclei. The output nuclei then send 
their efferents to the ventroanterior and ventrolateral nuclei of the thalamus before 
projecting back to the premotor and supplementary motor cortex. The cognitive 
circuit receives its input from the association cortex and passes through the caudate 
nucleus, basal ganglia output nuclei, ventroanterior and ventrolateral nuclei of the 
thalamus and then projects back to the preffontal cortex (Behan & Barker., 2001).
As well as these circuits, the circuitry of the basal ganglia is made even more 
complicated by an internal loop that projects from the striatum to the substantia nigra 
pars compacta and then back to the striatum, and by two different pathways that 
project from the striatum to the SNr and GPi, which function to modulate the 
inhibitory outflow of the output nuclei. One pathway is the inhibitory ‘direct’ pathway 
where striatal neurones containing GABA and substance P project directly to the SNr 
and GPi. The other pathway is the ‘indirect’ pathway where striatal neurones 
containing GABA and enkephalin project to the GPe, then to the subthalamic nucleus 
via a GABAergic pathway, and finally to the SNr and GPi via excitatory 
glutamatergic neurones (Fig. 1.2). Activation of the direct pathway causes 
disinhibition of the thalamus and results in excessive excitation of the cortex. 
Alternatively, activation of the indirect pathway causes disinhibition of the 
subthalamic nucleus, which results in excitation of the output nuclei, inhibition of the 
thalamus and overall inhibition of the cortex (Alexander & Crutcher., 1990; Alb in et 
a l., 1989). The two pathways therefore have opposing effects and a fine balance exists 
between them. This balance is regulated by the dopaminergic nigrostriatal projection 
neurones, which function by having an inhibitory effect on the striatopallidal pathway 
and a excitatory influence over the striatonigral neurones (Gerfen., 1992). Evidence 
for this opposing dopaminergic regulation has come from studies assessing dopamine- 
related glucose utilisation of the globus pallidus and substantia nigra via 2- 
deoxyglucose autoradiography (Engber et al., 1990), as well as from studies 
examining the electrophysiological activity of the globus pallidus (Bergstrom et al.,
1982) and substantia nigra (Waszczak et al., 1984). In addition, dopamine has been 
shown to regulate the expression o f enkephalin in the striatopallidal neurones and
3
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substance P & dynorphin in the striatonigral neurones, as demonstrated following 
neurotoxin-induced dopamine denervation o f  the striatum. In such studies, increased 
enkephalin mRNA expression in the striatopallidal neurones and decreased expression 
of substance P and dynorphin mRNA in striatonigral neurones are observed following 
neurotoxin-induced destruction o f the nigrostriatal pathway (Gerfen et a l., 1990; 
1991; Gerfen., 1992; Normand et al., 1988, Graybiel., 1990; Voom et al., 1987, 
Young III et al., 1986).
Cerebral Cortex
Brainstem and 
Spinal Cord
Striatum
(GABA Enk) (GABA SP)Indirect
Pathway'
Direct 
Pathway*
(G A B A )
(GABA)
Gni/SNr
Thalamus
Figure 1.2 Schematic diagram o f the circuitry and the neurotransmitters o f the basal 
ganglia-thalamocortical circuitry, showing the ‘indirect’ and ‘direct pathways’ from 
the striatum to the output nuclei. Inhibitory neurones are shown in black and 
excitatory neurones in grey. Abbreviations: DA, dopamine; Enk, enkephalin; GABA, 
y-aminobutyric acid; GPe, external segment of the globus pallidus; GPi, internal 
segment o f the globus pallidus; Glu, glutamate; PPN, pedunculopontine nucleus; SNc, 
substantia nigra pars compacta; SNr, substantia nigra pars reticulata; SP, substance P; 
STN, subthalamic nucleus. (Adapted from Alexander & Crutcher., 1990).
4
Chapter One
1.1.2 Patch/matrix organisation o f the striatum
The striatum is a highly organised structure that processes information at a number o f 
different levels (Gerfen., 1992). One of the levels of organisation is the patch/matrix 
compartmentalisation of the striatum, which was revealed following histochemical 
staining for the enzyme acetylcholinesterase (AChE) (Graybiel & Ragsdale., 1978). 
The patch compartments or striosomes, which were first defined as areas 
corresponding to AChE-poor regions in cats and monkeys, are embedded in the 
AChE-rich matrix. The patch compartments also correspond to opiate receptor 
binding-sites and exhibit high levels of immunoreactivity for enkephalin and 
substance P (Graybiel., 1990), whereas the matrix compartment can be distinguished 
by somatostatin immunoreactivity and neurones expressing the calcium-binding 
protein, Calbindin (Gerfen eta l., 1985; 1987b).
The patch and matrix compartments both have distinct input-output connections. The 
striatal afferents are organised into patch/matrix compartments and come from 3 main 
areas; the thalamic intralaminar complex, the cortex and the midbrain. The patch 
compartment has been shown to receive innervation from thalamic fibres arising from 
the centromedian nucleus (Kalil., 1978; Royce., 1978), cortical efferents from the 
deep layer V and layer VI o f the cortex (Gerfen., 1989; 1992) and dopamine 
projections from the ventral substantia nigra pars compacta and substantia nigra pars 
reticulata (Gerfen et al., 1987a; 1987b; Gerfen., 1989). The matrix compartment 
however, receives innervation from thalamic parafasicular nucleus (Gerfen., 1984; 
1985), cortical innervation from superficial layer V and supragranular layers of the 
cortex (Gerfen., 1989; 1992) and midbrain dopaminergic efferents from the ventral 
tegmental area (VTA, A10 cell group), the retrorubral area (A8) and the dorsal 
substantia nigra pars compacta (A9) (Gerfen., 1989). The outputs of the patch and 
matrix compartments are via medium spiny neurones, which predominately innervate 
the ventral dopamine neurones of the substantia nigra pars compacta and the entire 
substantia nigra pars reticulata respectively (Gerfen., 1984; 1985).
1.2 Diseases o f  the basal ganglia
Normal function of the basal ganglia is dependent on the balance between the direct 
and indirect pathways that regulate the inhibitory outflow of the output nuclei. 
Imbalance between these two pathways has been suggested to lead to a variety of 
motor disorders including Parkinson’s and Huntington’s disease (Albin et al., 1989;
5
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Delong., 1990). In Parkinson’s disease, the degeneration of the nigrostriatal dopamine 
neurones o f the pars compacta results in increased inhibitory outflow of striatal 
neurones to the GPe, which causes disinhibition of the subthalamic nucleus and 
therefore increased activity of the output nuclei. This increased activity ultimately 
results in inhibition of the thalamus and the cortex resulting in the hypokinesia 
(reduced levels of movement) of Parkinson’s disease (Jenkins et al., 1992; Hutchison 
et al., 1998) (see Fig. 1.2). In Huntington’s disease there is degeneration o f the striatal 
neurones that project to the GPe, causing reduced activity of the output nuclei. This in 
turn, causes disinhibition of the thalamus and excessive excitation o f the cortex 
resulting in hyperkinesia (excessive movement) (Albin eta l., 1989)
1.2.1 Parkinson's disease
Initially described by James Parkinson in 1817 in his Essay on the shaking palsy, 
Parkinson’s disease (PD) is a progressive, neurodegenerative disorder, which is 
second in prevalence only to Alzheimer’s disease. The incidence of PD increases with 
age, with approximately 2% of the population over the age of 65 being affected, rising 
to over 4% at the age of 85 and above (see reviews by Arenas., 2002, Kolchinsky., 
2001). PD is however, not essentially a disease of the aged, with onset in 3-10% of 
PD patients occurring before the age o f 40 (Tsai et al., 2002).
Parkinson’s disease is primarily characterised by the loss of dopaminergic 
nigrostriatal projection neurones (particularly the ventrolateral portion o f the A9 cell 
group), leading to a large reduction in dopaminergic innervation o f the striatum, as 
can be visualised by the loss of [18F]dopa uptake in the striatum by using positron 
emission tomography (PET) (Sawle et al., 1993). Specifically, the depletion of 
dopamine results in decreased innervation of the putamen, which is principally the 
“motor” division of the striatum, whereas the dopaminergic innervation of the caudate 
nucleus, which is more associated with cognitive function, is less affected (Agid.,
1991). In addition to the loss of dopamine, another pathological characteristic of PD is 
the presence o f intracellular inclusions termed Lewy bodies in the remaining neurones 
(although these are not specific to Parkinson’s disease) (Spillantini et al., 1997; Duda 
et al., 2000; Higuchi et al., 2004).
The disease symptoms only appear when 80% of striatal dopamine or 50% of the 
nigral cells are lost (Au et al., 2005) and predominantly result in a catalogue of 
movement impairments including bradykinesia (slowness o f movement), rigidity (due
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to increased muscle tone) tremor (characteristically involving the hands in a “pill- 
rolling” movement) and postural abnormalities (Caine et al., 1992; Samii et al., 
2004). Symptoms are however, not only associated with motor function and a number 
of non-motor symptoms are also seen. These include autonomic dysfunction, sensory 
symptoms, sleep disturbances and cognitive and psychiatric changes (Samii et al., 
2004). Cognitive dysfunction in PD is common, in particular dementia, which affects 
about 40% of patients (Emre., 2003), and depression, which affects nearly half of 
patients suffering from the disease (Cummings., 1992; Yamamoto., 2001; Allain et 
al., 2005). Along with the primary loss of dopamine neurones, depletion of 
noradrenergic neurones o f the locus coeruleits (German et al., 1992; Chan-Palay & 
Asan., 1989), cholinergic neurones of the nucleus basalis of Meynert (Candy et al.,
1983) and serotonergic neurones of the raphe (Halliday et al., 1990) are also evident 
in PD. The loss of these non-dopaminergic neuronal cells have been suggested to 
contribute to the non-motor symptoms of the disease, with noradrenergic loss being 
involved in the onset of both depression (Chan-Palay & Asan., 1989) and dementia 
(Zweig et al., 1993). PD depression is also closely associated to serotonin depletion, 
with a correlation between depression and reduced cerebrospinal fluid levels of the 
serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA) (Mayeux eta l., 1988).
The aetiology o f PD remains unknown, although, various environmental factors have 
been suggested in the development of the disease (Fuente-Femandz & Caine., 2002; 
Tsai et al., 2002), with rural living, well water drinking, farming, pesticide exposure 
(Priyadarshi et al., 2001) and viral infection (Pradhan et al., 1999) implicated as 
possible risk factors. In addition, genetic predisposition may also play a role in the 
development of PD (Pankratz & Foroud., 2004; Huang et al., 2004; Gasser., 2001; 
Cordato & Chan., 2004; Le & Appel., 2004), with a variety of genetic mutations 
having been discovered (summarised in table 1.1). The first ‘PD-gene’ to be identified 
was a gene for the protein a-synuclein, which is normally expressed throughout the 
brain (Golbe et al., 1990). Interestingly, the presence of abnormal aggregates of this 
protein is the main constituent of Lewy bodies.
There are currently many treatments available for the management of Parkinson’s 
disease^, with the majority concentrating on providing symptomatic relief through
f  A comprehensive review on the treatments available for the management o f Parkinson’s disease can be found in Movement Disorders Volume 17. 
supplement 4, 2000.
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drug therapy. Although a number of drugs with different modes of action are available 
(see review by Hely et a l., 2000), pharmacological treatments that increase CNS 
dopamine levels are the most effective in treating disease symptoms. Some dopamine- 
enhancing drugs, like Tolcapone (Tasmar®) and Entacapone (Comtan®), aim to inhibit 
dopamine breakdown and therefore increase the availability of endogenous dopamine. 
Other drugs act as dopamine agonists, thus directly stimulate dopamine receptors e.g. 
Bromocriptine (Parlodel®) and Pergolide (Permax®). The most effective and widely 
used drug in the treatment of PD is however, the dopamine precursor Levo-3,4- 
dihydroxyphenylalanine (L-dopa). Once administered, L-dopa crosses the blood-brain 
barrier and is converted to dopamine by dopa-decarboxylase thus increasing brain 
dopamine levels. However, while L-dopa and dopamine agonists are effective at 
alleviating symptoms of PD in early stages of the disease, the efficacy of dopamine 
drug therapy becomes limited by both disease progression and by the development of 
drug-associated dyskinesia (involuntary movements) (Obeso et al., 2000, Nutt.,
2001).
As a result of these limitations, alternative strategies for the treatment of PD are 
necessary and these alternatives may include a number of surgical procedures. 
Ablative techniques such as thalamotomy, pallidotomy and subthalamotomy (Obeso 
et al., 1997) as well as deep brain stimulation of these nuclei (Walter & Vitek., 2004) 
have been used with varying degrees of success. However, these strategies do not 
repair nor cure the underlying disease process, in contrast to neural transplantation 
strategies (see section 1.4) that aim to reconnect the degenerated circuitry caused by 
the disease.
Table 1.1 Genetics of Parkinson’s disease
Locus Gene 
(if known)
Chromosomal
Region
References
PARK 1 a-synuclein 4q21-23 Polymeropoulos et al., 1997; Zarranz et al., 2004
PARK 2 Parkin 6q25.2-27 K itadae/a/., 1998
PARK 3 ? 2pl3 Gasser eta l., 1998
PARK 4 ? 4pl4-16.3 Waters & Miller., 1994
PARK 5 UCH-L1 4pl4 Leroy eta l., 1998
PARK 6 ? lp35-36 Valente et al., 2001; 2002
PARK 7 DJ-1 lp36 van Duijn et al., 2001; Bonifati et al., 2003a; 2003b
PARK 8 ? 12pll.2-13.1 Funayama et al., 2002
PARK 9 ? lp36 Hampshire et al., 2005
PARK 10 ? lp32 Hicks et al., 2002
NURR 1 NR4A2 2q22-23 Le et al., 2002
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1,3 Animal models o f Parkinson’s disease
Replicating Parkinson’s disease in animal models can be achieved either by using 
neurotoxic compounds which destroy nigrostriatal dopamine neurones, or by using 
genetic engineering to remove/alter or add/overexpress certain genes that are known 
to be involved in the pathogenesis o f PD.
In this thesis, all animal models of Parkinson’s disease were established by the 
destruction of the nigrostriatal dopamine pathway using the neurotoxin 6- 
hydroxydopamine (6-OHDA). The lesions were unilateral, and depending on the site 
o f neurotoxin injection, lesions of the nigrostriatal pathway were either near total 
(medial forebrain bundle lesions, MFB) or partial (striatal lesions), resulting in 
depletion of dopamine in the target structure, the striatum. Since unilateral dopamine 
depletion of the striatum results in pronounced drug-induced rotational behaviour, the 
rotation model was used to quantify dopamine loss and to assess functional recovery 
following transplantation.
1.3.1 Neurotoxin models o f Parkinson’s disease
Although a number of neurotoxins such as Rotenone and Reserpine have been used to 
deplete the nigrostriatal dopamine pathway (see reviews by Betarbet et al., 2000;
2002), the two main toxins that are used in animal models of Parkinson’s disease are 
the neurotoxins 6-OHDA or l-methyl-4phenyl-l,2,3,6-tetrahydropyridine (MPTP).
1.3.1.1 6-Hydroxydopamine (6-OHDA)
The neurotoxic effect of 6-OHDA was described by the Swedish scientist Urban 
Ungerstedt who showed the depletion of dopamine cell bodies in the substantia nigra 
and dopamine terminals in the striatum following stereotaxic injections of this 
compound into the substantia nigra of rats (Ungerstedt., 1968). The mechanism of 6- 
OHDA-induced neuronal death is associated with the generation o f free radicals and 
subsequent oxidative stress. 6-OHDA is taken up by dopamine terminals and oxidised 
to produce hydrogen peroxide, thus damaging the neurones from within (Heikkila & 
Cohen., 1971; 1973; Cohen & Heikkila., 1974). Although hydrogen peroxide itself is 
not very toxic, in the presence of iron it can form the harmful hydroxyl radical via the 
Fenton reaction (Sachs & Jonsson., 1975; Olanow., 1993; Dunnett & Bjorklund.,
1999). In addition, 6-OHDA has also shown to reduce endogenous antioxidants
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(Perumal et al., 1992) and increase the production of superoxide free radicals by 
inhibiting mitochondrial complex I (Cleeter et al., 1992). Stereotaxic injection o f 6- 
OHDA into the area of interest is necessary to induce dopaminergic cell death since 6- 
OHDA is unable to cross the blood-brain barrier and therefore cannot be given 
systematically in adult animals.
1.3.1.2 l-methyl-4-phenyl-l, 2, 3, 6-tetrahydropyridine (MPTP)
The selective targeting and destruction o f midbrain dopamine neurones following 
MPTP administration was discovered inadvertently following its Parkinsonism- 
inducing effects in humans (Langston et al., 1983; Ballard et al., 1985). This toxin has 
since provided an alternative to the use o f 6-OHDA, and unlike 6-OHDA can be 
administered systematically. The toxicity of this compound is mediated by its 
conversion from MPTP into the toxic by-product l-methyl-4-phenylpyridinium 
(MPP ) by monoamine oxidase B. MPP+ is then taken up by the dopamine 
transporters and accumulates in dopamine neurones where it inhibits mitochondrial 
complex I, resulting in the generation o f reactive oxygen species (Shimohama et al., 
2003). Oxidative stress then ensues as evidenced by increased lipid peroxidation (Rios 
& Tapia., 1987) and decreased antioxidant levels (Sriram e ta l., 1997). The effects of 
MPTP however vary across and within species, with rats being resistant to this 
neurotoxin (Giovanni et al., 1994, Betarbet et al., 2002; Shimohama et al., 2003). 
MPTP is therefore not used in our present studies.
1.3.1.3 Behavioural effects o f neurotoxin-induced degeneration o f the nigro-striatal 
dopamine pathway
As a result of unilateral 6-OHDA lesion-induced dopamine depletion of the 
nigrostriatal pathway, marked motor disturbances in animals are observed, thus 
highlighting the importance of dopamine on motor function (Ungerstedt., 1968). This 
abnormal motor behaviour is characterised by spontaneous circling behaviour or 
rotations, which are ipsilateral to the lesion (Ungerstedt., 1968; Ungerstedt & 
Arbuthnott., 1970). Rotational behaviour has been shown to increase in response to 
stimulatory drugs such as the dopamine releasing drug amphetamine (Ungerstedt., 
1971a) and to the dopamine receptor agonist apomorphine (Ungerstedt., 1971b). 
However, when using apomorphine the direction of rotation is contralateral to the
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lesion, indicating supersensitivity of dopamine receptors in the denervated striatum 
(Ungerstedt., 1971b). Since the degree o f rotation correlates well to dopamine loss 
(Lee et al., 1996), measurement of rotational behaviour gives a good indication of the 
extent of dopaminergic innervation of the striatum. In addition to the rotation model, 
unilateral 6-OHDA lesioned rats show contralateral limb akinesia and are unable to 
initiate stepping movements with the contralateral paw. This initiation deficit can be 
assessed using the ‘stepping test’ (Schallert et al., 1992), which shows the ipsilateral 
paw of 6-OHDA lesioned rats frequently making adjusting steps as it is moved slowly 
sideways across a table. This is in contrast to the contralateral paw, which passively 
drags as the rat is moved (Schallert eta l., 1992; Olsson eta l., 1995). The contralateral 
paw is also impaired in reaching and grasping tasks when compared to the ipsilateral 
paw (Olsson et al., 1995), as measured using a simple food retrieval task (Whishaw et 
al., 1986) or the ‘staircase test’. This test is designed to assess skilled forelimb use by 
placing food on a staircase that is situated on either side of a central platform on 
which the lesioned animal is placed. The staircase has several graded stages of 
reaching difficulty, and therefore forelimb extension as well as grasping ability can be 
assessed (Montoya et al., 1991). Alternatively, limb impairment can be assessed by 
examining weight-shifting movements during spontaneous exploration using the 
cylinder test (Schallert et al., 2000). 6-OHDA lesions are also associated with sensory 
neglect of contralateral stimuli, as demonstrated by a variety of orientation tests such 
as whisker touch, snout probe and olfaction (Dunnett & Iversen., 1982). Contralateral 
neglect is also demonstrated using more complex tests such as operant tasks using the 
9-hole box, where animals are required to respond to visual stimuli by initiating and 
executing correct nose-poke responses to either side of the head (Carli et al., 1985; 
1989; Dowd & Dunnett., 2005).
Since the unilateral 6-OHDA-lesion model of PD displays a number of behavioural 
deficits that can be efficiently measured, this model allows the effective assessment of 
potential treatments, since any treatments that attenuate 6-OHDA lesion-induced 
behavioural deficits could prove to be clinically useful in providing symptomatic 
relief of Parkinson’s disease.
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1.3.2 Genetic models o f Parkinson’s disease
The precise aetiology o f Parkinson’s disease is unknown, however, underlying genetic 
causes have been identified in a small number of cases (see section 1.2.1). These 
genes have consequently been manipulated in vivo to create genetic animal models of 
Parkinson’s disease. This genetic modification of the genome is achieved in one of 
two ways. (1) by removing or altering a gene of interest so that it no longer functions 
(knock-out models), or (2) by adding a gene of interest to the genome so that it is 
expressed (transgenic models).
1.3.2.1 Gene Knock-out & Transgenic models o f Parkinson disease 
Since a-synuclein has been implicated in the pathophysiology o f Parkinson’s disease 
and is a main constituent of Lewy bodies (a pathological hallmark of the disease), the 
a-synuclein gene has attracted particular interest. However, while a-synuclein knock­
out mice have been developed, the genetically modified mice are viable, fertile, do not 
display any pathological features of Parkinson’s disease and do not exhibit alterations 
in dopaminergic pathways (Abeliovich et al., 2000). They do however show reduced 
striatal dopamine levels, attenuation o f dopamine-dependent locomotor activity which 
is induced by amphetamine challenge and increased dopamine release following 
paired stimuli which suggests that a-synuclein negatively regulates dopamine 
neurotransmission (Abeliovich et a l., 2000). Conversely, transgenic mouse models 
expressing wild-type human a-synuclein show a number of pathological features 
including the presence of a-synuclein and ubiquitin-positive intraneuronal inclusions 
in the neocortex, hippocampus and substantia nigra (Masliah et al., 2000). These 
inclusions however lack fibrillary aggregates which are typically seen in Lewy bodies 
(Orth & Tabrizi., 2003). In addition, TH-positive nerve terminals and TH levels in the 
striatum are markedly reduced and a significant deficit in motor performance is 
observed when compared to nontransgenic littermate controls (Masliah et al., 2000). 
In another study, transgenic mice expressing mutant and wild-type human a-synuclein 
also develop locomotor deficits, showed neuronal degeneration and exhibited Lewy 
body-like intraneuronal inclusions in some motor neurones (van der Putten et al.,
2000). These studies indicate that higher expression of a-synuclein can result in its 
accumulation, aggregation and neurodegeneration, and highlight a central role of a- 
synuclein in the pathological process of both familial and the more frequent sporadic 
forms of Parkinson’s disease.
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Although great focus has been placed on the a-synuclein gene other potential genetic 
models o f Parkinson’s disease have also been generated. These include the Parkin 
knock-out mice which show alterations in the extracellular dopamine levels in the 
striatum and deficits in behavioural tasks, but no loss of dopaminergic neurones in the 
substantia nigra (Goldberg et al., 2003), and the DJ-1 knock-out mice which show 
age-dependent and task-dependent motor deficits that are detectable by 5 months of 
age. While no degeneration of dopamine neurones in the substantia nigra is observed 
in this model, alterations in striatal dopamine levels, striatal dopamine release and re­
uptake are observed suggesting that DJ-1 plays a role in nigrostriatal dopamine 
function (Chen eta l., 2005).
Since the genetic models of Parkinson’s provide information of gene function, these 
models are extremely valuable research tools and are o f absolute importance so that 
we can further understand the genetic involvement in the pathogenesis of the disease. 
In addition, like the neurotoxin models, the genetic models of Parkinson’s disease will 
also help in the development of new therapies since any potential treatments would 
need to correct the deficits seen in these models.
1.4 Neurotransplantation as a treatment fo r  Parkinson disease 
Graft-induced functional recovery of behavioural deficits induced by striatal 
dopamine depletion was first described in the late 70’s when pieces of embryonic 
dopamine tissue, which were grafted into unilateral lesioned rats, showed attenuation 
of drug-induced rotational asymmetry (Perlow et al., 1979; Bjorklund et al., 1979). 
Since then improvements in a number o f behavioural impairments have been shown 
following intrastriatal grafting of dopamine neurones. The success of 
neurotransplantation in rodent and monkey models has consequently resulted in 
clinical trials of neurotransplantation in an attempt to provide an effective, long-term 
treatment for Parkinson’s disease.
1.4.1 Functional recovery o f lesion-induced behavioural deficits 
Transplantation of embryonic mesencephalic dopamine neurones into the striatum of 
unilateral depleted rodents and monkeys has provided evidence that grafted dopamine 
neurones can survive, integrate and improve lesion-induced motor deficits such as
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drug-induced rotational bias (Abrous et a l., 1993; Perlow et al., 1979; Bjorklund & 
Stenevi., 1979; Dun nett et al., 1983; Annett et al., 1994). Interestingly, drug-induced 
rotational asymmetry has not only been significantly reduced, but in some cases, 
grafts of dopamine neurones have resulted in overcompensation of rotational bias 
(Bjorklund et a l., 1980; Herman et al., 1985). Grafts of dopamine neurones have also 
shown improvements in other lesion-induced deficits such as contralateral sensory 
neglect (Dunnett eta l., 1987), hypokinesia (Dunnett eta l., 1981) and learning deficits 
(Dowd & Dunnett., 2004). Full recovery from all behavioural deficits is however not 
observed, with grafts unable to improve some behaviour impairments including 
skilled paw use and limb preference (Dunnett et al., 1987; Annett et al., 1994). This 
incomplete recovery may be attributed to partial restoration of striatal dopamine levels 
(Bjorklund. & Dunnett., 1983), and incomplete reinstatement of striatal dopamine 
synthesis levels (Bjorklund. & Dunnett., 1983), which are a result of poor survival of 
transplanted dopamine neurones (Bjorklund., 1992). Alternatively, absence of 
complete recovery of behavioural deficits could be a result of graft placement, since 
the location of grafts within the denervated striatum has shown to determine the type 
of deficit which is restored (Bjorklund et al., 1980; Dunnett et al., 1981).
1.4.2 Dopamine grafts -  mechanism o f function
The mechanisms by which grafted dopamine neurones have their effects are unclear, 
however, evidence suggests that functional recovery is not solely due to symptomatic 
relief via ‘pharmacological action’ of grafted dopamine neurones, but is also 
associated with disease recovery via graft integration and resultant cellular changes 
(Bjorklund., 1992). This is particularly highlighted by the effects o f dopamine 
delivery therapies. Polymer capsules that gradually release dopamine have been 
transplanted into the unilateral dopamine-depleted striatum and have shown to reduce 
apomorphine-induced rotations (Becker et al., 1990; Winn et al., 1989). However, 
while these treatments have shown to improve some behavioural deficits, they are 
unable to improve rotational behaviour induced by amphetamine stimulation, and 
therefore cannot account for the whole range of functional recovery which is observed 
following transplantation of dopamine neurones (Dunnett & Bjorklund., 1994). 
Dopamine grafts must therefore function by integrating with the host striatum in 
addition to having a pharmacological mechanism of action. Grafted dopamine
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neurones have been shown to integrate with the host striatum by growing extensive 
axonal projections which innervate the denervated striatum by forming specific 
synaptic contacts with host striatal medium spiny projection neurones (Freund et al., 
1985). Some o f these grafted neurones have shown similar electrophysiological firing 
properties to those neurones found in the intact substantia nigra, and have been shown 
to respond to stimulation of the cortex and the striatum (Fisher et al., 1991), 
indicating functional integration with host neurones. Grafted dopamine neurones have 
also been shown to correct cellular deficits caused by striatal dopamine loss. For 
instance, supersensitivity of postsynaptic D1 & D2 dopamine receptors which occurs 
following striatal denervation is normalised following grafts o f dopamine neurones 
(Savasta et al., 1992, Rioux et al., 1991; Dawson et al., 1991), as are levels of 
dopamine receptor-induced expression of the protein product c-fos (Cenci et al.,
1992), which have been shown to increase following apomorphine stimulation of 
postsynaptic dopamine receptors and to decrease in response to amphetamine-induced 
presynaptic dopamine release in the denervated striatum (Cenci et al., 1992). Further 
evidence for normalisation of striatal function has been shown by the reinstatement of 
normal striatal peptide levels. Levels of enkephalin and enkephalin mRNA in 
striatopallidal projection neurones and levels o f the GABA synthesising enzyme, 
GAD and expression of its mRNA in GABAergic striatal neurones are substantially 
increased following dopamine depletion of the striatum (Gerfen., 1992; Manier et al., 
1991; Mendez e f al'., 1993; Segovia et al., 1990). These levels are subsequently 
restored to normal levels, or are partially reduced following dopaminergic cell 
transplantation (Sirinathsinghji & Dunnett., 1991; Cadet et al., 1991; Manier et al., 
1991; Mendez et al., 1993; Segovia et al., 1989; 1991), thus demonstrating the ability 
of dopamine grafts to reinstate normal balance of striatal output activity.
1.4.3 Neurotransplantation - Clinical Trials
The functional benefits observed in animal models following intrastriatal grafts of 
dopamine neurones have resulted in a series of clinical trials where Parkinson’s 
disease patients have received intrastriatal grafts of mesencephalic tissue from aborted 
foetuses. Although results from these trials have not shown the complete reversal of 
disease symptoms, moderate improvement in a number of motor deficits including 
rigidity, hypokinesia and bradykinesia have been observed (for reviews see Olanow et
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a l., 1996; Lindvall., 1997 and references Wenning et al., 1997; Lindvall et al., 1990; 
1992; Kopyov et al., 1997; Peschanski et al., 1994; Freed et al., 1992). There are also 
improvements in on-going L-dopa treatment, with a reduction in time spent in ‘o ff 
phase (where L-dopa does not provide symptomatic relief) and an increase in the 
duration of positive L-dopa effects following a single dose (Freeman et al., 1995; 
Lindvall et al., 1994; Wenning et al., 1997). In some cases, grafts of dopamine 
neurones have resulted in L-dopa treatment being reduced (Wenning et al., 1997; 
Freed et al., 1992) and in at least one case, L-dopa treatment has been withdrawn 
completely (Lindvall et al., 1994). Confirmation of graft function is demonstrated 
using positron emission tomograpgy (PET), which shows increased uptake of 
[18F]fluorodopa dopa in the grafted striatum (Lindvall et al., 1990; 1994; Wenning et 
al., 1997; Kordower et al., 1995; Remy et al., 1995). Direct evidence of graft-induced 
clinical improvements has also come from the histological examination of the post­
mortem brain. Two patients, which displayed marked motor improvements and 
increased [18F]fluorodopa uptake following transplantation, who died over a year after 
transplantation from causes unrelated to surgery, showed the presence of large grafts, 
which contained thousands of dopamine neurones that extensively reinnervated the 
striatum (Kordower etal., 1995; 1998). The clinical benefits seen in some patients are 
also long-term as shown by sustained motor improvements and [18F]fluorodopa 
uptake years following transplantation (Lindvall., 1997; Lindvall etal., 1994; Dunnett 
etal., 2001).
Although these studies show that neurotransplantation can be effective for at least 
some patients, all of these clinical trials have used open-labelled studies (where there 
is no control group and both patient and physician are aware that transplant has been 
received) and are therefore subject to being influenced by placebo effects and 
physician bias (Freeman et al., 1999). To overcome these issues, two of the most 
recent transplantation studies have used randomised, double-blind, placebo-controlled 
trials, where patients either received grafts of dopamine neurones or sham surgery 
(burr holes were drilled but no tissue was implanted), with the patient and physician 
unaware of what procedure had been received (Freed et al., 2001; Olanow et al.,
2003). Interestingly, although [18F]fluorodopa uptake in these two studies provided 
evidence of graft survival and function, in the study by Freed, moderate 
improvements were only reported in patients under the age of 60 years 12 months 
after transplantation, and in the study by Olanow, no clinical benefit whatsoever was
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observed after 2 years. Both studies did however report the development of dyskinesia 
in a proportion o f patients, the severity o f which was much worse than that which has 
been reported in open-labelled trials.
Although these results raise considerable concerns about the readiness of cell 
replacement strategies for the clinical treatment of Parkinson’s disease, it is important 
to note that the transplantation methods used in these studies differed from the open- 
labelled trials, and could therefore account for the discrepancies in the results 
(Dunnett et al., 2001; Lang & Obeso., 2004; Winkler et al., 2005). In the study by 
Freed, less tissue was transplanted compared to most open-labelled trials with only 2 
donors used per transplant, tissue was stored for up to 4 weeks prior to transplantation 
and was implanted as a single concentrated deposit in the neostriatum using an 
unvalidated ‘noodle’ preparation. Furthermore, no immunosuppression was used 
(Dunnett et al., 2001; Winkler et al., 2005).
With the study by Olanow, tissue was grafted as solid pieces, unlike most of the open- 
labelled trials, which used cell suspensions, and although immunosuppression 
treatment was given, only cyclosporine was used and not the triple 
immunosuppressive treatment (cyclosporine, azathioprine & prednisolone) used in 
previous studies. In addition, cyclosporine was discontinued after 6 months, despite 
patients being followed for 2 years -  a level of immunosuppression which is probably 
insufficient to block early rejection of grafted dopamine neurones before they have 
had a chance to become fully established (Winkler et al., 2005).
The negative effects of these different methodologies on graft function and survival 
are clearly demonstrated. For instance, in the study by Freed, histological examination 
of the brains of two patients who died months following transplantation surgery, 
revealed the number of surviving dopamine neurones contained in the grafts were less 
than half o f what had been reported in previous open-labelled trials; 7000-40000 cells 
in double-blind trial vs. 80000-135000 cells in open-labelled trials (Dunnett et al., 
2001; Winkler et al., 2005). In addition, in the study by Olanow, patients grafted with 
tissue from 4 donors showed improvements up to 6 months after surgery, but then 
deteriorated back to pre-graft values after 18 months following transplantation. This 
deterioration might reflect a slow rejection process associated with incomplete 
immunosuppression.
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Despite the negative results from the double-blind, placebo-controlled studies, 
transplantation is still an effective strategy for the treatment o f PD, but it is clear from 
these results that certain cell preparation, storage and transplantation techniques need 
to be refined before further clinical trials are attempted. All studies should also assess 
the clinical effects of transplantation using the core assessment program for 
intracerebral transplantation (CAPIT) protocol, which would allow studies to be 
compared. In addition, use of tissue from aborted foetuses in transplantation studies is 
complicated because of a combination o f ethical issues, logistical problems, and the 
amount of tissue required per transplant (Bjorklund & Lindvall., 2000). 
Transplantation strategies will therefore, only provide a practical treatment for PD if 
these supply issues can be resolved, and if a suitable replacement tissue source can be 
found.
Tissue containing catecholamine secreting cells such as adrenal chromaffin cells or 
cells of the carotid body may be possible alternatives. Adrenal grafts transplanted into 
either the lateral ventricles or the striatum have shown reduction in behavioural 
deficits induced by unilateral 6-OHDA lesions in rats (Becker & Freed., 1988; Freed 
et al., 1990; Borlongan et al., 1998; Date., 1996). Similarly, glomus cells o f the 
carotid body, which normally release dopamine in response to hypoxic environments, 
have also been shown to alleviate behavioural deficits in dopamine depleted rats and 
monkeys following intrastriatal transplantation (Luquin et al., 1999; Espejo et al., 
1998; Toledo-Aral et al., 2002). However, an extensive series o f clinical studies 
during the 80’s and 90’s failed to find good survival and functional effect of such 
peripheral neuroendocrine autografts. Alternatively, replacement dopamine neurones 
could come from the use of stem cells since these cells have the ability to generate 
dopamine neurones under certain environmental conditions.
1.5 Stem cells
The ability of stem cells to generate cells of the central nervous system has resulted in 
a substantial amount of interest over the past decade, mainly because of their potential 
use in cell replacement therapies for neurodegenerative disease. This section gives a 
brief description o f stem cell characterisation, origin and function before discussing 
the potential use o f embryonic, foetal and adult neural stem cells in neural 
transplantation. The plasticity of multipotent stem cells and their ability to trans-
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differentiate into cells o f the nervous system will also be discussed in terms o f their 
use as a donor source for cell replacement strategies.
The terminology used to describe stem cells and their progeny varies from person to 
person and can become quite complicated. In this thesis I adopt a relatively inclusive 
definition. The term stem cell is used to describe a cell with multipotentiality and the 
capacity for self-renewal. Progenitor cells have limited self-renewal abilities and have 
uni- or multipotentiality, and the term precursor cell is used to describe either mixed 
or unknown proliferating populations (Weiss et al., 1996; Seaberg & van er Kooy., 
2002). For simplicity, in this thesis I will only use the term stem cell when describing 
cells that are definitely stem cells, and in all other cases I will use the term, progenitor 
cell.
1.5.1 What are stem cells?
Many definitions o f stem cells exist, but they are functionally defined as cells which 
have the ability to self-renew and generate differentiated progeny (Watt & Hogan., 
2000; Morrison et al., 1997; Temple., 2001). This self-renewal can be achieved by 
either symmetric division, where the two daughter cells are stem cells, or by 
asymmetric division, where one daughter cell is a stem cell and the other is a 
restricted progenitor cell. These progenitor cells have limited self-renewal capacities 
before terminally differentiating into multiple, yet distinct cell lineages (Watt & 
Hogan., 2000; Morrison et al., 1997).
Stem cells are prevalent in organs and tissues throughout the entire developing and 
adult organism, such as the heart (Beltrami et al., 2003; Urbanek et al., 2003), skin 
(Toma et al., 2001; Blanpain et al., 2004) and even in the central nervous system 
(McKay., 1997; Gage et al., 1995), where their discovery in the adult has overturned 
the long-standing dogma that the brain is a structure incapable of regeneration. Their 
function in development is to proliferate and generate cells enabling tissues and 
organs to mature, and in the adult, it is believed they participate in tissue homeostasis 
by replacing differentiated cells lost to physiological turnover or injury (Fuchs & 
Serge., 2000; van der Kooy & Weiss., 2000; Weiss etal., 1996).
The classification of stem cells is based on their lineage potentials, with the zygote an 
example of a totipotent stem cell since it gives rise to all cells that constitute a 
multicellular organism. From this totipotent state, generation of cells with more 
restricted differentiation capacities are formed. Embryonic stem cells are derived from
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the inner cell mass o f the developing blastocyst and can differentiate into ectodermal, 
endodermal and mesodermal derivatives (Kim etal., 2003, see section 1.5.2), but not 
into cells of the extraembryonic membranes that form cells of the placenta (Gage.,
2000). Embryonic stem cells are therefore slightly more restricted than totipotent cells 
and are thus referred to as pluripotent stem cells. Specialised cells restricted to 
forming cell phenotypes of a particular lineage are known as multipotent stem cells 
and are defined by the organ from which they are derived. Neural stem cells are 
examples of multipotent stem cells and are derived from the nervous system. These 
multipotent cells have the ability to produce lineage-restricted daughter cells called 
neural progenitor cells, which generate neurones, astrocytes and oligodendrocytes (for 
a review see Gage., 2000).
The ability to generate neurones from stem cells has provided a unique source of cells 
for the treatment of neurodegenerative disorders via neural transplantation strategies. 
However, for stem cells to be successful in the treatment of Parkinson’s disease they 
need to be directed not only into dopamine phenotypes, but also into dopamine 
projection neurones. Here we consider the possible stem cell sources that may be 
useful in the generation of dopamine neurones and the extent to which directed 
dopamine differentiation has been achieved.
1.5.2 Embryonic stem cells
Embryonic stem (ES) cells are undifferentiated, pluripotent cells derived from the 
inner cell mass of the blastocyst. Generated initially from embryos of mice (Evans & 
Kaufman., 1981; Martin., 1981), ES cells have now been successfully developed from 
monkey blastocysts (Thomson et al., 1995) and from human embryos acquired from 
patients undergoing in vitro fertilisation (IVF) treatment (Thomson et al., 1998; 
Reubinoff et al., 2000; Schuldiner et al., 2001). Like mouse ES cells (Evans & 
Kaufman., 1981; Martin., 1981), human ES cells can undergo unlimited in vitro 
proliferation whilst remaining in an undifferentiated state. Their pluripotent properties 
are also retained following proliferation, as shown by the injection of these cells into 
immuno-deficient SO D  mice and the subsequent formation of teratomas, which, by 
definition contain cells derived from all three germ layers of the developing embryo, 
including cells o f the nervous system (Thomson et al., 1998; Reubinoff et al., 2000).
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1.5.2.1 Neural differentiation o f ES cells
The potential o f  human ES cells to generate neural phenotypes, coupled with their 
ability to proliferate indefinitely could essentially provide a good, continuous source 
of neurones for transplantation. However, while human ES cells have been shown to 
behave like endogenous progenitors and generate olfactory bulb neurones following 
transplantation into the subventricular zone of rats (Tabar et al., 2005), the necessary 
requirements to generate sufficient quantities o f suitable neurones from these cells are 
unknown and are currently being explored. One approach to induce ES cell neural 
differentiation has been through the manipulation of the culture environment. Retinoic 
acid, a developmental factor involved in anterior-posterior patterning o f the neural 
tube, has been shown to be a potent neural-inducing factor (Takahashi et al., 1999) 
and its addition to mouse ES cells has resulted in the generation of large numbers of 
neurones (Bain et al., 1995; Fraichard et al., 1995). The addition of basic fibroblast 
growth factor (bFGF) (fibroblast growth factors are essential molecules involved in 
the development and regulation of cell proliferation, migration and differentiation) to 
proliferating mouse ES cells, and their subsequent differentiation following bFGF 
withdrawal has also been shown to promote neural differentiation, with over 60% of 
total cells expressing the neuronal marker MAP2, and up to 15% of total cells 
expressing the glial cell marker GFAP (Okabe et al., 1996). Furthermore, retinoic acid 
and 3 nerve growth factor (PNGF) have been shown to influence differentiation of 
human ES cells into neural phenotypes (Schuldiner et al., 2001). Interestingly, these 
neurones not only stain for neurofilament heavy-chain protein which is found in 
mature neurones, but they also express serotonin or dopamine receptors in addition to 
expressing dopa decarboxylase, which is an enzyme involved in the synthesis of these 
neurotransmitters (Schuldiner et al., 2001), thus indicating that these neurones may 
indeed be dopaminergic. The generation of dopaminergic neurones is essential if 
neural transplantation is going to be a successful treatment for Parkinson’s disease 
and so conditions that promote dopaminergic differentiation need to be defined. 
Recently, the expansion of mouse ES cells in media deficient in HEPES buffer but 
supplemented with bFGF, sonic hedgehog (a developmental factor involved in the 
dorsal-ventral patterning o f the neural tube) and fibroblast growth factor 8 (FGF8), 
followed by their withdrawal and addition of ascorbic acid, enhanced neural 
differentiation, with over 30% o f neurones being immunopositive for tyrosine
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hydroxylase (TH) (Lee et al., 2000). Mouse ES cells have also been shown to 
differentiate into dopamine neurones following their culture in media containing 
bFGF and epidermal growth factor (EGF) and differentiation in media consisting of a 
host of survival-promoting factors (Rolletschek et al., 2001). The addition of these 
survival-promoting factors showed increased gene expression of TH and NURR1, as 
well as increasing the percentage of neurones immunopositive for TH from 22% to 
43%.
Nurrl is a transcription factor specific to midbrain dopamine neurones alone 
(Zetterstrom et al., 1997) and mouse ES cells genetically modified to express this 
gene have shown a 4-5 fold increase in dopaminergic neurone expression (Chung et 
al., 2002). Exposing these cells to the conditions used by Lee and colleagues (see 
above) further increased dopamine differentiation, with 62% of neurones staining 
immunopositive for TH (Chung et al., 2002). Although TH is an enzyme involved in 
dopamine synthesis, one needs to be cautious when using it to label dopamine 
neurones since the enzyme is also involved in the synthesis of other neurotransmitters 
such as serotonin. Consequently neurones expressing TH are not necessarily 
dopaminergic. However, in all three o f these studies the absence of double labelled 
cells following double immunohistochemistry for TH and serotonin indicated that 
these neurones were indeed of dopaminergic phenotypes.
An alternative approach to inducing dopamine neurones is by the use of feeder layers. 
Mouse ES cells co-cultured with stromal feeder cells have shown enhanced dopamine 
neurone generation, with 30% of neurones staining positive for TH (Kawasaki et al.,
2000). When grafted into the striatum of unilateral 6-OHDA lesioned mice, the 
survival rate of dopamine neurones was shown to be 22%, quite impressive 
considering the survival of embryonic mesencephalic neurones is in the range of 3- 
10% (Olanow et al., 1996; Dunnett., 1992; Roybon et al., 2004). However, while 
survival was good, no examination of lesion-induced behavioural deficits or its 
subsequent recovery following grafting was reported, so whether or not these 
neurones were functional remains unknown.
1.5.2.2 Functionality o f ES-derived dopamine neurones
Over the past few years, great progress has been made in generating neurones o f a 
dopaminergic phenotype. Demonstrating their functionality is however, imperative if
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ES cells are going to be a serious candidate as a donor source for cell therapy in PD. 
Until a few years ago, such evidence was lacking, but two reports published in 2002 
have shown functional recovery o f 6-OHDA lesion-induced behavioural deficits 
following grafts of ES-derived dopamine neurones. The first of these two papers 
grafted a low concentration of ES cells into the rat striatum, arguing that a low 
concentration decreases ES cell-cell contact and thus increases the influence of the 
host striatum environment on these cells (Bjorklund et al., 2002). The second used 
mouse Nurrl ES cell lines (generated by the insertion o f the rat Nurrl cDNA 
fragment) and expanded them in the conditions defined by Lee and colleagues (see 
above) (Kim et al., 2002). Following transplantation o f these cells into the striatum of 
unilateral dopamine depleted rats, both groups reported significant reductions in 
amphetamine-induced rotational bias several weeks post-transplantation. Significant 
improvements in a variety of non-pharmacological behavioural tests such as adjusting 
step, cylinder and paw reaching tests were also observed and electrophysiological 
recordings of grafted dopamine neurones showed similar characteristics to 
endogenous mesencephalic neurones (Kim et al., 2002). Non-behavioural tests were 
also used in the study by Bjorklund to further confirm the functionality of their 
grafted dopamine neurones. Using positron emission tomography (PET) and carbon- 
11-labeled 2p-carbomethoxy-3P-(4-fluorophenyl) tropane ([n C]CFT), which is a 
dopamine transporter ligand, showed substantial reinnervation of the striatum. In 
parallel, functional magnetic resonance imaging (fMRI) showed restoration of 
appropriate haemodynamic changes in the striatum following amphetamine challenge. 
Collectively, these results provide encouraging evidence for the potential use of ES 
cells in cell replacement therapy for PD. The use of human ES cells is however, 
controversial and is associated with a number of ethical issues. The main ethical 
debate surrounds the moral status of the human embryo, with many people believing 
that the human embryo is equivalent to a human being. Therefore, destroying human 
embryos to obtain stem cells for research or disease treatment is seen as illegal (since 
it’s equivalent to murder) and immoral (since killing one person to save or treat the 
life of another person is unjustifiable) (McLaren., 2001; Robertson., 2001; Roche & 
Grodrin; 2000). There are also some safety concerns regarding the use o f these stem 
cells, for instance the potential for mutations is always a concern for cultured cells 
(Svendsen & Smith., 1999), and any grafted undifferentiated cells will have the ability
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to divide indefinitely in vivo resulting in the formation of tumours, as seen in five 
animals in the study by Bjorklund (Bjorklund et al., 2002) and more recently in the 
study by Thinyane and colleagues (Thinyane et al, 2005). This is particularly 
problematic since not all ES cells undergo differentiation, and therefore a rigorous 
selection process is required to remove or eliminate such undifferentiated cells. 
Although efforts have been made to eliminate the presence of undifferentiated cells by 
introducing suicide genes (Schuldiner etal., 2003; Fareed & Moolten., 2002) all these 
issues need to be fully addressed before ES cells enter clinical trials. On a separate 
issue, introducing genes into human embryos has raised great concern, since such 
techniques could open the door to creating offspring with certain desirable 
characteristics (Robertson., 2001).
1.5.3 Neural stem cells
Neural stem cells are multipotent cells capable of generating neurones, astrocytes and 
oligodendrocytes. They can be isolated from the developing or adult brain and 
cultured in the presence of certain mitogens such as epidermal growth factor (EGF) 
(Reynolds and Weiss., 1992; Winkler et al., 1998) or basic fibroblast growth factor 
(bFGF) (Qian eta/., 1997; 2000). These cells can proliferate as monolayer cultures or 
form free-floating aggregates of undifferentiated cells called neurospheres (Reynolds 
& Weiss., 1992), and differentiate into neural phenotypes following mitogen 
withdrawal, the addition of serum and exposure to suitable substrates. The presence of 
specific mitogens in the culture environment is essential for cell expansion, however 
experimental evidence suggests that EGF and bFGF act on different progenitor 
populations, with EGF favouring proliferation of glial progenitors and bFGF 
favouring the proliferation of neuronal progenitors (McKay., 1997; Kuhn et al., 1997; 
Kilpatrick & Bartlett., 1995). In addition to the in vitro manipulation o f these cells, 
neural stem cells can also be transplanted into the intact or lesioned brain where they 
show the ability to survive, migrate and differentiate into cells of the nervous system 
(Gage et al., 1995b; Minger et al., 1996; Fricker et al., 1999; Englund et al., 2002).
1.5.3.1 Foetal neural stem cells
Foetal neural stem cells can be isolated from various regions o f  the developing brain, 
including (but not restricted to) the ventral mesencephalon (VM), the cortex (CTX)
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and from the whole (WGE), lateral (LGE) and medial (MGE) segments of the 
ganglionic eminence (Smith et a l., 2003). Stem cells from these areas have been 
isolated at a variety of ages (see chapter three), and from a range of species including 
mice (Murphy et a l., 1990; Reynolds & Weiss., 1992), rats (Smith et al., 2003; Rosser 
et al., 1997; Carvey et al, 2001), and pigs (Armstrong et al., 2002; 2003). Similarly, 
the isolation, proliferation and neural differentiation of human neural stem cells has 
also been achieved (Svendsen et a l, 1998; Carpenter et a l, 1999; Caldwell et a l, 
2001), and has generated particular interest due to their potential clinical use in PD. 
However, while these cells have demonstrated their ability to spontaneously 
differentiate into neurones, the generation o f dopamine neurones is typically low and 
decreases significantly with cell expansion (Yan et al., 2001). Enhancing dopamine 
differentiation is therefore crucial if these cells are going to provide a source of cells 
for transplantation. However, whilst extensive research has focused on this area, the 
differentiation of neural stem cells into dopamine phenotypes is still proving difficult.
1.5.3.2 Enhancing dopamine differentiation in vitro
One approach to enhance dopamine differentiation of neural stem cells is by the use 
of genetically immortalised neural stem cells, which overexpress the transcription 
factor Nurrl. This factor has been shown to be essential for the induction of midbrain 
dopamine neurones, which fail to develop in Nurrl-depleted mice (Zetterstrom et al.,
1997), due to inadequate neural survival and the inability o f mesencephalic neurones 
to terminally differentiate into dopaminergic phenotypes (Saucedo-Cardenas et a l ,
1998). Although differentiation of these immortalised cells does not generate 
neurones (Wagner et a l,  1999; Kim et a l,  2003), their co-culture with primary E16 
VM cells and specifically with ventral mesencephalic type 1 astrocytes results in a 
substantial increase in the number of TH positive neurones, with over 80% of cells 
staining immunopositive for TH (Wagner et al., 1999). Interestingly, these TH 
positive neurones also release dopamine upon depolarisation and they also express 
midbrain markers. Similarly, enhanced TH expression is observed following co- 
culturing o f Nurrl-overexpressing neural progenitor cells with primary astrocytes 
derived from human foetal brains (Kim et a l,  2003). In addition, this dopaminergic 
differentiation can be further enhanced by culturing Nurrl-overexpressing cells in the 
presence of sonic hedgehog (SHH) and FGF8 (Kim et a l, 2003), which are
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developmental signals of midbrain dopamine neurones and have previously shown to 
promote ventral midbrain fates in rat neural plate explants (Ye et al., 2003). The 
combination of Nurrl-overexpressing neural progenitor cells, SHH and FGF8 result 
in more than 90% of neural progenitor cells expressing TH, therefore indicating that 
sonic hedgehog and FGF8 are potent inducers of dopaminergic phenotypes. 
Alternatively, enhanced dopamine differentiation of neural progenitor cells has been 
achieved by the addition of a variety of factors into the culture environment. For 
instance, the differentiation of bFGF-expanded human foetal VM tissue shows 64- 
69% of cells expressing the neuronal marker MAP2 and about 12% of cells 
immunopositive for TH. However, following differentiation in media supplemented 
with dopamine (lOpM), forskolin (lOpM) and 50ng/ml brain derived neurotrophic 
factor (BDNF), TH expression is significantly enhanced, with over 60% of cells 
expressing TH (Riaz et al., 2002). The addition of extrinsic cytokines to the 
differentiation media has also been shown to increase dopamine differentiation. Rat 
EI4.5 VM cells expanded in media containing EGF and differentiated in serum 
containing media supplemented with interleukin-1 (IL-1), showed increased TH 
expression in developing neurones (Ling etal., 1998). Further differentiation in media 
containing 10% serum, IL-1, interleukin-11 (IL-11), leukemia inhibitory factor (LIF) 
and glial cell line-derived neurotrophic factor (GDNF) not only enhanced the 
development of TH cells, but also further increased TH expression, with 25% of all 
cells expressing TH. Interestingly, the addition of conditioned media from striatal cell 
cultures and fragments of mesencephalic membranes to the cocktail o f cytokines 
resulted in TH neurones acquiring more mature morphologies, which included large 
somas and numerous branching processes with varicosities (Ling et al., 1998). Using 
the same differentiation protocol, human ventral mesencephalic progenitors have also 
been demonstrated to generate mature neurones with dopaminergic phenotypes, which 
release dopamine and express the dopamine transporter protein (DAT) (Storch et al., 
2001). In this study, long-term EGF & bFGF-mediated expansion of ventral 
mesencephalic cells was only achieved following proliferation in 3% atmospheric 
oxygen, a concentration representative of normal interstitial O2 levels, instead of the 
standard 20% O2. The importance of O2 levels on proliferation and differentiation of 
neural progenitor cells has also been reported elsewhere. The expansion E 12 rat VM 
bFGF-responsive progenitor cells in 3% atmospheric oxygen resulted in increased cell
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expansion compared to cells grown in standard (20%) oxygen environments (Studer 
et al., 2000). This increased expansion was as a combined result o f increased cell 
proliferation and decreased cell death. Following 5 days differentiation, when cells 
exposed to lower oxygen levels were compared to cells grown in standard conditions, 
an increase in neurogenesis (73% vs. 63%) and an increase in dopamine 
differentiation (56% vs. 18%) was observed (Studer et al., 2000). The detrimental 
effects of high oxygen environments may be mediated through oxidative stress, a 
process which has been suggested to contribute to the death of substantia nigra 
dopamine neurones in PD (Sian et al., 1994; Olanow., 1993; Fahn & Cohen., 1992; 
Olanow & Tatton., 1999). Indeed, neuroprotective effects o f anti-oxidants on 
dopamine neurones have been demonstrated by a number of studies (see chapter four). 
The antioxidant N-acetylcysteine has shown to increase dopamine differentiation of 
E14 rat VM cells expanded in EGF (Rodrigues-Pallares et al., 2001), and lazaroids, 
which are compounds that prevent lipid peroxidation and oxidative stress, have been 
shown to increase the survival of dopamine neurones in primary E l 4 rat VM cultures 
(Frodl et al., 1994). Interestingly, the anti-oxidant ascorbic acid has also been shown 
to increase dopaminergic neurone differentiation of expanded rat E 12 VM progenitor 
cells (Yan et al., 2001). However, rather than being a neuroprotective agent and 
defending against oxidative stress, the authors of this study suggest that ascorbic acid 
may increase dopamine expression by activating dopamine differentiation pathways.
1.5.3.3 Transplantation o f expanded neural progenitor cells
Although a considerable number of studies have reported manipulation of progenitor 
cells in vitro, the number of reports assessing the behaviour of expanded neural 
progenitor cells following transplantation is relatively scarce. However, results from 
this limited number suggest that grafted progenitor cells can survive for long periods 
o f time, migrate extensively and differentiate into neuronal and glial phenotypes. 
These characteristics have been shown following transplantation of bFGF-expanded 
rat basal forebrain progenitor cells into various regions of the adult rat brain. Grafted 
cells are apparent 7 months post-transplantation and differentiation into neuronal and 
glial cells is observed (Minger et al., 1996). Similarly, transplants of long-term 
expanded human neural progenitor cells into the striatum and neurogenic regions of 
the neonate brain show differentiation into neural phenotypes, extensive migration
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and cell survival for up to 1 year post-transplantation (Englund et al., 2002). 
Interestingly, when transplanted into the adult brain these neural progenitor cells are 
influenced by local signals to migrate and differentiate into specific cell types (Fricker 
et al., 1999; Englund et al., 2002), thus indicating the sensitivity of these cells to the 
environment in which they are placed.
1.5.3.4 Dopamine differentiation o f transplanted neural progenitor cells 
The generation o f dopamine neurones from expanded neural progenitor cells 
following transplantation is currently proving extremely difficult. A number of studies 
have attempted to address this issue but have generally yielded disappointing results. 
Unlike transplantation of primary dopamine neurones, which show large grafts and 
the attenuation of behavioural deficits in animal models of PD, EGF-expanded human 
and rat ventral mesencephalon progenitors grafted into 6-OHDA lesioned rats form 
small grafts, show limited cell migration, few surviving dopamine neurones and no 
functional recovery of lesion-induced behavioural deficits (Svendsen et al., 1996). 
Porcine EGF and bFGF-expanded VM progenitors transplanted into the 6-OHDA 
lesioned rat generated large surviving grafts 9 weeks post-transplantation, however 
little dopaminergic differentiation was observed and again, no improvements in 
rotational bias were evident (Armstrong et al., 2002; 2003). Slight progress has been 
achieved following expansion of human VM progenitors in a combination of EGF & 
bFGF before their subsequent transplantation into the dopamine depleted striatum of 
rats. At 2 weeks post-transplantation, large grafts were observed indicating good cell 
survival, however by 20 weeks post-transplantation, graft size was markedly reduced, 
the grafts contained few cells, and a large number o f astrocytes where observed 
migrating away from the graft into the host striatum. Importantly, in this study partial 
reduction in amphetamine-induced rotational bias was observed in 2 animals and 
analysis of the grafts showed the presence of numerous TH positive neurones in these 
two cases (Svendsen et al., 1997a). Although encouraging, results are inconsistent and 
when compared to grafts of primary tissue, dopamine differentiation and cell survival 
is less than impressive.
To date, the most promising results have been observed by differentiating cells prior 
to transplantation. In a study by Studer et al., (1998), rat VM cells were expanded 
with bFGF for 7 days and then differentiated them as free floating aggregates in
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roller-tube cultures with serum containing media. Following 7 days differentiation 
cells were transplanted as aggregates into 6-OHDA lesioned rats. 3 months post­
transplantation, grafts were reportedly of similar size to those found after primary cell 
transplantation and contained over 1200 TH positive neurones. These TH neurones 
significantly reduced amphetamine-induced rotations in 5 out of 7 grafted rats, thus 
demonstrating their functionality (Studer et al., 1998). Reduction in amphetamine- 
induced rotational bias was also observed following transplantation of clonal cell lines 
derived from E l4.5 rat VM cells (Carvey et al., 2001). These cells were pre­
differentiated for 5 hours in media containing 10% serum, interleukin-1 (IL-1), 
interleukin-11 (IL-11), leukemia inhibitory factor (LIF) and glial cell line-derived 
neurotrophic factor (GDNF) prior to transplantation in 6-OHDA lesioned rats. An 
88% reduction in rotational bias was observed 8 weeks post-transplantation and grafts 
contained numerous dopamine neurones. However, when compared to grafts of 
primary VM tissue, significantly less dopamine neurones were observed, and 
importantly, the survival rate of grafted dopamine neurones was low (Carvey et a l , 
2001).
The pre-differentiation procedures used in these studies seem logical since instructive 
signals that influence dopaminergic differentiation seem to be absent from the 
striatum (Tang et al., 2002). However, while the differentiation of expanded neural 
progenitors into functional dopamine neurones is extremely encouraging, the survival 
rates of grafted dopamine neurones demonstrated in these studies are inadequate. For 
neural progenitors to be considered a valid source of cells in cell replacement 
therapies, not only do sufficient numbers of functional dopamine neurones need to be 
generated from cells undergoing longer expansion periods, but also, the survival of 
dopamine neurones following transplantation needs to be enhanced. Only when these 
issues are addressed will these cells be valuable in clinical trials.
1.5.4 Adult neural stem cells
The belief that the adult brain is a structure incapable o f  regenerating has now been 
proved wrong with evidence showing the existence of continued neurogenesis in 
specific areas o f the adult brain. Neurogenesis has been reported in a variety of brain 
areas (Gritti et al,. 2002; Gould et al., 1999; Zhao et al., 2003), but predominantly 
occurs in two neurogenic regions, namely the dentate gyrus of the hippocampus and
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the subventricular zone (SVZ) of the lateral ventricles (Altman & Das., 1965; Gage et 
al., 1995; Kuhn & Svendsen., 1999; Seaberg & van der Kooy., 2002). The generation 
of new neurones in the dentate gyrus was first revealed over 40 years ago using H- 
thymidine autoradiography (Altman & Das., 1965), and it has been reported that cells 
from this region migrate from the subgranular layer o f the dentate gyrus into the 
granular cell layer where they differentiate into hippocampal granule cell neurones 
(Altman & Das., 1965; Kuhn et al., 1996). In the SVZ, neural stem cells are 
continuously generated and migrate along the rostral migratory stream into the 
olfactory bulb where they differentiate into dopaminergic and GABAergic 
interneurones {Lois & Alvarez-Buylla., 1993). Multipotent adult neural stem cells can 
be isolated from the central nervous system, proliferated in culture and differentiated 
into a host of neural phenotypes. This procedure is now well established with cells 
from rodents (Reynolds & Weiss., 1992; Richards et al., 1992; Gritti et al., 1996), 
monkeys (Gould et al. 2001), humans (Roy et al., 2000a; 2000b, Arsenijevic et al.,
2001) and even post-mortem human brain (Palmer et al., 2001) all showing the 
generation of neural phenotypes after periods of in vitro proliferation. Neurones 
generated from adult neural progenitor cells have also shown appropriate 
electrophysiological properties (Westerlund et al., 20003), thus demonstrating their 
functionality.
In the absence of specific stem cell markers, the characteristics used to define stem 
cells in vitro are based on the ability of cells to self-renew and show multipotent 
properties (Reynold & Weiss., 1992; 1996; Gage et al., 1995a; 2000). Although these 
features have been demonstrated for cells isolated from the SVZ (Gritti et al., 2002), 
there is some controversy over the self-renewal and multipotency of hippocampal 
cells. Cells isolated from the hippocampus have shown long-term self-renewal and the 
ability to differentiate into a range of neural phenotypes (Palmer et al., 1995; 1997), 
however, cells dissected specifically from the dentate gyrus have been shown to have 
limited self-renewal capacities and unipotent characteristics, therefore indicating that 
these cells represent a population of restricted progenitors rather than stem cells 
(Seaberg & van der Kooy., 2002). The precise location of SVZ stem cells is also an 
area currently causing considerable debate. It has been suggested that these stem cells 
reside in the ependymal layer that line the ventricle walls, since when isolated, these 
cells are capable o f self-renewal and generating neurones, astrocytes and 
oligodendrocytes (Johansson et al., 1999). Other reports however, indicate that the
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stem cells originate from subependymal layer, which lies adjacent to the ependyma. 
Evidence for this has been demonstrated following specific isolation o f ependymal 
and subependymal cells and their subsequent in vitro proliferation and differentiation. 
These studies show that although ependymal cells can generate neurospheres in 
culture, they are unable to generate secondary neurospheres thus indicating their 
inability to self-renew (Chiasson et al., 1999; Morshead & van der Kooy., 2001). 
Furthermore, ependymal cells only have unipotent potentials since they can only 
differentiate into glial phenotypes (Chiasson et al., 1999; Laywell et al., 2000). In 
contrast, subependymal cells showed self-renewal properties (Chiasson et al., 1999; 
Morshead & van der Kooy., 2001) and multipotent characteristics (Chiasson et al., 
1999), therefore demonstrating that subependymal and not ependymal cells fulfil the 
characteristics of true stem cells. The discrepancy between the reports could be a 
result of dissection protocol used by Johansson et al for the isolation of the ependymal 
cell layer. They injected Dil, a fluorescent lipophilic dye, into the lateral ventricle of 
rodents to label ependymal cells, which were then isolated. However, while 
ependymal cells were accurately labelled, it is possible that the dye also labelled the 
adjacent subependymal cells and resulted in the isolation of both cell types. The stem 
cell properties observed in their study could therefore reflect the presence of 
subependymal and not ependymal cells (Morshead & van der Kooy., 2001). 
Interestingly, other studies have not only agreed with the finding of Chiasson et al, 
but also, it has been reported that the adult stem cell is a type of astrocyte, since glial 
fibrillary acidic protein (GFAP) immunopositive cells give rise to olfactory bulb 
neurones in vivo (Doetsch et al., 1999) and multipotent neurospheres in vitro (Doetsch 
et al., 1999; Laywell et al., 2000). Similarly, astrocytes of the dentate gyrus have also 
shown to generate neurones (Seri et al., 2001). From these results, it has been 
suggested that these neurogenic astrocytes may be derived from neurogenic radial 
glial cells, which exist at earlier developmental periods (Alvarez-Buylla et a l ,  2001). 
Regardless o f cell identity and origin, the generation of neurones from adult neural 
progenitor cells has generated considerable excitement, not only because these cells 
offer another alternative source of neurones for cell replacement therapies, but also 
their use avoids many o f the difficult ethical issues that are currently limiting the 
progression o f embryonic and foetal stem cells. The use of adult neural progenitor 
cells also offers the possibility o f autologous transplantation, thus avoiding the 
rejection issues associated with transplanting foreign tissue. However, as yet, no
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evidence for the generation of neurones with dopaminergic phenotypes from adult 
neural stem cells has been reported. There are also limited grafting studies showing 
the behaviour of these cells in vivo. One study has showed that expanded adult neural 
progenitors from dentate gyrus differentiate into neurones only when injected into the 
dentate gyrus (Gage et al., 1995b), while another has shown that adult neural 
progenitor cells can behave like endogenous stem cells and migrate along the rostral 
migratory stream and differentiate into olfactory bulb neurones when grafted into the 
SVZ (Suhonen et al., 1996). More recently, grafts of adult neural progenitor cells into 
the intact or 6-OHDA lesioned striatum demonstrated good survival and migration but 
extremely low levels o f  neuronal differentiation (Dziewczapolski et al., 2003). 
Therefore, for adult neural stem cells to be a valid source of neurones for 
transplantation, research must focus on enhancing both the generation of neurones and 
differentiation of these cells into dopaminergic phenotypes. Once this is achieved, 
demonstrating the functionality of these neurones in animal models of PD is an 
essential prerequisite. Interestingly, the ability of endogenous adult neural stem cells 
to generate new neurones in response to ischemic insults (Arvidsson et al., 2002; 
Nakatomi et al., 2002), and infusions o f certain growth factors (Kuhn et al., 1997; 
Fallon et al., 2000; Pencea et al., 2001), has resulted in the exciting possibility of 
simulating endogenous stem cells for the induction of self-repair. Adult neural stem 
cells therefore remain an attractive option. However, substantial progress in this field 
needs to be made before these cells can be considered as a practical option in the 
treatment for Parkinson’s disease.
1.5.5 Plasticity o f  multipotent stem cells
Multipotent stem cells were originally thought to be restricted to forming only cell 
types of the tissue in which they reside. Recent experimental evidence however, has 
questioned this concept, with a plethora of reports showing that multipotent stem cells 
have broader lineage potentials, and respond to regional environmental cues to 
differentiate into a variety o f other cell types.
This remarkable plasticity of stem cells has been demonstrated with cells isolated 
from a diverse range of tissues (for review see Verfaillie., 2002). For instance, bone 
marrow stem cells can differentiate into muscle cells and participate in muscle 
regeneration following injection into damaged muscles (Ferrari et al., 1998), mouse 
skeletal muscle cells can differentiate into a range of blood cells following injection
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into the haematopoietic system o f irradiated mice (Jackson et a l., 1999) and 
haematopoietic stem cells can generate cells o f the liver when intravenously injected 
into a mouse model of liver disease (Lagasse et al., 2000). Neural stem cells, which 
under normal circumstances give rise to neurones, astrocytes and oligodendrocytes, 
have also shown the ability to transdifferentiate and are capable of generating cell 
types from all three germ layers when injected into the developing chick embryo 
(Clarke et al., 2000). These stem cells also generate skeletal muscle both in vitro and 
when injected into regenerating tibialis anterior muscle of the adult mouse (Galli et 
al., 2000), and blood cells when injected into the haematopoietic system of irradiated 
mice (Bjornson et al., 1999). The generation o f neural phenotypes from stem cells o f 
non-neural origins has also been reported and has consequently opened up the 
possibility o f using non-neural cells to provide a source of neurones for 
transplantation studies. Neural cells have been generated from isolated human 
umbilical cord blood cells, which have been shown to express markers associated 
with neurones and glial cells following exposure to specific culture environments 
containing a mixture of growth factors (Sanchez-Ramos et al., 2001; Buzanska et al.,
2002). Bone marrow stem cells also express markers for neural precursors, neurones 
and astrocytes when expanded in epidermal growth factor (EGF), and subsequent 
differentiation in media containing brain derived neurotrophic factor (BDNF) 
(Sanchez-Ramos et al., 2000). Bone marrow stem cells grafted into the brain can 
adopt neural phenotypes, with intraventricular grafts of bone marrow cells into 
neonatal mice showing extensive migration and the generation of astrocytes (Kopen et 
al., 1999). Interestingly, human bone marrow stem cells grafted into the cortex of 
experimental rat stroke models generate functional neural cell types that improve the 
neurological deficits induced by cortical ischemia (Zhao et al., 2002). Functional 
recovery of motor and cognitive deficits is also observed when adult bone marrow 
cells are intravenously injected into mouse models of traumatic brain injury (Lu et al.,
2001).
Collectively, these studies indicate that multipotent stem cells are extremely 
responsive to the environment in which they are placed, and that cells destined to 
generate cells of a particular type could be influenced down alternative pathways, i.e. 
multipotent stem cells show extensive plasticity. The discovery that non-neuronal 
stem cells can transdifferentiate into functional neuronal phenotypes also provides an 
attractive source o f  neurones for cell replacement therapies, particularly because these
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non-neuronal stem cells are relatively more accessible than neural stem cells, and they 
offer the possibility o f autologous transplantation. However, while this cell plasticity 
has generated great excitement in the stem cell field, caution has also been raised, 
with the validity o f transdifferentiation reports being questioned (Vogel., 2002; 
Wurmser & Gage., 2002). Since most reports identify cell types by either their 
morphological characteristics, or by the expression of particular proteins, it has been 
argued that cells may adopt some of the characteristics of other cells, rather than 
completing changing their phenotype, and therefore giving the impression of 
transdifferentiation (Anderson et al., 2001). It has been also suggested that plasticity 
of cultured stem cells could be a characteristic that is acquired through the in vitro 
proliferation of these cells, rather than being an original property of the stem cells 
(Andersen et al., 2001). Support for this cautious approach regarding
transdifferentiation has been recently provided by examining the apparent 
pluripotency of adult bone marrow stem cells (Terada et al., 2002). In this study, adult 
bone marrow stem cells, tagged with the green fluorescent protein (GFP) marker, 
were cultured with embryonic stem cells and shown to generate a variety of different 
cell types including beating cardiac myocytes, thus indicating transdifferentiation. 
However, on closer inspection it was revealed that all transdifferentiated cells 
contained twice as many chromosomes than usual, implying that bone marrow and 
embryonic stem cells had fused together. The generation of the diverse range of cell 
types was therefore, probably a result of embryonic stem cell differentiation and not a 
consequence of adult bone marrow stem cell transdifferentiation. Cell fusion events 
have also been shown to be responsible for the generation of hepatocytes from bone 
marrow stem cells (Wang et al., 2003; Vassilopoulos et al, 2003), and the apparent 
pluripotency of mouse neural stem cells when cultured with embryonic stem cells 
(Ying et al., 2002).
Since the frequency at which cell fusion occurs is lower than the reported rate of 
transdifferentiation (Wurmser & Gage., 2002), the possibility of transdifferentiation 
events cannot be excluded, however, future transdifferentiation studies must proceed 
with caution. Identifying converted cells by merely examining protein expression and 
cell morphology is insufficient, and more rigorous criteria that include testing whether 
the converted cells are functional must be used to conclude that total conversion of 
cells has been achieved.
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1.6 The aims o f this thesis
The research outlined above clearly demonstrates that neurotransplantation can be 
successful in the treatment of Parkinson’s disease under appropriate conditions, and 
that neural progenitor cells have the potential to provide a source of neurones for this 
therapeutic strategy. However, as yet, insufficient neuronal and dopaminergic 
differentiation has been achieved using these cells, and the survival of dopamine 
neurones following transplantation is poor. The following experiments have therefore 
attempted to address these issues by looking at the parameters which affect progenitor 
cell differentiation, and the effects of antioxidant treatment on dopamine survival. In 
chapter three, I assess the capacity o f rat VM, WGE & CTX  neural progenitor cells, 
isolated from a range of embryonic ages to differentiate into neurones following 
different periods o f in vitro expansion. In chapter four, the effects of ascorbic acid on 
the survival of dopamine neurones is examined. Since the in vitro dopaminergic 
differentiation of adult neural progenitor cells has not been reported, chapter five 
evaluates whether these cells have the potential to do so. The following two chapters 
(chapters six & seven) focus on validating a mouse animal model of PD suitable for 
the efficient assessment of the functional potential of mouse embryonic stem cells. In 
chapter six, a unilateral 6-OHDA-lesion mouse model has been established, which 
shows appropriate motor asymmetry following amphetamine stimulation, and in 
chapter seven, the ability of this model to demonstrate graft functionality by 
attenuating rotational bias is assessed.
The results from these experiments will be of fundamental use in future research 
studies, and will also address key issues that need to be resolved before the use of 
stem cells will be of any value in clinical trials of Parkinson’s disease.
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Materials and Methods
This chapter describes the various techniques used in this thesis. The dissections, in 
vitro and surgical techniques employed are discussed in detail The recipes for all 
buffers, solutions etc., can be found in the appendix.
2.1 Subjects
All experiments have been undertaken in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and subject to local ethical reviews. Only female Sprague- 
Dawley rats (Harlan, UK) and female 129P2/OLA Hsd mice (Harlan, UK) were used 
in experiments presented in this thesis. Rats were housed in maximum groups of 4, 
and mice in groups o f 6 per cage. Animals experienced a regular 12 hour light. 12 hour 
dark cycle and had free access to food and water. When necessary, animals were 
killed using schedule 1 procedures that have been approved by the Home Office, UK.
2.2 Embryonic tissue dissection
2.2.1 Isolation o f the embryonic brain
Following terminal anaesthesia and decapitation of mother (schedule 1), pregnant 
rats/mice were laid on their back and the hair from the abdomen was trimmed, 
swabbed with betadine then 70% alcohol. The peritoneum was opened using a vertical 
midline cut first through the skin and then through the fascia o f the abdomen. Using 
clean forceps each uterine horn was gently lifted and the tissue attaching the uterine 
horns to the abdomen was trimmed off using sterile scissors. Embryonic sacs were 
removed from the uterine horns and transferred to a 50ml tube containing fresh sterile 
Hanks buffered saline solution (HBSS, Invitrogen, Paisley, UK). In the dissection 
hood, embryonic sacs were transferred into a Petri dish where embryos were removed 
from their amniotic sacs and transferred into fresh sterile HBSS. At this point the 
embryonic age of the embryos was comfirmed by measuring the Crown-Rump length 
(CRL) of each embryo (Fig. 2.1a). The CRL for embryos aged E ll ,  E l 2, E l 4, E l 6,
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E18 & E20 are 6, 9, 11, 15, 17 & 19mm respectively. Once the embryonic age was 
confirmed the brain was removed (Fig. 2.1a-c). For compliance with legislation, 
embryos older than E l l  are killed by decapitation before brains were removed. The 
method for brain removal was dependant on embryonic age. For embryos under the 
age of El 8, the embryo was placed with the head on the side, and a vertical cut was 
made with a scalpel. The scalpel was drawn along the base of the brain just over the 
eye and snout. Care was taken not to damage the VM or the base of the forebrain. In 
some cases, the brain emerges and is removed, if not, a pair of fine forceps was used 
to slide up under the skull at the start of the cut and the skin and meninges were gently 
peeled away, allowing easy removal o f the brain (Fig. 2.1 a-c). For older 
embryos/neonates (E l8 onwards), after decapitation the thin layer of skull was 
removed by a midline cut from the spine to the snout, along the dorsal surface of the 
brain by using small scissors. The skin and skull were then peeled back each side to 
expose the brain. The brain was then carefully removed and transferred to a 50 ml 
tube containing sterile HBSS kept on ice. The brains were rinsed by transferring 
brains through two Petri dishes containing sterile HBSS.
2.2.2 Dissection o f  the Ventral mesencephalon (VM)
The isolated brains were laid on their side and two vertical cuts were made at each 
ends of the mesencephalic flexure. Two horizontal cuts were also made one-third up 
of the dorsal and ventral surface of the flexure, which ran along the length of the VM 
and between the two vertical cuts (Fig. 2.1d-f). The VM was then separated from its 
surrounding meningeal layer by using forceps to tease the two layers apart, and VM 
tissue was transferred to small sterile Eppendorfs containing HBSS, kept on ice.
2.2.3 Whole ganglionic eminence (WGE) and cortex (CTX) dissection
The brains were laid dorsal side up and the striatal primordial was exposed by making 
a longitudinal cut around the midline of the cortex. The cortex was then cut away. 
When removing the whole ganglionic eminence (WGE), a horizontal cut was made 
underneath the heart-shaped structure, with care taken to avoid going too deep into the 
underlying cortex. If removing the LGE or MGE selectively, first a vertical cut is 
made to divide the LGE from MGE then a horizontal cut is made to remove the tissue
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(Fig. 2.1h-j). The pieces were transferred to small sterile Eppendorfs containing 
HBSS, kept on ice.
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Figure 2.1 Removal and dissection of the rodent embryonic brain. Embryonic age is 
confirmed by measuring the Crown-Rump length (CRL) of each embryo (a). The 
embryos are killed by decapitation (this is required by the Animals Scientific 
Procedures Act 1986 for embryos older than El l ) .  A cut is made across the eye and 
snout (a), and forceps are used to remove the skin (b). The brain is fully exposed and 
is removed ready for dissection (c). To dissect the ventral mesencephalon (VM) (d-f), 
two ventral cuts at the ends of the mesencephalic flexure (1 & 2 in d), and two 
horizontal cuts are made, one on the dorsal surface (3 in d) and one on the ventral 
surface of the brain (4 in e). The butterfly shaped VM tissue is then removed (f). The 
lateral view (g) shows the angles of the two vertical cuts and the location of the 
substantia nigra (sn). To dissect the cortex and the striatal eminence a longitudinal cut 
is made along the cortex, close to the midline (h), this is gently opened up to reveal 
the striatal primordia, and the cortex is cut away (i). To remove the whole ganglionic 
eminence (WGE), a horizontal cut is made underneath the heart-shaped structure (j). 
(Figure adapted from Dunnett & Bjorklund 1992).
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2.3 Adult tissue dissection
2.3.1 Isolation o f  the adult brain and dissection o f  hippocampal tissue
Following schedule 1, 6-week-old Sprague Dawley rats (Harlan, UK) were 
decapitated and the skin on the head was vertically cut from the spine to the snout to 
expose the skull. Using rongeurs, the skull was peeled away with care taken to avoid 
damage the underlying brain. The brain was then carefully removed and transferred to 
a 50 ml centrifuge tube containing sterile HBSS (Invitrogen, Paisley, UK) kept on ice. 
Adult brains were bisected into separate hemispheres and each hippocampal lobe was 
separated from the overlying cortex using the natural separation line along the alveus 
hippocampus (Palmer etal., 1999). The hippocampi were placed in cold sterile HBSS 
and then diced into fine pieces using scalpel blades and placed into a 15ml centrifuge 
tube containing sterile HBSS.
2.4 In vitro techniques - Embryonic tissue
2.4.1 Embryonic Tissue dissociation
Tissue in the Eppendorfs was washed three times with sterile HBSS by using a P I000 
Gilson pipette. Care was taken not to suck up the pieces into the pipette. The final 
wash was removed and tissue was enzymatically digested using a solution of 0.1% 
trypsin (Worthington, Lakewood, USA) and 0.05% DNase (Sigma), at 37°C for 20 
minutes. The trypsin/DNase solution was removed and the dissected tissue was 
washed three times with 200pl 0.05% DNase (Sigma). The final wash was replaced 
with a 200pl volume of DNase (Sigma) and the tissue was mechanically triturated into 
single cells using a P200 Gilson pipette set at approximately 160pi. 10-15 (max) 
aspirations were done initially, and any pieces were left to settle. Further aspirations 
were done if pieces of tissues remained. To determine the number of cells within the 
suspension a cell count was necessary (See section 2.6.1).
2.4.2 Cell Plating, maintenance and differentiation o f embryonic cells
Cells were plated out at an initial density of 100,000 cells per ml of growth media, 
and were seeded in a 25cm2 flask. Thereafter, at each passage, new flasks were seeded 
with 50,000 cells per ml. Growth media consisted of neurobasal medium (Invitrogen), 
supplemented with 1% B27 (Gibco), 1% antibiotic/antimycotic solution (Invitrogen), 
30mM glucose (Sigma), ImM glutamine (Invitrogen), 5mg/m 1 heparin (Sigma) and 
20ng/ml human recombinant bFGF (R&D Systems, Abingdon, UK).
40
Chapter Two
The flasks were then placed in the incubator set at 37 °c, 5% CO2, and 2ml of growth 
media were added to cell cultures every other day.
When cells became confluent or when neurospheres grew to a pre-defined size, cells 
were passaged (see section 2.4.3) and re-plated at a density of 50,000 cells/ml. At the 
same time, 50,000 cells in 30pl differentiation media was plated into wells of a 24- 
well plate containing cover glass slips (13mm diameter) coated with 100pi/ml 
polylysine (Sigma) and 10pl/ml laminin (Sigma) Cells were left in wells for 4-6 hours 
before 0.5ml differentiation media was added, this allowed for sufficient cell 
attachment. Wells were supplemented with 0.5ml differentiation media every other 
day following seeding. Differentiation media consisted of neurobasal medium 
(Invitrogen), supplemented with 1% B27 (Gibco), 1% antibiotic/antimycotic solution 
(Invitrogen), 30mM glucose (Sigma), ImM glutamine (Invitrogen), 50ng/ml bovine 
serum albumin (Sigma), and 1% foetal calf serum (Invitrogen).
2.4.3 Embryonic cell passaging
When cells become confluent, or neurospheres reached a pre-defined size (typically 
0.8- 1mm diameter), cells were transferred from their flasks to 50ml centrifuge tubes. 
Neurospheres and media were withdrawn from their flasks using a pipette, but those 
cells which had adhered to the surface of the flasks were scraped off by using cell 
scrapers, and then media was pipetted into a 50ml centrifuge tube. Cells were then 
centrifuged at 700 rpm for 6 minutes, resulting in cells forming a pellet. The 
supernatant from the centrifuged tubes were poured off into a waste bottle, with the 
final drops of supernatant removed by using a P200 Gilson pipette set at lOOpl. Care 
was taken not to dislodge the pellet o f cells. lOOp! of HBSS was added to the pellet 
and it was gently dislodged. All cells were drawn up into the pipette tip and 
transferred into a sterile 1.5ml Eppendorf. Any further media and cells from the tube 
was removed and placed into the Eppendorf. A further lOOpl of HBSS was used to 
wash down the side of the tube to get all cells, and again transferred into the 
Eppendorf. Using a P200 Gilson set at 160jnl the cells were mechanically dissociated 
by -25 aspirations of the pipette. For the first 10 aspirations, the pipette tip was kept 
pressed against the bottom of the Eppendorf, it was then pulled up slightly for the 
remainder of the aspirations. The aspirations were quite fast,_but care was taken not to
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get too many air bubbles in the medium. A cell count was then taken (see section 
2.6.1) and cells were re-plated at 50,000 cells/ml.
2.5 In vitro techniques - Adult tissue
2.5.1 Adult tissue dissociation
Dissected tissue was enzymatically digested using a solution of 0.01% Papain 
(Worthington Biochemicals, Freehold, NJ). 0.1% neutral protease (Dispase; 
Boehringer Mannheim, Indiaapolis, IN) and 0.01% DNase (Worthington 
Biochemicals, NJ) dissolved in HBSS, at 37°C for 30-45 minutes. The PPD solution 
was removed and replaced by 5-10ml DMEM/F12 (1:1, Invitrogen, Paisley, UK) 
containing 10% FBS (Invitrogen, Paisley, UK). Tissue was mechanically dissociated 
into single cells by gentle trituration using a 10ml pipette. A maximum of 10-15 
aspirations were done before tissue was centrifuged at 400 x g  for 5 minutes. The 
supernatant was removed and the trituration, washing and centrifugation steps were 
repeated at least two more times to ensure the complete removal of PPD and 
maximum tissue dissociation. After the final wash, the supernatant was removed and 
tissue was fractionised using the Percoll buoyancy fraction method (Palmer et al.,
1999). Tissue was mixed with 35% isotonic Percoll solution (Amersham Pharmacia 
Biotech, Uppsala, Sweden) and the cell suspension was then fractionated by 
centrifugation for 10 minutes at 1000 x g. 100% isotonic Percoll solution was made 
by mixing nine parts of Percoll with one part o f 10 * PBS and was diluted to the 
desired concentration by the addition of DMEM/F12 containing 10% FBS. Floating 
myelin and tissue debris were discarded and the cell pellet resuspended in 65% 
Percoll solution and fractionated again by centrifugation for 10 minutes at 1000 x g. 
Any remaining floating debris were removed and the floating neural progenitors 
(~2ml above pellet of red blood cells) were collected and washed free of Percoll by 
centrifugation in DMEM/F12 containing 10% FBS at 400 x g for 5 minutes in 15ml 
centrifuge tubes. The supernatant was removed and cells resuspended in 200pl 
DMEM/F12 containing 10% FBS. To determine the number of cells a cell count was 
required (see section 2.6.1).
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2.5.2 Cell Plating, maintenance and differentiation
Aduit progenitor cell suspension was plated on poly-l-omithine (lOpg/ml, Sigma) and 
laminin (5pg/ml, Sigma) coated 100mm Petri dishes at a density of 500,000 cells per 
dish in DMEM/F12 containing 10% FBS. The dishes were placed in the incubator set 
at 37°c, 5% CO2. After 24 hours, media is removed and replaced by growth media 
consisting of DMEM/F12 supplemented with 1% N2 (Invitrogen, UK) and 20ng/ml 
bFGF (R&D Systems, Abingdon, UK). Most cells will be non-adherent so care must 
be taken when removing media. 75% growth media is replaced every other day, with 
removed media kept as ‘conditioned media’. When cells became confluent the cells 
were passaged see section 2.5.3 and re-plated at 250,000 cells/dish. At the same time,
25,000 cells in 30pl differentiation media were plated into Falcon 8-chamber culture 
slides, coated with poly-l-omithine (10pg/ml) and laminin (5jug/ml). Cells were left in 
chambers for 4-6 hours before 0.5 ml differentiation media was added, this allowed 
for sufficient cell attachment. Chambers were supplemented with 0.5ml differentiation 
media every other day following seeding. Differentiation media consisted of 
DMEM/F12 supplemented with 1% N2, 1% FCS and 0.5pg/ml irons- retinoic acid 
(Sigma).
2.5.3 Cell passaging
When the adult cells become confluent, media were removed and the dish was rinsed 
with 0.025% trypsin solution (Worthington, Lakewood, USA). Trypsin was 
immediately removed and dish incubated at 37°c for 1-2 minutes until the cells began 
to detach. Cells were flooded with conditioned medium and the dish gently tapped to 
loosen cells. The conditioned media and cells were transferred to a 15ml centrifuge 
tube, and centrifuged at 400x g  for 5 minutes to pellet cells. The supernatant from the 
centrifuged tubes was poured off into a waste bottle, with the final drops of 
supernatant removed by using a P200 Gilson pipette set at lOOpl. Care was taken not 
to dislodge the pellet of cells. lOOpl o f conditioned media was added to the pellet and 
it was gently dislodged. All cells were drawn up into the pipette tip and transferred 
into a sterile 1.5ml Eppendorf. A further lOOpl o f conditioned was used to wash down 
the side of the tube to get all cells, and again transferred into the Eppendorf. Using a 
P200 Gilson set at 160pi the cells were mechanically dissociated by -10 aspirations of 
the pipette. The aspirations were quite fast, but care was taken not to get too many air
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bubbles in the medium. A cell count was then taken (see section 2.6.1) and cells were 
resuspended in fresh growth media supplemented with 20% conditioned media and 
re-plated at a density of 25,000 cells/dish.
2.6 General In vitro techniques
2.6.1 Cell counting
Counting the number of cells in the suspension was achieved by using a 
haemocytometer. Because of the substantial numbers of cells in the suspension, the 
cell suspension was diluted prior to the cells being counted. A dilution factor of 50 
was often used and was achieved by the following method.
lOpl cell suspension was transferred into 40pl HBSS and mixed thoroughly. lOpl 
solution was taken from this cell/HBSS mixture and put into another 40pl of fresh 
HBSS. lOpl was then taken from this mixture and put into lOpl trypan blue by using a 
P20 Gilson set at lOpl. With the Gilson set at lOpl, the cells were mixed with the 
HBSS and trypan blue three times. lOpl of cell/trypan blue solution was drawn up and 
transferred under the cover slip o f the haemocytometer and cells were viewed using 
an Olympus stereo microscope.
The grid on the haemocytometer has 25 large squares sub-divided into 16 smaller 
squares. The whole grid was counted. When counting the cells the inclusion/exclusion 
rule was applied -  thus cells touching any of the three lines o f the upper edge and left 
hand side where counted, but cells that touched any o f the three lines on the right hand 
and lower edge were not, even if they were inside the grid. If clumps of cells were 
observed under the microscope, the original suspension was dissociated further by 
more trituration and the counting procedure was repeated. Both live and dead cells 
were counted (live cells are white whereas dead cells stain blue due to the uptake of 
trypan blue through damaged cell membranes), and the total number o f viable cells 
present in one pi of the cell suspension was calculated using the following formula .
No. live cells / pi = number of white cells in whole grid x dilution factor x 10
2.6.2 lmmunocytochemistry and microscopy
After 7 days differentiation, each well containing cells in the 24-well plate or chamber 
slides was emptied o f its media and was washed once with either 0.1M phosphate 
buffered saline (PBS) or HBSS solution (see appendix for further details of solutions).
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PBS or HBSS was removed and cells were fixed with 4% paraformaldehyde (PFA) 
for 20 minutes at 4°C (for GABA staining, cells were fixed a solution o f 4% 
paraformaldehyde and 1% glutaldehyde for 20 minutes at 37°C). PFA was removed 
and cells washed three times with PBS. Cells were then permeabilised with 100% 
ethanol for two minutes. Following 3 washes in PBS, coverslips/chambers were pre­
incubated in 5% normal goat serum (NGS, Dako, Denmark) in PBS for 1 hour at 4°C. 
Coverslips or chambers were incubated with a range of antibodies (13-tubulin-III, 
1:400, Sigma; TH, 1:1000, Chemicon; GABA, 1:100, Diasorin Inc., Stillwater, USA; 
GFAP, 1:2000, Dako, Denmark) in 1% NGS in PBS and left over night at 4°C. 
Primary antibody was not added to at least one well o f each condition, this acted as 
the control. Following 3 washes with PBS, coverslips/chambers were incubated with 
Alexa 488 goat anti-mouse secondary antibody (1:200, Molecular probes, USA) & 
Alexa goat anti-rabbit secondary antibody (1:200, Molecular probes, USA) with 1% 
NGS in PBS or 2 hours at 4°C in the dark. Coverslips and chambers were rinsed with 
PBS then treated with I .25pl/ml o f 0.2mg/ml Hoechst (Fisher, Acros Organics, 
Loughborough, UK) for 4.5 minutes. Following 3 final washes in PBS, coverslips 
were mounted onto uncoated glass microscope slides and chamber slides were 
covered with coverglass using PVA-DABCO mountant and stored at 4°C.
Cells were visualised under UV fluorescence using a Leitz stereomicroscope. Initially 
UV was used to identify Hoescht stained nuclei to obtain a total cell count within a 
grid randomly placed on the coverslips and viewed under 50x magnification. Each 
cell immunopositive for Hoescht was checked for expression of 13-tubulin under 
fluorescence. Cells immunopositive for 13-tubulin were also checked for expression of 
TH or GABA under a different UY wavelength. Counts were made on at least 5 fields 
per coverslip, including a minimum of 250 cells, and on replicates of 3-4 coverslips 
per treatment.
2.7 Surgical procedures
2.7.1 6-Hydroxydopmaine (6-OHDA) lesion
Female Sprague-Dawley rats (~250g) and female 129P2/OLA Hsd mice (~25-30g), 
were anaesthetised using gaseous isoflurane (2-5% in 2:1 02:N2) and received 
unilateral stereotaxic injections of 6-hydroxydopamine hydrobromide (6-OHDA, 
Sigma). Rats received lesions into the right medial forebrain bundle (anterior -4.4,
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lateral -1.8, ventral -7.8, incisor bar -2.3), with mice receiving lesions in either the 
right medial forebrain bundle (anterior-2.0, lateral -0.7, ventral, -4.8, incisor bar 0.0) 
or the right midstriatum (anterior 0.4, lateral -1.8, ventral -3.5, incisor bar 0.0).
Each animal received 4p,g/pl of 6-OHDA dissolved in physiological saline containing 
0.01% ascorbic acid. 6-OHDA was infused over a three-minute period for rats and 
over a one-minute period for mice, at a rate of lpl/min. To allow sufficient diffusion 
o f 6-OHDA, the cannula was left in place for at least 2 minutes before being slowly 
removed.
After lesioning, rats and mice were sutured and injected with 5ml or 0.5ml 0.9% 
saline/glucose solution respectively to prevent dehydration. The drinking water was 
supplemented with Paracetamol for the following 48 hours and animals were carefully 
monitored post-surgery. All animals were allowed to recover for at least 10 days 
before behavioural testing commenced.
2. 7.2 VM cell grafts in 6-OHDA model
Before cell grafting, VM tissue was dissected from E14 rat or E l3 mouse embryos 
and a single cell suspension was prepared as described previously (section 2.2.2). 
Lesioned animals were anaesthetised using gaseous isoflurane (2-5% in 2:1 0 2:N2), 
and VM cells were grafted into the right midstriatum (rats: anterior 0.8, lateral -3, 
ventral -5  & -4.5, incisor bar -2.3; mice, anterior 0.8, lateral -1.8, ventral -3  & -2.5, 
incisor bar -0.0). The cell suspension contained 125,000 cells/jul, with a total of
500,000 being deposited (2pl at each depth) using a Hamilton microsyringe over a 4 
minute period. The syringe was left in place for a further 4 minutes to allow for the 
diffusion of the suspension and to prevent withdrawal of suspension along the needle 
tract. After surgery, rats and mice were sutured and injected with 5ml or 0.5ml 0.9% 
saline/glucose solution respectively to prevent dehydration. The drinking water was 
supplemented with Paracetamol for the following 48 hours and animals were carefully 
monitored post-surgery. All animals were allowed to recover for at least 10 days 
before behavioural testing commenced
2.8 Rotations
The induction o f rotational bias in unilateral dopamine depleted animals following 
pharmacological stimulation was first described by the Swedish scientist Urban
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Ungerstedt in the early 1970’s (Ungerstedt et a l, 1970; Ungerstedt, 1971a; 
Ungerstedt, 1971b). Since rotation reflects the amount o f dopamine loss, this model 
provides a useful way o f assessing the potential of curative treatments by examining 
the attenuation of rotational behaviour.
This model has therefore been extensively used throughout this thesis to assess the 
potential of stem cells, progenitors and neurones to provide functional recovery and 
thus alleviation of rotational bias.
2.8.1 Behavioural testing: Rats
2.8.1.1 Amphetamine and Apomorphine-induced rotations
Amphetamine and apomorphine-induced rotational behaviour was assessed only after 
full recovery from 6-OHDA lesion surgery.
Rats were placed in automated rotation bowls with a diameter of 32cm and height of 
14cm and allowed to habituate for 10 minutes before being injected intraperitoneally 
with either 2.5mg/kg of methamphetamine (Sigma) or subcutaneously with 
0.05mg/kg (dissolved in 0.2% ascorbic saline) apomorphine hydrochloride (Sigma). 
Rats were monitored for either 90 minutes (amphetamine-induced rotations) or 60 
minutes (apomorphine-induced rotations) in a closed room to avoid any 
environmental disturbance. The difference in rotation times was due to the difference 
in the metabolism of the two drugs.
At any one time, 8 rats were rotated simultaneously and the extent of dopamine 
depletion was calculated as a measure of total full body turns. Both ipsilateral and 
contralateral rotations were recorded automatically by an on-line connection to a 
computer (Rotometer activity system, Cambridge, UK). At the end of the testing 
interval, net turns in the dominant direction were calculated.
2.8.2 Behavioural testing: Mice
2.8.2.1 Amphetamine and Apomorphine-induced rotations
Amphetamine and apomorphine-induced rotational behaviour was assessed only after 
full recovery from 6-OHDA lesion surgery.
Mice were placed in cylinders with a diameter of 11.5cm and height of 14cm and 
allowed to habituate for 10 minutes before being injected with either a dose of d- 
amphetamine (Sigma) i.p or with apomorphine hydrochloride (Sigma) s.c.
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Mice were monitored for either 90 minutes (amphetamine-induced rotations) or 48 
minutes (apomorphine-induced rotations) in a closed room to avoid any 
environmental disturbance. The difference in rotation times was due to the difference 
in the metabolism of the two drugs. At any one time, 6 mice were rotated 
simultaneously and the extent of dopamine depletion was calculated as a measure of 
total full body turns. Both ipsilateral and contralateral rotations were recorded over 
the testing interval, with net turns per minute calculated in the dominant direction. 
Each mouse was observed for 1 minute every 6th in a cycle order and rotations were 
recorded. Therefore a total of 15 x 1 minute recordings were made for each mouse 
during amphetamine-induced rotation and 8 x 1 minute recordings during 
apomorphine-induced rotation. Rotation values for each mouse were totalled at the 
end of each run, and values averaged to give the average rotation per minute.
2.9 Histological procedures
2.9.1 Perfusion and sectioning o f 6-OHDA lesioned brains
After behavioural testing, aminals were terminally anaesthetised with 0.5ml Euthatal 
and transcardially perfused with phosphate buffered saline (PBS), pH 7.4 for 1 
minute, followed by fixation in 4% paraformaldehyde (PFA), pH 7.4 for 2 minutes for 
mice or 3-4 minutes for rats. The brains were removed and post fixed in PFA for a 
further 24 hours before being placed in PBS containing 25% sucrose. The brains were 
left overnight at room temperature by which time the brains had sunk and were ready 
for sectioning.
Brains were coronally sectioned on a microtome at 40pm and stored in 96 well plates 
at 4°C in Tris buffered 0.9% saline (TBS), pH 7.4, containing 0.5% sodium azide. 
Sodium azide was added to inhibit bacterial and fungal growth that may damage the 
tissue sections. While sectioning the midbrains, the non-lesioned side (left side) was 
marked by pushing a fine needle through the brain towards the cerebellum, and a cut 
was made on the left hand side cortex. This provided a clear marking which 
distinguished the lesioned side from the non-lesion side of the brain.
2.9.2 Immunohistochemical staining o f brain sections
Selected brain sections were quenched with 10% hydrogen peroxide and 10% 
methanol in distilled water for 5 minutes followed by three 10-minute washes in Tris
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Buffered Saline (TBS). Sections were then placed in TXTBS (TBS containing 0.2% 
Triton X-100) containing 3% normal goat serum (NGS) for 60 minutes. Without 
washing, brain sections were incubated overnight at room temperature, or over 2 
nights at 4°c in TXTBS containing the primary rabbit anti-tyrosine Hydroxylase (TH) 
antibody at a concentration of 1:1000 (Chemicon int., Temecula, CA). After three 10 
minute washes with TBS, sections were incubated at room temperature for 3 hours in 
the secondary biotinylated goat anti-rabbit antibody at a concentration of 1:200 
(DAKO, Denmark) in TBS. Sections were washed in TBS before being incubated for 
a further 2 hours at room temperature in strepavidin-biotin complex (DAKO) in TBS 
with 1% normal goat serum. After three 10 minutes washes in TBS, sections were 
washed in TNS (distilled water containing 0.6% trizma base), and left overnight at 
4°C. TH positive cells in the substantia nigra were visualised by the reaction with 
vector SG kit (DAKO) until appropriate colour change had taken place. Washing 
sections twice in TNS stopped the reaction.
Sections were mounted on gelatinised glass slides, air dried overnight and dehydrated 
in an ascending series of alcohols, cleared in xylene, and coversliped with DPX.
2.9.3 Lesion analysis
Counting the number of TH positive cells in the substantia nigra was achieved by 
counting every third 40pm coronal brain section at a magnification o f 250X using a 
Leitz Dialux 22 microscope. Only those cells that were clearly stained and with 
dentritic processes were counted on both the lesioned and non-lesioned side of the 
brain. Counting cells on the non-lesioned side served as a control. Segregation of the 
ventral tegmental area (VTA) and the substantia nigra was achieved by using the 
medial terminal nucleus of the accessory optic tract as a landmark, as described by 
Lee et al., (1996) and Bensadoun et al., (2000).
TH cell numbers on the lesioned and non-lesioned sides of the brain were totalled and 
the percentage TH loss on the lesioned side was calculated, thus giving an indication 
of the degree of lesioning. Figure 2.4 shows photographs of a typical 6-OHDA 
lesioned mouse brain. There is dopamine depletion at the striatal level, and obvious 
dopamine reduction in the substantia nigra on the lesioned side. The medial terminal 
nucleus of the accessory optic tract, which separated the VTA from substania nigra, is 
also shown.
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Figure 2.4 Unilateral 6-OHDA lesions of the 129 OLA mouse brain. Unilateral 
lesions of dopaminergic neurones are clearly visible due to the reduction of tyrosine 
hydroxylase staining on the lesioned side (right). At both the levels o f the striatum (A) 
and the substantia nigra (SN) (B), the lesioned side is depleted of dopamine. Cutting 
the cortex and punching the brain on the non-lesioned side provided a suitable 
marking confirming the lesioned and non-lesioned side (black arrows in B). The 
medial terminal nucleus of the accessory optic tract (MTN) was used as a landmark 
allowing the distinction between the dopamine neurones of the ventral tegmental area 
(VTA) and the substantia nigra (C). Only cells with clearly labelled cell bodies and 
dendritic processes where counted (D). Scale bars in A & B = 1mm, C = 0.5mm, D = 
100pm.
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2.9.4 Striatal dopaminergic graft analysis
Counting the number o f TH positive ceils in the striatum was achieved by counting 
every sixth 40jj.ni coronal brain section at a magnification of 200X using a Leitz 
Dialux 22 microscope. Only those TH cells that were clearly stained and with 
dentritic processes were counted. Once sections from a single animal brain were 
counted, the number of TH cells from each section was combined, thus giving the 
total number o f TH cells per animal. The average TH cell diameter was then 
calculated by measuring at least 50 random TH positive cells using an Olympus BX50 
microscope and an Olympus C A S T  grid system.
The total number of TH cells present in each brain was calculated using the 
Abercrombie correction formula (Abercrombie., 1946).
Abercrombie correction formula: 
Total number of cells = F x A x M/(D+M)
Where F = Frequency of sections i.e. 1 in 6 
A = Cell counts for entire animal 
M = Section thickness 
D = Average cell diameter
Figure 2.5 shows photographs of a typical grafted rat brain. Grafts of dopamine 
neurones in the denervated striatum are shown and individual TH positive dopamine 
neurones are observed at higher magnification.
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Figure 2.5 VM grafts into the striatum o f the rodent brain. Figure A shows the striata 
o f a non-lesioned brain. TH expression in both the left and right striatum is evident 
(A). Unilateral 6-OHDA lesions o f  the medial forebrain bundle results in decreased 
TH expression in the striatum as shown in B. Figure B also shows the presence of 
grafts o f VM tissue within the striatum and the characteristic halo o f  TH innervation. 
At higher magnification, the graft is more evident (C), and individual TH neurones 
derived from the grafts are clearly visible (D). Scale bars in A & B = 1mm, C = 
0.5mm, D = 100pm.
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(Experiment One - dhe effects o f region, progenitor age and in 
vitro proliferation on the neurogenic potentiaC of rat neural
progenitor cells
Summary
This chapter discusses the effects o f progenitor age and prolonged in vitro 
proliferation on the neurogenic potential o f neural progenitor cells.
Neural progenitor cells were isolated from the developing rat VM, WGE and CTX, at 
ages ranging from E l l  to E20, and cultured in vitro for up to 40 days. Following 
periods of proliferation, progenitor cells were differentiated into neural phenotypes, 
and the neurogenic potential o f the progenitors was assessed by counting the number 
of cells immunopositive for the neuronal marker P-tubulin-III.
The results from this study show regional differences in the neurogenic potential of 
progenitors, with cells from the WGE generally generating the highest percentage of 
neurones and progenitors from the VM generating the least. The yield of primary 
neurones and percentage neurogenesis of progenitor cells was also shown to differ 
with age, with the neurogenic capacity of WGE and CTX progenitors behaving 
similar to each other, but different to progenitor cells o f the VM across the age range. 
A significant decrease in neurogenesis was also observed with all progenitors, at all 
ages after increasing time of expansion in vitro, with passage 5 progenitor cells 
generating ~2% neurones, compared to passage 1 progenitors where a maximum yield 
of 25% neurones was observed.
From this assessment we propose that neural progenitor cells isolated from the same 
region but different ages, behave differently, and that the capacity of neural progenitor 
cells to differentiate into neurones is significantly reduced with increased time in 
vitro.
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3.1 Introduction
The initial reports showing the successful in vitro proliferation and neural 
differentiation o f progenitor cells isolated from the embryonic and adult mouse brain 
(Murphy et al., 1990; Reynolds et al., 1992; Reynolds & Weiss., 1992) have provided 
a useful in vitro model for studying neural development.
With the establishment of this in vitro model, a plethora of reports have been 
published evaluating the characteristics o f progenitor cells isolated from distinct areas 
of the rodent (Rosser et al., 1997; Tang et al., 2002; Smith et al., 2003; 
Dziewczapolski e ta l., 2003), pig (Armstrong et al., 2003) and human brain (Storch et 
al., 2001; Riaz et al., 2002; Wu et al., 2002; Li et al., 2005).
During proliferation, these progenitor cells typically form cell clusters or free-floating 
aggregates termed “neurospheres” (Reynolds & Weiss., 1992), with mitogens such as 
epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) being 
essential for the survival and proliferation of these cells (Murphy et al., 1990; 
Mytilineou et al., 1992; Vescovi et al., 1993; Qian et al., 1997). Subsequent 
differentiation into a host of neural phenotypes is achieved by mitogen withdrawal, 
although, neuronal differentiation down particular phenotypic lineages has been 
shown to be influenced by a variety of additional factors. This plasticity o f progenitor 
cells has resulted in the manipulation of the culture conditions for optimal generation 
of specific neuronal phenotypes, in particular dopamine neurones that can be used to 
replace the dopaminergic neurones lost in Parkinson’s disease (Ling et al., 1998; 
Studer et al., 2000; Yan et al., 2001).
Neural progenitor cells have been shown to generate neurones in culture and when 
transplanted into the brain, therefore the use of progenitor cells as an alternative 
source of tissue for transplantation in neurodegenerative disease has great potential, 
providing that these progenitors can survive, integrate and generate functional 
dopamine neurones following grafting into the adult brain.
When expanded human and rat EGF-responsive progenitor cells, isolated from the 
developing mesencephalon or striatum, are transplanted into ibotenic acid or 6- 
OHDA lesioned rats however, there is poor survival o f cells, resulting in thin grafts, 
limited migration into the surrounding host tissue and no attenuation o f rotational 
behaviour (Svendsen et al., 1996). Similarly, grafts of expanded progenitor cells 
isolated from the developing pig ventral mesencephalon have also failed to show any
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attenuation o f rotational bias in 6-OHDA lesioned rats (Armstrong et al., 2003), 
suggesting that progenitor cells may not be capable o f generating neurones that are 
functional. However, bFGF and EGF-responsive human progenitor cells, when 
expanded and grafted into the dopamine-depleted rats have shown more encouraging 
results. Not only were large grafts formed, but progenitor cells also showed migration 
and differentiation into astrocytes and functional dopamine neurones that reduced 
rotational bias (Svendsen et al., 1997a). Although only 2 rats showed a reduction in 
rotation, this report illustrates that expanded progenitor cells do have the ability to 
generate neurones capable of alleviating behavioural deficits. More recently, the 
differentiation o f expanded rat VM progenitors into functional dopamine neurones 
has also been shown following transplantation into the brain, with resultant grafts 
being similar in size as those typically seen with grafts of primary tissue (Studer et 
al., 1998). In this study, progenitor cells were expanded and transplanted as 
differentiated floating aggregates, thus avoiding the enzymatic or mechanical 
dissociation of cells that can lead to destruction o f axodendritic trees and cell death. 
Together these reports indicate that progenitor cells have the capacity to generate 
functional neurones, and therefore the use of progenitor cells in neurotransplantation 
strategies is a real possibility.
The potential o f neural progenitor cells to generate neurones is apparent at a variety of 
ages, with progenitors isolated from E12 (Studer et a/., 2000; Yan et al., 2001), E 14 
(Brundin et al., 1988; Ostenfeld et al., 1999; 2002), E16 (Brundin et al., 1988; 
Svendsen et al., 1997b), E l8 (Svendsen et al., 1995), E20 (Brundin et al., 1988) and 
from the adult brain (Gage et al., 1995b; Palmer et al., 1995; 1997) all showing 
proliferation and differentiation into a range of neural phenotypes.
At present a clear difference in the neurogenic potential between embryonic and adult 
progenitors is apparent, with embryonic progenitors being able to generate abundant 
neurones, but adult progenitors showing restricted neurogenesis. However, it is 
currently unclear whether progenitor cells from the same region, but at different 
gestational ages are the same and have similar neurogenic potentials, or are different 
and have distinct properties. Previous reports indicate that age has a significant effect 
on the behaviour o f progenitor cells, with progenitors isolated from the developing 
pig VM at ages corresponding to E ll/1 2  & E14 in the rat, having different in vitro 
and in vivo characteristics (Armstrong et al., 2003). Primary rat VM-derived neurones
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of different ages have also shown different properties, with neurones isolated at E l4- 
16 showing functional recovery o f behavioural deficits induced by 6-OHDA lesions, 
compared to neurones isolated at E20 that do not (Brundin et al., 1988). More 
recently, a report has shown the importance of the age of rat neural progenitor cells 
isolated from the VM at ages El 2-El 4. In this study, the size of neurospheres, 
percentage of neurones and TH positive neurones, as well as percentage of 
oligodendrocytes and astrocytes generated were dependent on progenitor age 
(O’Keeffe & Sullivan., 2004). Together these reports suggest that progenitors from 
different ages behave differently.
There is also a degree of uncertainty about the neurogenic potential o f progenitor cells 
after prolonged periods in vitro (Smith et a l., 2003). In theory, one of the 
characteristics of progenitor cells, which make them so appealing, is their ability to 
generate a continuous and plentiful source of neurones. If  progenitor cells cannot 
fulfil this requirement, these cells will be of no benefit in providing an alternative 
source of neurones for transplantation.
To address these issues, progenitor cells have been isolated from the ventral 
mesencephalon (VM), whole ganglionic eminence (WGE) and the cortex (CTX) of 
the developing rat brain, at ages ranging from embryonic day 11 (E ll)  to embryonic 
day 20 (E20). Progenitor cells underwent 7 days differentiation at the time of 
dissection (primary cells), and following 7-10 days (passage 1), 21-25 days (passage 
3) and 35-40 days (passage 5) of in vitro proliferation. The extent of neurogenesis has 
been assessed for progenitors at each age, region and passage, thus providing a large, 
parametric study on the neurogenic potential of rat neural progenitor cells.
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3,2 Experimental Procedure
A detailed description o f the dissection procedure and the in vitro techniques used in 
this chapter can be found in chapter two, section 2.2, 2.4 & 2.6.
Before dissection of the relevant brain tissue, the gestational age of the rat embryos 
was confirmed by measuring the crown-rump length (CRL, see chapter two, section 
2.2). Dissected tissue was dissociated (chapter two, section 2.4) and proliferated in 
growth media consisting o f neurobasal medium, supplemented with, 20ng/ml bFGF, 
1% B27 (Gibco), 1% antibiotic/antimycotic solution (Invitrogen), 30mM glucose 
(Sigma), ImM glutamine (Invitrogen) and 5mg/ml heparin (Sigma) at 37°C & 5% 
CO2. Cells were carefully monitored in vitro, and when neurospheres reached a pre­
defined size (typically 0.8-lmm diameter), the neurospheres were dissociated into 
single cells (passaged, see chapter two, section 2.5.3) by mechanical trituration and 
re-plated at 500,000 cells/ml, thus preventing death o f those cells within the centre of 
the spheres. Cells were differentiated over a 7 day period in differentiation media 
consisting o f neurobasal medium, supplemented with 1% B27, 1%
antibiotic/antimycotic solution, 30mM glucose, ImM glutamine, 50ng/ml bovine 
serum albumin, and 1% foetal calf serum. Primary cells were differentiated at the time 
of dissection (passage 0), and progenitors following 7-10 days (passage 1), 21-25 days 
(passage 3) and 35-40 (passage 5) days of proliferation. Following 7 days 
differentiation, cells were fixed in 4% PFA and stained with the marker j3-tubulin-III 
for the identification of neurones. Neurones were also stained for TH and GABA 
expression (see chapter two, section 2.6.2).
To normalise the variance data was plotted on a log scale rather than a linear scale.
All experiments were repeated three times and statistical tests o f analysis of variance 
(ANOVA) were analysed using the statistical package Genstat v7.2, with further 
analysis of the results being achieved by using the Neuman Keuls t-test.
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3.3 Results
3.3.1 Cell culture
Cells isolated from the ventral mesencephalon (VM), whole ganglionic eminence 
(WGE) and the cortex (CTX), at ages ranging from El 1-20 all generated free-floating 
aggregates (neurospheres) within two days of in vitro proliferation (Fig. 3.1 A). 
Neurospheres proliferated extensively in vitro and were dissociated into single cells 
(passaged) when they reached a pre-defined size, a point that was typically reached 
after approximately 7-10 days in vitro. Interestingly, cells isolated at ages ranging 
from E ll-E l 6 generally proliferated faster than cells isolated at older donor ages and 
were subsequently passaged at earlier time points.
During differentiation, all cells formed monolayer cultures that adhered to the culture 
flasks, and based on their morphological characteristics, cultures o f cells from all 
regions and ages contained different cell phenotypes. All neuronal phenotypes were 
identified using the neuronal marker p-tubulin-III (Fig. 3 .IB). Dopaminergic and 
GABAergic neurones were also identified by examining neurones immunopositive for 
the antibodies tyrosine hydroxylase (Fig. 3.1C) and GABA (Fig. 3.ID) respectively.
' ■ "•
Figure 3.1 Cell cultures of neural progenitor cells. All cells types proliferated as 
neurospheres (A). Following differentiation, neurones were identified using the 
neuronal marker p-tubulin-III and visualised using green fluorescence (B). 
Dopaminergic and GABAergic neurones were identified using TH (C) and GABA 
(D) respectively, and were visualised using red fluorescence. Scale bar = 0.5mm in A 
& 100pm in B, C &D.
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3.3.2 Neuronal expression o f  primary cells
The generation o f neurones from primary ceils (cells differentiated at the time of 
dissection), isolated from the ventral mesencephalon (VM), whole ganglionic 
eminence (WGE) and cortex (CTX), at ages ranging from E11-E20 can be seen in 
Fig. 3 .2. Since these cells did not undergo any in vitro expansion, the majority of the 
cells immunopositive for p-tubulin-III probably reflect the number of neurones 
isolated at the time of dissection, rather than the number being derived by neural 
progenitor cells. For this reason, primary cell data and data from expanded cells 
cannot be directly compared.
Primary cell cultures from all three regions, and at all ages showed large neuronal 
yields, with nearly all cultures yielding over 50% neurones, and some exceeding a 
neuronal yield of 70% (Fig. 3.2a). A significant difference in the percentage of 
neurones isolated from different regions was observed (F(2,226)=58.64, p<0.001), with 
primary cells from the WGE and CTX showing higher neuronal yields compared to 
the cells from VM at most ages. A significant effect o f embryonic age on neuronal 
yield was also seen (F(6,226>= 12.52, p<0.001). Peak neuronal expression of VM 
primary cells occurred at E l4, with a decline in neuronal expression post E14 (Fig. 
3 .2a & 3 .2b). At E20, primary VM cells showed significantly less neurones compared 
to the cells isolated from the VM at the ages E13 (NK: 6)=6.391, p<0.05) & E14
(NK: t(6,7)=8.355, p<0.01) (Fig. 3.2a & b).
Neurones from WGE primary tissue at ages E ll-13  showed little variation in 
neuronal numbers with all three ages showing approximately 60% neurones. The 
optimal age to isolate neurones from the WGE was at E l4-18. At these ages, WGE 
primary cells yielded significantly more neurones compared to all other ages 
(p<0.01). At E20, primary cells expressed the same number o f neurones as seen at 
E l 1-13 (Fig. 3.2a & c).
Primary cells isolated from the cortex (CTX) behaved in a similar fashion to primary 
WGE cells with significantly higher number of neurones being observed at ages EM- 
18 compared to all other ages (p<0.05). At earlier ages (Ell-13), there were slight, 
but insignificant fluctuations in the percentage of neurones, with all three ages 
generating between 55-62% neurones. E20 primary cells showed similar properties to 
these early age cells by yielding approximately 57% neurones (Fig. 3.2a & d).
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Figure 3.2 Neurogenic properties o f primary cells isolated from three different brain
regions (VM; black bars, WGE; grey bars & CTX; white bars) at different embryonic 
ages (a). Both a significant difference in neurogenic potential with region (p<0.001) 
and with embryonic age (p<0.001) was observed. Individual graphs showing the 
neurogenic properties of primary cells isolated from the VM (b), WGE (c) & CTX (d) 
at different embryonic ages are also shown. VM cells generate higher numbers of 
neurones at ages E l4, with a reduction post E l4 (b). Peak neurogenesis for primary 
WGE & CTX cells occurs at ages E14-18 (c & d), with cells at E20 showing a 
reduction in neuronal yields. Data expressed as mean ± S.E.M. across three separate 
experiments. **p<0.01 vs. E l l ,  E12, E13 & E20, *p<0.05 vs. E l l ,  E12, E13 & E20,
**a p<0.05 vs. E13, **b p<0.05 vs. E14
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3.3.3 Generation o f  TH positive and GABAergic neurones from primary cells 
The proportion o f primary cell-derived neurones, which were of GABAergic and 
possible dopaminergic phenotypes, was determined by examining the number of 
neurones immunopositive for gamma-amino butyric acid (GABA) and tyrosine 
hydroxylase (TH) respectively (It is important to note that TH is not a specific 
dopaminergic marker and therefore all cells that are immunopositive for this antibody 
are only potentially of dopaminergic phenotypes) (Fig. 3 .1C & D).
TH immunopositive neurones were only expressed in neurones derived from VM 
cells, and not in WGE or CTX primary neurones (Fig. 3.3a), whereas, GABA 
expression was evident in neurones derived from all three regions (Fig. 3 .3b).
The percentage of TH positive neurones expressed by primary VM cells varied 
significantly with age (F(6,98)=33.09, p<0.001), with values ranging from ~4-12% (Fig. 
3.3a). Neurones derived from E12-14, generated significantly higher percentages of 
neurones immunopositive for TH compared to all other ages (p<0.01), with no 
significant difference between these ages being observed. At ages, E11,E16, E18&  
E20, the percentage of TH positive neurones varied between 4-7% and were not 
significantly different from each other.
For the expression o f GABA, only four age points (E l2, E l4, E16 & E20) for each 
region were compared. The percentage o f neurones immunopositive for GABA 
ranged from ~1-17% (Fig. 3.3b), with a significant difference in GABA expression 
across the age range (F(3,80)=41.49, p<0.001), region (F(2,80)= 109.56, p<0.001), and 
with region x age (F(5.80)=23.11, p<0.001) being observed. Primary WGE neurones 
expressed a greater percentage of GABA at all ages, with primary CTX neurones 
expressing the least, apart from at E20 where VM cells expressed fewer GABAergic 
neurones (Fig. 3.3b). (NB Glutamate, the main neurotransmitter for CTX cells was not 
examined in this study because CTX cells were only used as control group for 
proliferation and differentiation tests).
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Figure 3.3 Percentage TH (a) and GABA (b) neurones generated from primary VM, 
WGE & CTX cells at different ages. Only VM cells generated TH positive neurones. 
A significant effect o f age on TH expression was observed (p<0.01). Although 
GABAergic neurones were generated by primary cells from all regions, a significant 
difference in neurones from different regions expressing GABA was observed 
(p<0.001). Data expressed as mean + S.E.M. across three separate experiments. 
**p<0.01 vs. E l 1, E l 6, E l 8 & E20.
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3.3.4 Neurogenic potential o f  short-term cultured progenitor cells 
Figure 3.4 shows the percentage o f neurones generated by different aged progenitor 
cells isolated from three different brain regions after 7-10 days proliferation and 
subsequent 7 days differentiation (passage 1).
Progenitor cells from all three regions and at all ages generated neurones, with 
neuronal yield ranging from 10-25% (Fig. 3.4a). A significant difference in the 
percentage of neurones generated by progenitors from different regions was observed 
(F(2,2i9)=52.85, p<0.001), with VM progenitor cells generating fewer neurones 
compared to WGE and CTX progenitors at most ages. Progenitor cells isolated from 
the CTX generated the most neurones, except at E14 & E16 where neurogenesis of 
WGE progenitors was greater (Fig. 3 .4a).
A significant difference of age on the neurogenic capacity of progenitors was also 
observed (F(2,2i9)=991, p<0.001). Peak neurogenesis o f VM progenitors was 
significantly higher at E14 than at E l3 (p<0.05), and all other ages (p<0.01, Fig. 3.4a 
& 3.4b). WGE progenitors showed significantly higher neurogenesis at E l4-16 when 
compared to all other ages (p<0.01, Fig. 3.4a & 3.4c), however, little difference was 
observed with CTX progenitors, with all ages generating similar percentage of 
neurones (Fig. 3.4a & 3.4d).
When compared to primary cell data, a significant reduction in neurogenesis for all 
cultured progenitors was observed (F(i54g)=5944.88, p<0.001, Fig. 3.5a & b).
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Figure 3.4 Neurogenic properties of different aged progenitor cells isolated from 
three different brain regions (VM, WGE & CTX), following 7-10 days proliferation 
(a). Both a significant difference in region and embryonic age on neuronal yield is 
observed (p<0.001 & p<0.001 respectively). Individual graphs showing the 
neurogenic properties o f different aged progenitor cells isolated from the VM (b), 
WGE (c) & CTX (d), following 7-10 days proliferation are also shown. VM 
progenitors generate higher numbers of neurones at ages E13-14. Peak neurogenesis 
for WGE progenitors occurs at E14-16. No significant peak in neurogenesis is 
observed for progenitors isolated from the CTX. Data expressed as mean ± S.E.M. 
across three separate experiments. **a p<0.01 vs. all ages except E13, *b p<0.05 vs. 
E 13, **cp<0.01 vs. all ages except E16, *Vp<0.01 vs. all ages except E14
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Figure 3.5 A significant difference in the neurogenic potential of primary cells (a) 
and cultured progenitor cells (b) is clearly observed (p<0.001). Data expressed as 
mean ± S.E.M. across three separate experiments.
65
Chapter Three
3.3.5 Generation o f  TH positive and GABAergic neurones from cultured progenitor 
cells
After 7-10 days proliferation and 7 days differentiation (passage 1), progenitor cells 
isolated from the VM, WGE & CTX failed to generate any neurones expressing TH. 
Neurones did show the expression of GAB A, however, the percentage of GABAergic 
neurones was fewer than 5% for all regions and ages (Fig. 3 .6).
Because of the relatively low numbers of GABAergic expression, there was no 
significant difference in the amount of GABAergic neurones generated by progenitor 
cells from different regions (F(2,78)=0-78, n.s), or at different ages F(3j8)=0.64, n.s).
10.0  -
> i
I
Figure 3.6 Percentage of GABAergic neurones generated from progenitors following 
7-10 days in culture. Fewer than 5% of neurones expressed GABA for all regions and 
ages. No significant difference in the numbers of GABAergic neurones generated by 
progenitors from different regions or across the age range is observed. Data expressed 
as mean ± S.E.M. across three separate experiments.
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3.3.6 Neurogenic potential o f long-term cultured progenitor cells 
Figure 3.7 shows the effect o f  in vitro proliferation o f E 12, E 14, E 16 & E20 rat VM, 
WGE & CTX progenitor cells for up to 40 days (passage 5). The behaviour of 
primary and short-term cultured (passage one) progenitor cells has been described 
previously (section 3.3.2 & 3.3.4), so only passage 3 and passage 5 data will be 
discussed here.
Following 21-25 days proliferation and subsequent differentiation (passage 3), 
progenitor cells isolated from the VM, WGE & CTX generated less than 10% 
neurones (Fig 3.7c). WGE & CTX progenitors generated similar percentages of 
neurones, except at E20 where neurogenesis o f  CTX progenitors was greater. VM 
progenitors again generated lower number o f neurones when compared to progenitors 
from the WGE & CTX (Fig. 3.7c).
The neurogenic capacity of VM & CTX progenitors was not affected by age, with 
progenitors generating constant percentages of neurones across the four ages. An 
effect of age was however observed for WGE progenitors with a decline in 
neurogenesis at E20 (Fig. 3.7c).
After 35-40 days proliferation (passage 5), progenitor cells from all regions generated 
less than 2% neurones (Fig. 3.7d). At E12 & E l4, VM progenitors generated the 
lowest percentage of neurones, with WGE progenitors generating the most. At E l 6 & 
E20 however, most neurones were generated by progenitors isolated from the CTX. 
Neurogenesis of CTX progenitors remained stable over the age range with no change 
in neurogenesis. WGE progenitors showed decreased neurogenesis at E l6 & E20, 
with VM progenitors showing decreased neurogenesis at E20 (Fig. 3 .7d).
Statistical comparison of all o f the data showed an effect of region (F(2,497)=33.60, 
p<0.001), age (F(3,497)=23.53, p<0.001) and proliferation (F(3,497)=2716.86, p<0.001) 
on the percentage of neurones generated by progenitor cells.
The decline in neurogenesis for progenitors from all regions following culturing is 
highlighted in Fig. 3.8a-c. The rate of neurogenesis for VM progenitors at E12, E14 & 
E16 was similar, however, E20 VM progenitors showed a reduced rate of 
neurogenesis at passage three (21-25 days proliferation) when compared to the other 
ages (Fig. 3.8a). WGE progenitors at E l2, E14 & E20 showed similar rates of 
neurogenesis, with E16 progenitors showing slightly higher rates at passage five (Fig. 
3 .8b). No difference in the rate of neurogenesis was observed with CTX progenitors at 
all ages (Fig. 3.8c).
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Figure 3.7 Neurogenic potential of primary (a) and 7-10 day (a), 21-25 day (c) & 35- 
40 day (d) proliferated progenitor cells, isolated from the VM, WGE & CTX. A  
significant decline in neurogenesis is observed following the culturing of progenitor 
cells from all regions (p<0.001). Data expressed as mean ± S.E.M. across three 
separate experiments.
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Figure 3.8 Rate o f neurogenesis for progenitors isolated from the VM (a), WGE (b) 
& CTX (c). The decrease in neurogenesis following time in culture is clearly observed 
for all progenitors.
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3.3.7 Percentage Neurones vs. Total neurones
During cell analysis, it was apparent that the number o f cells on the coverslips varied 
with age. To see whether this had any significance on the results, the percentage 
neuronal yield (percentage of 250-300 viable cells counted that were neurones) was 
compared to total neuronal yield (calculated from the total number of viable cells per 
culture) (Fig. 3 .9-3 .11). Since the percentage of neurones derived from primary VM, 
WGE & CTX cells have been discussed previously (section 3.3.2) only total neurone 
data will be discussed here.
Similar to the percentage neuronal yield of VM cells (see section 3.3.2), the total 
number of neurones derived from VM cells showed an age dependent effect 
(F(6,55)=47.15, p<0.001). However, unlike the percentage neuronal yield data where 
peak neuronal expression for VM cells was observed at E l4, total neuronal counts 
showed that E12 VM cells generated a significantly higher neuronal yield compared 
to all other ages (p<0.01), with neuronal yield gradually declining at E13 & E14, and 
a large decline at E l6 being observed (Fig. 3.9a). In addition, the total number of 
neurones derived from E ll ,  E13 & E14 were not significantly different from each 
other, but were significantly higher than the neuronal yield from cells at E16-E20, 
(p<0.01, Fig. 3.9a).
Data showing the percentage of TH positive neurones generated from VM cells is 
described in section 3.3.3. Similar to this data, the total number of TH positive 
neurones derived from VM cells also showed a significant effect of age (F(6,5 >=81.76 
p<0.001). Significantly more neurones expressing TH, were however derived from 
E12 VM cells when compared to cells derived from E13 & E14 (NK; t(6,2)=5.298, 
p<0.05) & (NK: t(6,3>=5.978, p<0.05), which is in contrast to the percentage TH data 
where cells from El 2-El 4 showed peak TH expression.
No significant difference in number o f neurones expressing TH at E13 and E 14 was 
observed (NK: t<6,2)=0.680, n.s), and primary cells from E l l ,  E16, E18 & E20 derived 
significantly less TH neurones when compared to progenitors from all other ages 
(p<0.01, Fig. 3.9b).
When counting total neurones derived from WGE cells, a significant variation in 
neuronal numbers generated by primary cells from different ages was observed
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(F(6,4i)=9.12, p<0.001). Primary cells from E l6 generated greater numbers of neurones 
than at all other ages, with the amount o f neurones declining at E18 & E20 (Fig. 
3.10a). This is in contrast to the percentage neuronal yield data, where peak neuronal 
expression was observed at E l4-18.
The total number of GABAergic neurones generated by primary WGE cells is shown 
in Fig 3.10b. Like percentage WGE data (see 3.3.3), the total number of GABAergic 
neurones generated by WGE cells varies significantly with age (F(3,23)=13.93, 
P<0.001), with peak GABAergic expression occurring at E l6, and the lowest number 
of GABAergic neurones being generated at E20 (Fig. 3.10b). Analysis of the data 
shows that GABAergic expression at E16 is significantly higher compared to 
expression at E12 (NK: t(3,3) = 10.8, p<0.01), E14 (NK: t^ 3,2>=9.272, p<0.01) & E20 
(NK: to,4)=13.435, p<0.01).
Figure 3 .11a shows the total number of neurones generated by primary cells isolated 
from the CTX. Similar to the data showing the percentage of neurones generated by 
CTX cells, the total number of neurones showed significant variation with age 
(F(6.4i)=5.07, p<0.001). However, despite the percentage neuronal data showing peak 
neuronal yield at E l4-18 (see sction 3.3.2), the data from total number of neurones 
shows that the neuronal yield remains relatively stable across the ages of E l 1 -E l6, 
with a reduction in neurones at E l8 & E20 being observed (Fig. 3.1 la).
In addition, while the percentage GABAergic neurones generated by primary CTX 
cells shows no significant effect of age, the total number of neurones expressing 
GAB A does; (F(3j23)=3.7, p<0.05), with GAB A expression peaking at E14 (Fig. 
3.11b).
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Figure 3.9 Graph showing the total neuronal yield (a), and the total number of TH 
positive neurones (b), derived from primary cells isolated from the VM at different 
ages. A significant difference o f age on both the total number of neurones and TH 
positive neurones derived from VM cells is observed (p<0.001). Data expressed as 
mean ± S.E.M. across three separate experiments. **a p<0.01 v.v. all other ages, **b 
p<0.01 vs. E l6, E l8 & E20, *a p<0.05 vs. E l3, *b p<0.05 vs. E 14, **c p<0.01 vs. 
E l l ,  E16, E18 &E20.
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Figure 3.10 Graph showing the total neuronal yield (a), and the total number of 
GABA positive neurones (b), derived from primary cells isolated from the WGE at 
different ages. A significant difference o f age on both the total number of neurones 
and GABA positive neurones derived from VM cells is observed (p<0.001). Data 
expressed as mean ± S.E.M. across three separate experiments. **p<0.01 v.v. all other 
ages.
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Figure 3.11 Graph showing the total neuronal yield (a), and the total number of 
GABA positive neurones (b), derived from primary cells isolated from the CTX at 
different ages. A significant difference of age on both the total number of neurones 
(p<0.001) and GABA positive neurones (p<0.05) derived from VM cells is observed 
Data expressed as mean ± S.E.M. across three separate experiments.
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3A Discussion
All primary cells isolated from the developing rat VM, WGE and CTX, at gestational 
ages ranging from E l l  to E20 showed the expression of the neuronal marker {}- 
tubulin-III. Progenitor cells expanded from these regions and ages also showed the 
generation of neurones, even when progenitors were expanded for up to 40 days. The 
degree of neurogenesis from these progenitors however varied considerably, with 
region, progenitor age, proliferation time in vitro and progenitor origin all having a 
significant effect on neuronal yield.
Although primary cells from all regions and ages showed neuronal yields ranging 
from -50-70%, this probably reflects the proportion of cells that have pre­
differentiated into neurones at the time of dissection, rather than the percentage of 
neurones generated from progenitor cells in vitro. Because of this reason and because 
these cells did not undergo periods of proliferation, these primary cells cannot be 
compared to expanded progenitor cells and will therefore be discussed separately. The 
neuronal yield o f primary neurones isolated from the VM, WGE & CTX  at different 
ages does however provide a baseline to which we can measure (but not directly 
compare) the potential of progenitor cells.
3.4.1 Differentiation o f progenitor cells
Although the generation of neurones was seen from expanded progenitors isolated 
from the VM, WGE & CTX at different ages, not all cells differentiated into neuronal 
phenotypes. Results show that the maximum percentage of neurones were generated 
from E14 WGE 7-day expanded progenitors, where -25%  of all cells were neurones, 
indicating that 75% of cells were o f non-neuronal phenotypes. Although not identified 
in this study, the remaining cell types probably consisted of a mixture 
oligodendrocytes and astrocytes, with a possibility of some cells being non­
differentiated, uncommitted progenitor cells. Evidence for glial differentiation of 
expanded progenitors has recently been shown in progenitors from the VM (O’keeffe 
& Sullivan., 2004). In this report, differentiated progenitor cells isolated from ages 
El 2-El4 showed to be immunopositive for both GFAP & myelin basic protein (MBP) 
indicating the presence o f astrocytes and oligodendrocytes respectively. Interestingly, 
both the expression o f astrocytes and oligodendrocytes was shown to increase with 
progenitor age. The presence of nestin-positive cells reported in this study also
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indicates, and supports our suggestion that undifferentiated cells are also contained 
within the medley o f differentiated cell types. The presence o f oligodendrocytes and 
astrocytes following differentiation o f expanded progenitor cells has not only been 
shown for VM tissue, but differentiation of progenitors down a glial pathway has also 
been demonstrated for striatal progenitors (Svendsen et al., 1995; Ostenfeld et al., 
2002). From these reports and others (see reviews Gage et al., 1995a, McKay., 1997), 
we are confident that the majority of non-neuronal cells seen in our cultures are a 
mixture of oligodendrocytes, astrocytes and undifferentiated cells.
The range of different cell types that have been reported to be generated from these 
progenitors illustrates the multipotency o f  these progenitors and suggests that 
progenitors may contain both unipolar progenitors that generate only neurones and 
bipolar progenitors that are capable o f generating neurones and glia (Kilpatick & 
Bartlett., 1993; Vescovi etal., 1993).
3.4.2 Regional specification o f progenitor cells
Primary and progenitor cells isolated from the VM, WGE & CTX all showed different 
expressions of the neuronal marker (3-tubulin, with WGE cells generating the most 
neurones in primary cultures and CTX progenitor cells generally generating the most 
neurones at passage one. Interesting progenitors isolated from the VM generated the 
least number of neurones in both primary and passage one cultures. This regional 
difference in neuronal expression from primary cells and progenitors from different 
regions indicate that these progenitors still keep some of their regional properties i.e. 
they show regional specification.
Although this pattern of neurogenesis from VM, WGE & CTX progenitors has been 
reported previously for cultured E l4 rat progenitors (Ostenfeld et al., 2002), the data 
presented in this study shows that this pattern of neurogenesis is consistent for 
expanded progenitors isolated from ages ranging from El 1-E20.
In the data reported here, the percentage of neurones generated by E14 rat WGE and 
CTX progenitors following 7-10 days proliferation is similar to earlier reports 
(Ostenfeld et al., 2002), however, VM progenitors generated more neurones than 
previously observed (Ostenfeld et al., 2002; O’Keeffe & Sullivan., 2004). This 
difference in the percentage of neurones generated by VM progenitors may be 
because of the difference in the passaging technique, or it may be down to culture
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conditions used in the different studies. Our passaging regime meant that cells were 
only passaged when fully confluent or when neurospheres reached a pre-defined size, 
rather than at fixed intervals as in the reports by Ostenfeld et a l,  (2002) and O’Keeffe 
& Sullivan., (2004). This not only allowed sufficient cell-cell contact which is 
important when proliferating progenitor cells in vitro, but it also prevented 
neurospheres becoming too large, and thus stopped cells in the core of the 
neurospheres dying from the lack of media contact. Passaging cells as soon as they 
were confluent also prevented cell stress due to ‘overcrowding’ of proliferation flasks. 
Although the studies by Ostenfeld and O’Keeffe and others (Armstrong et a l, 2003; 
Svendsen et a l, 1995, 1997b; Li et a l ,  2005), have used both EGF & bFGF in the 
proliferation of progenitor cells, the progenitor cells used in this study were 
proliferated in the presence of bFGF alone. The absence of EGF in our culture 
conditions however, would not have been responsible for the increase of VM 
neurones since EGF has shown not to have beneficial effects on the differentiation of 
these cells (Smith et a l, 2003).
The rational for using bFGF alone in this experiment was based on two main reasons. 
Firstly, progenitor expansion by bFGF alone is sufficient, with differentiation of 
progenitors being comparable to the differentiation o f progenitors expanded in EGF & 
bFGF, as shown in our previous study (Smith et al., 2003). Secondly, EGF may not be 
the optimal mitogen to use when looking at neurogenesis since its use has been 
suggested to favour glial cell differentiation (McKay., 1997).
Evidence for the involvement of EGF in promoting gliogenesis is shown in the adult 
rat brain where infusion of EGF into the brain showed a decrease in the number of 
newborn neurones, and an increase in the generation of astrocytes migrating to the 
olfactory bulb. Infusions of bFGF on the other hand, resulted in an increase in 
newborn olfactory bulb neurones being observed (Kuhn e ta l ,  1997). Further support 
for the role of EGF in glial differentiation comes from clonal analysis studies where 
EGF was shown to stimulate only glial lineage restricted cells, whereas bFGF showed 
stimulation of multipotent progenitors capable of generating neurones and astrocytes 
as well as these glial restricted progenitors (Kilpatrick & Bartlett., 1995).
The reasons for the regional differences in neurogenesis observed in this study are 
unclear, but perhaps it’s due to the composition of progenitors isolated from different
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regions. With the existence of different progenitor populations that give rise to 
specific cell types (Kilpatrick & Bartlett., 1995; Vescovi et al., 1993), perhaps 
progenitors from the WGE contain more unipolar progenitors than bipolar 
progenitors, whereas VM progenitors may primarily consist of the bipolar type, thus 
explaining why VM tissue generates less neurones. Alternatively, the difference in 
neurogenesis may be because the culture conditions used were more favourable for 
WGE progenitors rather than for VM progenitors. Interestingly, proliferation of VM 
progenitors at lower oxygen levels has shown to be greater when compared to higher 
oxygen levels, with progenitors from the forebrain showing no difference in 
proliferation (Storch et al., 2001). Proliferation o f  VM progenitors in lower oxygen 
has also showed increased neurogenesis (Studer et al., 2000) indicating that VM 
progenitors are highly sensitive to oxygen levels.
The oxygen levels in our study may therefore have been too high for optimal VM 
proliferation and differentiation to occur, whereas WGE progenitors may have been 
unaffected, similar to the forebrain progenitors seen in the study by Storch, thus 
contributing to the regional variation in neurogenesis seen in the data reported here. 
The regional differences are also highlighted by looking at the phenotypic identity of 
the neurones generated by primary cells from each region, with only cells from the 
VM generating neurones immunopositive for TH. TH immunopositivity of VM 
progenitors is expected since this is where dopaminergic neurones of the substantia 
nigra originate. No evidence of TH staining was observed in WGE or CTX cell 
cultures, unlike previous reports where progenitors from the cortex have been shown 
to contain cells immunopositive for TH (Roybon et al., 2004). The level of TH 
expression observed with VM progenitors was dependent on the progenitor age, thus 
emphasising the importance of gestational age of progenitors.
Primary cells from all regions showed evidence of GABA expression, but this again 
varied with region, with neurones from the WGE showing the highest expression and 
neurones from the CTX showing the least. Following 7-10 days proliferation, GABA 
expression was still evident by progenitors from all regions but no neurones generated 
by VM progenitors at any age were immunopositive for TH. This reduction in TH 
expression is consistent with previous reports (Yan et al., 2001; Ostenfeld et al.,
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2002; O’Keeffe & Sullivan., 2004), and is thought to be because of the restricted 
proliferation o f dopamine neuroblasts (Ostenfeld etal., 2002).
This failure of VM progenitors to differentiate into dopamine neurones is of great 
concern because if progenitors cannot generate sufficient numbers of dopamine 
neurones even after short-term expansion, then their use as a replacement for foetal 
tissue in neuronal replacement therapies is futile. Perhaps VM progenitors require 
exposure to a range or combination of factors/signals rather than to bFGF/EGF alone, 
as shown by Storch et al., (2001), where human mesencephalic tissue expanded for 
several months was shown to generate dopaminergic neurones following 
differentiation in the presence o f interleukin-lb, interleukin-11, LIF and GDNF.
3.4.3 Effect o f age on neuronal differentiation
The data reported in this chapter shows significant variation in the neuronal 
expression of primary and progenitor cells with age. This variation is particularly 
apparent when looking at primary cell data, where WGE & CTX progenitors show 
peak neuronal expression at E l4-18, and VM progenitors at E14 (Fig. 3.2a-d). 
Although less neurones are generated in passage one cultures (see section 3.3.4), this 
pattern of neurogenesis with age is still apparent, particularly for WGE and VM 
progenitors (Fig. 3.4a-d).
Similar observations showing the different effects of progenitor age on neural 
differentiation have recently been reported in a smaller study by O ’Keeffe & Sullivan 
(2004). In this report, a difference in neural differentiation of progenitors isolated 
from the VM at ages E12 to E14 was observed (O’Keeffe & Sullivan., 2004). Taken 
together, both the study by O’Keeffe and the data reported here illustrate the 
importance of progenitor age on neurogenesis and in selecting the appropriate 
progenitor age when investigating the neural potential of rat neural progenitor cells.
The difference in the degree of neuronal expression with age is probably related to the 
timing of neural development of the different brain regions. Neurogenesis in the VM 
has been reported to occur between ages E12 and E l5 (Ostenfeld et al., 2002; Altman 
& Bayer., 1981; Marchand & Poirier., 1983), with neurogenesis in the WGE 
occurring between E12 to E22 (Ostenfeld et al., 2002; Fricker-gates et al., 2004) and 
neurogenesis in the CTX occurring between E13.5 to E19.5 (Ostenfeld et al., 2002).
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Within these neurogenic time windows, regulation of neurogenesis must occur to 
account for the variation o f neurogenesis that has been observed in this study. The 
mechanisms involved in this regulation are unknown, but perhaps progenitors respond 
to regional environmental cues to up- or down-regulate neurone production via cell 
mitosis. During the developmental maturation of particular brain regions, high 
requirements of neurones may be needed, so progenitor cells may undergo several 
rounds of mitosis at particular ages to generate more progenitor cells with the 
potential to generate neurones. For the WGE, this developmental maturation may 
occur between E l4-18, whilst for the VM it is at E l4, thus explaining the peaks of 
neurogenesis. Birth dating studies using BrdU have shown increased generation of 
striatal neurones at E l4-18 (Fricker-gates et al., 2004), which is consistent with our 
data. Altman & Bayer (1981) used tritiated thymidine to show that VM neurones are 
bom between E13-15, and Sinclair et al have shown a decrease in neurogenesis at E16 
(Sinclair et al., 1999), this again is similar to the results observed in our study.
After these periods of development, and towards the end of the neurogenic time 
window, the full complement of neurones are probably present resulting in 
progenitors undergoing their final mitotic division, which means fewer progenitors, 
and less neurogenesis thus explaining why by E20, less neurones are generally 
observed.
Evidence of differing degrees of mitosis with age has been observed with VM 
progenitors where neurospheres generated from early aged VM progenitors are larger 
and contain more cells than neurospheres generated by older progenitors (O’Keefe & 
Sullivan., 2004). Analysis of our data showed similar behaviour, with more cells 
present in cultures derived from younger aged VM progenitors compared to older 
progenitors. Differing cell numbers were also observed in WGE & CTX cultures of 
different ages, indicating that mitosis might explain the variation in neurogenesis with 
progenitor age. This difference in cell number must be due to the mitotic nature of the 
progenitors and not a result of the cell plating procedure since a fixed number of cells 
(50,000 cells/coverslip) were plated for all progenitors from all ages.
Interestingly, although the report by O’Keeffe and ourselves indicate a difference in 
neural differentiation with age, a difference in the percentage of neurones generated 
by VM progenitors is observed between the two reports. O’Keeffe report that 
progenitor cells from E12 VM generate more neurones than progenitors from E l4 
VM, we however, show more neurones from E14 than E l2. This difference is
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probably due to the way results are analysed. In this study, the percentage neurones 
generated was calculated by counting the percentage o f 250-300 viable cells that were 
neurones. O’Keeffe however, counted the number of neurones generated from total 
number of cells. Because of the variation in cell numbers with progenitor age, 
counting the total number of neurones or calculating the percentage number of 
neurones from total cells and not a proportion of the cells will provide a more accurate 
measurement of the neurogenic capacity o f neural progenitor cells.
To make our results more meaningful, and more representative, the total numbers of 
neurones from primary progenitor cells from all three regions and all ages were 
counted. Comparison between the percentage and total neurones generated by the 
cells shows marked differences (Fig. 3.9-3.11), thus highlighting the difference 
between the methods of analysis. Interestingly, numbers of neurones and TH neurones 
generated by primary VM progenitors were higher at E12 than at E14 when 
represented as total numbers (Fig. 3.9a). E12 VM progenitors following 7-10 days 
proliferation also showed to generate more neurones than E14 progenitors (data not 
shown), consistent with the results observed by O ’Keeffe and Sullivan.
The observation of E12 VM progenitors generating more neurones and in particular 
TH neurones is o f great importance, especially when considering transplantation 
studies involving the grafting of VM cells into the brain. Most of these studies have 
used VM progenitors isolated from embryo’s aged E14 or older and have shown low 
survival rates (3-10%) of TH cells after transplanting into the brain (Olanow et al., 
1996, Dunnett., 1992, Roybon et al., 2004). Since progenitors from E l2 VM generate 
more neurones and importantly more TH neurones than E14 VM cells, we propose 
that the use of E12 VM tissue will result in more surviving TH cells and thus provide 
better functional grafts than those produced by E14 VM tissue.
3.4.4 Effect o f in vitro proliferation on neurogenesis
Although progenitors from all regions of the embryonic rat brain continued to 
generate neurones up to passage 5 (-40 days), this continued proliferation of 
progenitor cells resulted in a significant reduction in neurogenesis. Proliferation of 
progenitors resulted in a neuronal yield o f 2% by passage 5, compared to -25% at 
passage 1. This reduction in neurogenesis is also observed when looking at the total 
number of neurones (data not shown). This loss of neurogenic potential is consistent
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with our previous finding (Smith et al., 2003), and although the precise reason for this 
decrease in neurogenesis is unknown, a number of reasons have been suggested. 
Perhaps the culture conditions may be missing essential factors causing a failure of 
the progenitors to follow a neuronal lineage. This deficiency in differentiation 
conditions has been the suggested reason for the restriction in the differentiation 
potential for expanded progenitors isolated from the mouse LGE (Skogh et al., 2003). 
Another possibility is that over time, progenitors undergo a specific asymmetric 
division called the ‘switch point’ at which progenitors down regulate neurone 
production and increase glial generation (Qian et al., 2000). Alternatively, progenitors 
destined to become neurones may be more vulnerable than non-neuronal progenitors 
and are therefore lost during the passaging regime. Because the method of cell 
dissociation is relatively severe, cell-cell contact is disrupted and cells are stripped of 
their receptors causing cellular trauma and probably cell death thus resulting in an 
overall decrease in neurogenesis with increased passaging. Dissociation of cells using 
the ‘chopping’ method described by Svendsen et al., (1998) will be less traumatic to 
the cells and may increase the neurogenesis of these progenitors. Whatever the reason 
may be, its clear from the data that progenitors isolated from the optimal age of tissue 
based on primary cell data are unable to make significantly higher neurones after 
proliferation. This failure to retain the ability to generate large number of neurones 
after periods in vitro is a big concern and this issue needs to be addressed if stem cells 
are to be a valuable tool in supplying a source of neurones for transplantation.
In summary, the data reported here show that the neurogenic capacity of primary and 
progenitor cells isolated from the developing brain is dependent on both region and 
age. Regional variations in the neurogenic potential of progenitors are observed, with 
progenitors from the WGE generally generating more neurones than progenitors from 
the VM and CTX. More importantly however, the gestational age at which primary 
and progenitor cells are isolated from the brain has a significant effect on neurogenic 
capacity of progenitors. Selecting progenitor cells of the appropriate gestational age is 
therefore crucial when investigating the characteristics of these progenitors. Since 
primary and progenitor cells from E12 VM generate more neurones and importantly 
more TH neurones (primary cells) than E14 VM cells, we propose that the use ofE12 
VM tissue in transplantation experiments will result in more surviving TH cells and
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thus provide better functional grafts than those produced by E l4 VM cells, which is 
the standard age used at present.
Another important finding is that the ability of progenitors to generate neurones is 
severely reduced following short periods of proliferation. This is of major concern and 
unless this problem is addressed, this may jeopardise the use of stem cells as a 
potential source of neurones for transplantation.
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(Experiment Ewo - Effect ofascorBic acid on the yield of 
dopaminergic neurones
Summary
This chapter discusses whether pre-treating mesencephalic cells with the antioxidant, 
ascorbic acid, can increase the numbers o f dopamine neurones both in vitro and in 
vivo.
Primary E14 rat mesencephalic cells were differentiated for 7 days in media 
containing different concentrations o f ascorbic acid, and the percentage of surviving 
dopamine neurones were counted. At concentrations ranging from 20-100pM, a 
significant increase in the percentage of neurones expressing TH was observed when 
compared to controls, but at higher concentrations (500pM and above), ascorbic acid- 
induced neurotoxicity was evident.
Mesencephalic cell suspensions supplemented with lOOpM ascorbic acid were also 
transplanted into unilateral 6-OHDA lesioned rats, and behavioural rotation was 
assessed 2, 4 & 6 weeks post-transplantation. Although grafts pre-treated with 
ascorbic acid contained more surviving dopamine neurones compared to non-treated 
grafts, no significant difference in rotation score was observed, with both groups 
showing a reversal o f rotational bias. Rotational behaviour is therefore a sensitive test 
for graft functionality, but suffers ceiling effects that limit the ability to discriminate 
functional differences associated with graft size.
The increased number of dopamine neurones observed following ascorbic acid 
treatment is likely to reflect a selective survival effect. However, the possibility of 
ascorbic acid increasing the number dopamine neurones by stimulating dopaminergic 
differentiation cannot be excluded.
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4.1 Introduction
Transplantation o f embryonic mesencephalic tissue into the dopamine deleted 
striatum has shown clear functional improvements by ameliorating behavioural 
deficits in a variety of animal models (Brundin et al., 1986; Low et al., 1987; 
Sirinathsinghji et al., 1990; Annett et al., 1994; 1997). The extent of functional 
recovery is however limited, with grafts unable to reverse all lesion-induced 
behavioural abnormalities. This partial recovery has been documented in rats, with 
grafts showing a reduction in rotation asymmetry but no improvement in neglect and 
grasping ability of the contralateral paw in food retrieval tasks (Dunnett et al., 1987). 
Grafts of embryonic dopamine neurones in unilateral 6-OHDA lesioned monkeys 
have also shown the attenuation of rotational bias, but no attenuation of ipsilateral 
head orientation, ipsilateral hand preference and neglect of contralateral stimuli 
(Annett et al., 1994). This limited recovery may in part relate to poor graft survival 
(only 5-10% of dopamine cells typically survive transplantation, Dunnett., 1992) 
since the degree o f functional recovery is dependent on the number of surviving 
dopamine neurones in the grafts (Brundin et al., 1994; Kordower et al., 1997). The 
low survival of dopamine neurones following transplantation means that for sufficient 
functional benefits to be achieved in Parkinson’s disease patients, transplantation of 
mesencephalic tissue from 4-8 human embryos is required per side of the brain 
(Brundin et al., 2000). This requirement for large quantities of human embryonic 
tissue for each patient makes widespread clinical delivery impractical; therefore, 
increasing dopamine graft survival needs to be achieved if neuronal replacement 
therapies are going to succeed (Brundin et al., 2000).
The mechanisms involved in dopamine cell death have been shown to be mediated 
through apoptosis (Mahalik et al., 1994) with the majority o f dopamine cells dying 
rapidly following cell isolation and preparation. Time course studies have shown that 
significant dopamine cell death occurs over the first 24 hours following cell 
dissociation (Zawada et al., 1998), and in particular the first 8 hours where 50% of all 
dopamine cells die (Branton & Clarke., 1999). Grafted dopamine neurones have also 
been shown to die rapidly with the majority of cell loss occurring over the first 7 days 
after transplantation (Barker et al., 1996; Brundin et al., 2000).
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Although the specific reasons involved in the cell death of dopamine neurones are 
unclear, cell preparation methods have been shown to be very important, with the 
number of in vitro and in vivo dopamine neurones being influenced with trituration 
technique, trypsin type and incubation time in trypsin (Barker et al., 1995).
One possible reason for the poor survival o f dopamine neurones may be because of 
oxidative stress caused by free radicals, a mechanism which has been implicated in 
the death of substantia nigra dopamine neurones in Parkinson’s disease (Sian et a l, 
1994; Olanow., 1993; Fahn & Cohen., 1992). Strong evidence for the involvement of 
oxidative stress in dopamine cell death comes from studies showing decreased 
sensitivity to the neurotoxin MPTP following antioxidant treatment. Neurotoxicity of 
substantia nigra dopamine neurones, caused by free radicals generated by the 
metabolism of MPTP, is abolished in transgenic mice with increased superoxide 
dismutase activity (Przedborski et a l, 1992). Similar observations have been observed 
in mice treated with the antioxidants a-tocopherol, (3-carotene, ascorbic acid or N- 
acetylcysteine prior to MPTP administration (Perry et a l ,  1985). In addition, in MPTP 
injected mice, glutathione (a naturally occurring antioxidant present in a variety of 
brain regions including the substantia nigra) (Sian et a l ,  1994), is depleted, however 
this depletion is prevented following antioxidant treatment (Yong et a l, 1986). 
Together, these studies suggest that oxidative stress plays an important role in the 
pathogenesis of Parkinson’s disease.
Similarly, the underlying cause for why dopaminergic neurones are vulnerable when 
either cultured or transplanted into the brain may also be because of oxidative stress. 
It is thought that oxidative stress caused by hypoxia and cellular trauma during 
dissection and tissue preparation is one of the mechanisms contributing to poor 
dopamine survival (Brundin et a l, 2000). Removing cells from low oxygen 
environments and exposing them to standard oxygen levels of 20% may also promote 
oxidative stress and therefore decrease dopamine cell survival. This might explain 
why increased dopamine survival is observed when mesencephalic tissue is cultured 
in oxygen levels representative of those levels found in developing tissues (Colton et 
a l, 1995; Studer e ta l,  2000; Storch et a l,  2001).
The neuroprotective effects of antioxidants on isolated mesencephalic cells also 
provide convincing evidence that the cell death of dopamine neurones is mediated via
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oxidative stress (Colton etal., 1995; Love etal., 2002). Supplementing mesencephalic 
cell suspensions with glutathione shows increased survival of dopamine neurones 
(Love et al., 2002). Conversely, inhibition of glutathione synthesis by using L- 
buthionine sulfoximine, results in a significant reduction in the survival of these cells 
(Grasbon-Frodl etal., 1996). Dopamine neurones in glutathione-depleted cultures can 
be rescued by treating cultures with lazaroids (Grasbon-Frodl et al., 1996). Lazaroids 
inhibit lipid peroxidation and the formation of free radicals, and have been also shown 
to increase dopamine survival in vitro (Frodl et al., 1994), as well as increasing cell 
viability of dissociated mesencephalic cells and importantly increasing dopamine 
survival in grafts (Nakao et al., 1994). The increased dopamine survival in grafts 
following lazaroid treatment is reflected in amelioration o f rotational bias in unilateral 
lesioned rats, with faster recovery of rotational asymmetry being observed compared 
to rats receiving non-treated grafts (Nakao et al., 1994). Interestingly, grafts pre­
treated with glutathione alone, do not show increased survival of dopamine neurones 
and attenuation of rotational behaviour when compared to controls (Love et al., 2002), 
however when glutathione is combined with ascorbic acid, an increase in dopamine 
survival and reduction in rotation asymmetry is apparent (Agrawal et al., 2004).
Because the majority of dopamine cell death occurs over the first 24 hours from cell 
dissociation and this coincides with rapid ascorbic acid depletion in cultured cells 
(Kalir & Mytilineou., 1991), we investigated whether the anti-oxidant effects of 
ascorbic acid alone, could increase dopamine survival in both cultured neurones and 
in grafts transplanted into the unilateral 6-OHDA lesioned rat brain.
E14 rat mesencephalic tissue was dissociated and differentiated in media containing 
different concentrations of ascorbic acid, and the number of neurones and TH positive 
neurones was assessed. Cells supplemented with ascorbic acid were also grafted into 
the unilateral 6-OHDA lesioned rat brain. The effect of grafts supplemented with 
ascorbic acid was compared to untreated grafts on rotational behaviour at 2, 4 & 6 
weeks post-transplantation.
After behavioural testing, the numbers of dopamine neurones in grafts pre-treated 
with or without ascorbic acid were counted and compared.
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4.2 Experimental Procedure
A detailed description of the dissection procedure and in vitro techniques used in this 
chapter can be found in chapter two, section 2.2.1, 2.2.2, & 2.6.
For cell viability tests, dissected VM tissue was dissociated (see chapter two, section
2.4) and incubated at 37°C, 5% CO2 for 1 hour in HBSS supplemented with different 
concentrations of ascorbic acid. Following incubation, the viability of cells was 
assessed by counting cells while using trypan blue as an indicator of dead cells (see 
chapter two, section 2.6.1).
For in vitro experiments, dissociated cells were differentiated for 7 days in media 
consisting of neurobasal medium supplemented with 1% B27, 1%
antibiotic/antimycotic solution, 30mM glucose, ImM glutamine, 50ng/ml bovine 
serum albumin, 1% foetal calf serum and ascorbic acid ranging from l-5000pM at 
37°C & 5% CO2. Following 7 days differentiation, cells were fixed in 4% PFA and 
stained with the marker P-tubulin-III for the identification o f neurones. Neurones 
were also stained for TH for the identification o f dopamine neurones (see chapter two, 
section 2.6.2).
For in vivo experiments, adult female Sprague Dawley rats (~225g) received 6-OHDA 
lesions of the right medial forebrain bundle (see chapter two, section 2.7.1) and were 
rotated for 90 minutes following 2.5mg/kg amphetamine stimulation (see chapter two, 
section 2.8.1.1). Only rats showing good rotational behaviour (at least 600 net 
ipsilateral turns over 90 minutes) were used in this experiment. As a control, non- 
lesioned rats were also tested for rotation bias. Approximately 3 weeks after lesioning 
rats received transplants of either VM cells into the right striatum (n=9, group 1), VM 
cells with 100pM ascorbic acid (n=10, group 2) or lOOpM ascorbic acid only (n=8, 
group 3). Group 4 (n=8) consisted of animals with unilateral lesions only, and group 5 
(n=6) consisted of non-lesioned animals. All groups were rotated at 2, 4 & 6 weeks 
post-transplantation. After behavioural testing, animals were sacrificed, brains were 
isolated and the striatal dopamine grafts were analysed (see chapter two, section
2.9.4).
All in vitro experiments were repeated three times and statistical tests of analysis of 
variance (ANOVA) were analysed using the statistical package Genstat v7.2, with 
further analysis of the results being achieved by using the Neuman Keuls t-test.
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4.3 Results
4. 3. I  Cytotoxicity o f  ascorbic acid
To examine whether ascorbic acid had any cytotoxic effects, primary VM cells were 
incubated in ascorbic acid at concentrations ranging from ljiM-5mM. Following 
incubation for one hour at 37°C, cell viability was assessed using the trypan blue 
exclusion assay. Viable cells appeared phase bright and spherical when observed 
under the microscope, whereas damaged cells appeared blue.
The effects of ascorbic acid concentration on cell viability can be seen in figure 4.1. A 
significant effect of ascorbic acid concentration on cell toxicity was observed 
(F(io.32)= 10 .55 , p<0.001), with cells exposed to concentrations of 2500pM (2.5mM) & 
5000pM (5mM) showing significantly increased cell death when compared to 
controls (-9% compared to 4%, p<0.01) and all other concentrations (p<0.01). Cells 
exposed to ascorbic acid concentrations ranging from 1-lOOOpM did not show any 
significant toxic effects when compared with control cultures (Fig. 4.1).
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Figure 4.1 Cytotoxicity of ascorbic acid. A significant effect of ascorbic acid 
concentration on cell death is observed (p<0.001), with cells exposed to 
concentrations of 2500pM & 5000pM showing significantly higher cell death rates 
than compared to all other concentrations (p<0.01). Cytotoxic effects of ascorbic acid 
at concentrations ranging from lpM-lOOOpM are not significantly different to control 
(OpM). Data expressed as mean ± S.E.M. across three separate experiments.
** a p<0.01 vs. all concentrations except 5000pM, ** b p<0.01 vs. all concentration 
except 2500pM.
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4.3.2 Cell differentiation
Cells isolated from E 14 rat ventral mesencephalic tissue were differentiated 
immediately following dissection in media containing different concentrations of 
ascorbic acid ranging from lpM-5mM. After one day of differentiation, cells were 
observed to generate a variety of cell phenotypes as apparent by the presence of 
different cell morphologies. Although no obvious difference in cell differentiation was 
observed at low ascorbic acid concentrations (l-250pM), ascorbic acid-induced cell 
death was evident at higher doses (500-5000|iM) since the establishment of cell 
cultures was not apparent. Following 7 days differentiation, neuronal phenotypes were 
identified using the neuronal marker P-tubulin-III and dopaminergic neurones were 
identified by examining neurones immunopositive for the antibody tyrosine 
hydroxylase (TH) (Fig. 4.2).
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Figure 4.2 Fluorescent immunochemistry of p-tubulin-III positive cells and TH 
positive neurones. Neurones are stained using p-tubulin-III and visualised by green 
florescence. TH neurones are stained using TH and visualised by red fluorescence. All 
cell bodies are stained blue with Hoechst. More TH positive neurones are observed at 
20pM and lOOpM ascorbic acid when compared with controls (OpM). At lOOOpM 
ascorbic acid, no neurones are evident. Scale bar = 100 pm
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4.3.3 Effect o f ascorbic acid on neuronal yield
A significant effect o f ascorbic acid concentration on neuronal yield was observed 
(F(7,io4)=17.36 , p<0.001), with cultures treated with 500pM ascorbic acid showing a 
significant reduction in the generation of neurones when compared to control cultures 
(42% vs. 69%, NK: t(7,g)=13.023, p<0.01), and concentrations of 1000-5000pM 
generating no neurones at all (p<0.01, Fig. 4.3). At ascorbic acid concentrations 
ranging from 1-25OpM, there was no significant difference in neuronal expression 
when compared to controls, with neuronal yield ranging from 61-70%.
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Figure 4.3 Effect of ascorbic acid concentration on neurone survival. A significant 
effect of ascorbic acid concentration on neuronal generation is observed (p<0.001), 
with concentrations of 500pM and above significantly reducing the percentage of 
neurones generated (p<0.01). Data expressed as mean ± S.E.M. across three separate 
experiments. ** p<0.01 vs. 0 - 250pM.
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4.3.4 Effect o f ascorbic acid on survival o f dopamine neurones 
In addition to examining the neuronal yield of primary' VM cells, the effect of 
ascorbic acid concentration on the expression of TH positive neurones (presumed 
dopaminergic) was also assessed. A significant effect of ascorbic acid concentration 
on TH expression was observed (F(7,io4)=51.77. p<0.001), with cells exposed to 
concentrations of 20 pM, 50pM, lOOpM (p<0.01) and 250pM (p<0.05) generating 
significantly more TH immunopositive neurones when compared to controls (Fig. 
4.2). TH expression at 20, 50 and lOOpM was significantly higher than at all other 
concentrations, with no difference in TH expression between these three 
concentrations being observed (p<0.01). Interestingly, cells treated with 500pM 
ascorbic acid generated significantly less TH positive neurones compared to all other 
conditions (p<0.01). At low ascorbic acid concentrations of lpM  & lOpM, no 
significant difference in TH expression was observed compared to controls (Fig. 4.4).
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Figure 4.4 Effect of ascorbic acid concentration on dopamine neurones. A significant 
effect of ascorbic acid concentration on TH expression is observed (p<0.01), with
concentrations of 20pM, 50pM and lOOpM ascorbic acid generating significantly
higher TH expression compared to all other concentrations. Data expressed as mean ±
S.E.M. across three separate experiments. **a p<0.01 vs. controls and all other 
concentrations except 50 8c lOOpM, **b p<0.01 vs. controls and all other
concentrations except 20 & lOOpM, **c p<0.01 vs. controls and all concentrations 
except 20 & 50pM, *d p<0.05 vs. controls.
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4.3.5 VM grafts and amphetamine-induced rotations
To examine whether dopamine grafts treated with ascorbic acid could increase the 
number o f surviving dopamine neurones in vivo, primary VM cells treated with 
lOOmM ascorbic acid were grafted into unilateral 6-OHDA-lesioned rats, and 
rotational behaviour was assessed.
The effect of E l4 rat VM grafts transplanted with and without lOOpM ascorbic acid, 
on unilateral 6-OHDA lesion-induced rotational asymmetry can be seen in figure 4.5. 
Also shown is rotational behaviour o f rats that received lOOpM ascorbic acid only, 
and lesioned only and non-lesioned rats.
Rats receiving VM grafts only (n=9, group 1), showed no difference in rotational 
behaviour at 2 weeks post-transplantation compared to pre-graft scores (NK: 
t(2,4 )= 1  023, n.s). Significant decrease in rotational behaviour towards the ipsilateral 
side o f the lesion at 4 weeks (NK: t(3,4)=16.442, p<0.01) and 6 weeks post­
transplantation (NK. t(4,4)= 17.098, p<0.01) were however observed, with the graft 
causing overcompensation of motor asymmetry resulting in rotations contralateral to 
the side o f the lesion.
Similar behaviour was observed for rats receiving VM grafts + lOOpM ascorbic acid 
(n=10, group 2). No significant difference in rotational behaviour was observed at 2 
weeks post-transplantation when compared to pre-graft scores (NK: t(2,4>=l.l 12, n.s). 
Significant rotational behaviour was however observed at 4 (NK: tp,4)= 17.683, 
p<0.01) and 6 weeks (NK: t(4,4>= 19.483, p<0.01) post-transplantation. No significant 
difference in rotational behaviour between the two VM grafted groups was observed 
at 4 weeks (NK: t(2,i2>=0.138, n.s) or 6 weeks (NK: t^2,i2>=0.711, n.s) post­
transplantation.
Rats that received ascorbic acid only (n=10, group 3) and the lesion only group (n=10, 
group 4) showed stable rotations over the 6-week period, with no significant change 
in rotational behaviour. Non-lesioned rats (n=6, group 5), showed no significant 
rotational bias. Statistical analysis o f the data confirms a significant difference in 
rotational behaviour with groups (F(4,i67)= 12.66, p<0.001). A significant difference in 
rotations with time is also observed (F(3ji67)= l5.23, p<0.001).
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Figure 4.5 Amphetamine-induced rotational behaviour. A significant difference in 
rotational bias with groups is observed (p<0.001), with both the VM grafted and VM 
+ ascorbic acid groups showing a reduction in rotation at 4 and 6 weeks when 
compared to pre-graft rotation scores. No significant difference is however observed 
between these two groups. Lesion only and ascorbic acid only groups show no 
significant difference in rotational behaviour. Non-lesioned rats show no significant 
rotational bias. **p<0.01 vs. pre-graft scores. Data expressed as mean ± S.E.M.
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4.3.6 Number o f  TH positive neurones in grafts
Grafts o f dopamine neurones into the dopamine depleted rat striatum can cleariy be 
seen along with the characteristic halo of dopamine innervation (Fig. 4.6C). Grafts 
treated with or without ascorbic acid both contain numerous TH positive neurones 
which extensively project throughout the grafted site (Fig. 4.6D & E).
By using the Abercrombie correction formula (see chapter two, section 2.9.4), the 
number o f grafted TH positive present in the each rat brain was calculated. Analysis 
of the data showed VM grafts with lOOpM ascorbic acid contained significantly 
higher numbers of TH neurones when compared to grafts of VM cells only (p<0.05) 
(Fig. 4.7).
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Figure 4.6 TH immunohistochemical staining in brain sections moving rostral-caudal 
from left to right through the levels of the striatum and the substantia nigra. Control 
groups show equal staining for TH in the striatum and substantia nigra on both sides 
of the brain (A). Lesion groups show clear depletion of TH staining on right hand 
side, in both the striatum and the substantia nigra (B). Scale bar represents 2.5 mm. 
Grafts can be clearly seen in the striatum (C). Grafts of VM tissue alone and VM + 
ascorbic acid show the presence of many TH neurones (D & E respectively). Scale 
bars in C = 1 mm. D & E = 100pm.
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in grafts. Grafts of VM tissue 
transplanted in the presence of ascorbic 
acid show significantly more TH 
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4.4 Discussion
Transplantation o f embryonic mesencephalic dopamine neurones into the brains of 
Parkinson’s disease patients has shown proof of the concept that neuronal replacement 
strategies are successful as clinical treatments (Lindvall et al., 1994). Although results 
from these trials are encouraging, with improvements in symptoms being observed, 
not all aspects o f disease symptoms are ameliorated which is probably attributed to 
inadequacies in graft survival (Annett et al., 1997). For neuronal replacement 
strategies to succeed, increasing the number of surviving dopamine neurones in grafts 
is therefore an imperative requirement (Brundin & Bjorklund., 1998).
Because o f the substantial experimental evidence implicating the involvement of 
oxidative stress in dopamine vulnerability (Frodl et al., 1994, Grasbon-Frodl et al., 
1996; Nakao et al., 1994; Love et al., 2002), and evidence showing that the majority 
of transplanted dopamine cells die over the first 24 hours (Zawada et al., 1998) which 
is coincidently consistent with a rapid reduction in ascorbic acid levels (Kalir & 
Mytilineou., 1991), we investigated whether ascorbic acid could increase the survival 
of both cultured and transplanted dopamine neurones possibly by exerting its anti­
oxidant effects and protecting against free radical damage.
4.4.1 Cytotoxicity o f ascorbic acid
Before examining the effects of ascorbic acid on the survival of dopamine neurones, it 
was important to assess whether ascorbic acid had any cytotoxic effects on dissociated 
mesencephalic cells. Using the trypan blue exclusion assay, the percentage of dead 
cells were counted following incubation in ascorbic acid at concentrations ranging 
from I-5000pM. Although no cytotoxicity was observed at low concentrations when 
compared to controls (Fig. 4.1), an increase in cell death was observed at ascorbic 
acid concentrations of 2500 & 5000jliM. The precise reasons for this toxicity are 
unclear but perhaps the addition o f large concentrations o f ascorbic acid resulted in 
the cell environment being too acidic for cells to survive. Interestingly, severe toxicity 
was observed in neuronal cultures exposed to 500pM ascorbic acid (Fig. 4.3). At this 
concentration a significant reduction in the percentage of neurones was observed 
when compared to controls, with higher concentrations resulting in total neurone 
death. It is surprising that ascorbic acid at these concentrations has adverse effects on 
neurones since neuronal ascorbic acid levels in vivo are in the region of lOmM (Rice
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& Russo-Menna., 1998). Perhaps the absence of buffering systems in the culture 
environment again resulted in an excessive acidic environment that neurones cannot 
tolerate. Alternatively, high concentrations o f ascorbic acid may favour free radical 
formation and therefore oxidative stress of cultured neurones. Auto-oxidation of 
ascorbic acid can generate the superoxide free radical (Grunewald., 1993) and 
hydrogen peroxide (Clement et al., 2001) which damage critical biological molecules. 
Evidence for this has been shown in cultures of fibroblast cells where the addition of 
catalase (an enzyme that removes hydrogen peroxide) to fibroblast cells exposed to 
300(iM ascorbic acid prevents cell death (Arakawa et al., 1994). Signs o f free radical- 
mediated damage caused by ascorbic acid have also been shown in vivo where 
lymphocyte DNA isolated from volunteers whose diets were supplemented with 
500mg of vitamin C showed increased levels of 8-oxoadenine -  a marker for free 
radical-mediated DNA damage (Podmore etal., 1998).
Together, these studies show that ascorbic acid can produce harmful products capable 
of damaging cells, and the cytotoxicity o f cultured neurones observed in this study is 
probably due to its pro-oxidant properties. It is important to note that because of the 
presence of endogenous antioxidants which protect against such oxidative insults, it is 
unlikely that this toxicity would occur normally in vivo where the neuronal ascorbate 
concentrations are higher. The difference between the in vivo and in vitro 
environments means that extrapolating conclusions made from in vitro data and 
applying them to in vivo situations must therefore be done with caution.
4.4.2 Vulnerability o f  dopamine neurones
Although all cells are susceptible to free radical damage, dopamine neurones are 
particularly vulnerable because dopamine itself can be toxic (Hastings et al., 1996; 
Filloux & Townsend., 1993) through oxidative metabolism and the generation of free 
radicals. Similar to the neurotoxicity caused by 6-OHDA administration, where 6- 
OHDA is taken up by dopamine terminals and oxidised producing hydrogen peroxide 
(H2O2, Box 1, equation 1) and killing neurones from within (Cohen & Heikkila., 
1974; Heikkila & Cohen., 1971; 1973), dopamine can also produce hydrogen 
peroxide following its metabolism by monoamine oxidase (Box 1, equation 2, 
Olanow., 1993; Dunnett & Bjorklund., 1999). Alternatively, dopamine can also 
undergo auto-oxidation to produce the superoxide radical (0 2~), this in turn can react
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with further dopamine producing hydrogen peroxide (Box 1, equation 3, Olanow., 
1993; Dunnett & Bjorklund., 1999). Hydrogen peroxide itself is not excessively toxic 
and it is normally removed by glutathione (Olanow., 1993; Box 1, equation 4), 
however, hydrogen peroxide has the ability to generate harmful free radicals which 
makes its presence so dangerous. In environments where oxidative stress is favoured 
i.e. during dissection and preparation of tissue, hydrogen peroxide can interact with 
the superoxide radical and form the extremely reactive and toxic hydroxyl ion (*OH, 
Haber-Weiss reaction, Box 1, equation 5, Olanow., 1993). Hydrogen peroxide can 
also react with iron, again leading to the formation o f harmful hydroxyl ions (Fenton 
reaction, Box 1, equation 6, Olanow., 1993; Dunnett & Bjorklund., 1999). These 
additional oxidative pathways increase the possibility o f free radical formation and 
subsequently oxidative stress and therefore may explain why dopamine neurones are 
exceptionally vulnerable.
Bax 1. Formation o f hydrogen peroxide and free radicals
(1) Oxidation o f  6-Hydroxydopamine
6 -OHDA + O : --------► Q + H 20 2
(2) Enzymatic metabolism o f  dopamine
DA + 0 2 + H 20  ------- ► 3,4-DOPAA + NH 3 + H 20 2
(3) Auto-oxidation o f  dopamine
DA + 0 2 --------► SQ + 0 2~ + H
DA + 0 2~ + 2H  ► SQ + H 20 2
(4) Clearance o fH 2 0 2
2GSH + H 2O2  ► GSSG + 2H:0
(5) Haber-Weiss reaction
H2 O 2 + o r  ► o h  + o h '+  o r
(6) Fenton reaction
H2O: + Fe2 ------- ► 'OH + OH + Fe,+
Abbreviations:
6-OHDA -  6-hydroxydopamine 
H 2O2 - Hydrogen peroxide 
DA -  Dopamine 
3,4-DOPAA - 3,4 
dihydroxyphenylacetaldehyde 
O -  Quinone 
SO - Semiquinone 
O 2 ~ ~ Superoxide anion 
GSH -  Glutathione 
GSSH — oxidised glutathione
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4.4.3 Increased expression o f  dopamine neurones following treatment with ascorbic 
acid
Pre-treating cultured dopamine neurones with ascorbic acid showed a dose-dependant 
effect on the expression o f dopamine neurones. At concentrations ranging from 20- 
100pM, dopamine neurone expression was significantly higher compared to controls 
with almost a 2-fold increase in dopamine expression being observed. This increase in 
dopamine neurones following ascorbic acid treatment is consistent with an earlier 
report that showed increases in dopamine and its primary metabolite 3,4 
dihydroxyphenylacetic acid (DOPAC) in cultured mesencephalic neurones following 
treatment with the same anti-oxidant (Kalir & Mytilineou., 1991).
Transplanted cells pre-treated with lOOpM ascorbic acid also showed a significant 
increase in the number o f dopamine neurones when compared to non-treated grafts. 
Although increases in grafted dopamine neurones haven’t been reported following 
ascorbic acid treatment alone, similar observations have been reported following 
ascorbic acid and glutathione treatment (Agrawal et al., 2004).
Increased survival o f  dopamine neurones have also been shown in a number of 
previous studies following treatment with different anti-oxidants and lazaroids 
(Colton et al., 1995; Frodl et al., 1994; Love et al., 2002; Nakao et al., 1994), which 
suggests that ascorbic acid also has its effects by reducing the likelihood of oxidative 
stress.
However, although ascorbic acid is a major antioxidant, it also has a variety o f other 
functions such as being involved in excitatory amino acid release, acting as co-factor 
in the synthesis o f neuropeptides, stimulating myelin formation by Schwann cells and 
stimulating acetylcholine and noradrenaline release from synaptic vesicles (Rice., 
2000; Griinewald., 1993; Kalir & Mytilineou., 1991). Because we did not assess 
oxidative stress mediated toxicity which can be measured by analysing the levels of 
certain markers such as 8-oxoadenine, 8-oxoguanine (Podmore et al., 1998), 8- 
hydroxyguanine and 8-hydroxydeoxyguanosine (Helbock et al., 1999) and coupled 
with the fact that ascorbic acid has multi-functional properties, the implication that 
ascorbic acid increased dopamine survival by reducing oxidative stress mechanisms 
would only be an assumption. The possibility that ascorbic acid increased dopamine 
expression through another mechanism, other than reducing oxidative stress, therefore 
cannot be excluded.
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Interestingly, a previous report showed that the increase in dopamine neurones from 
proliferated mesencephalic progenitors treated with ascorbic acid showed no 
difference in the expression o f markers for oxidative stress when compared to control 
cultures, nor did any other anti-oxidant mimic the effect of ascorbic acid. From this it 
was concluded that ascorbic acid exerts its effects not by acting as an anti-oxidant and 
increasing the survival of dopamine neurones, but rather by activating differentiation 
pathways and promoting the dopaminergic differentiation of neurones (Yan et al.,
2001).
Increased differentiation as opposed to increased survival o f dopamine neurones could 
also explain the increase in dopamine neurones observed in this study. It has been 
previously reported that the expression o f dopamine neurones in rat cortical cell 
cultures was increased by exposing cells to dopamine and subsequent stimulation of 
D1 and D2 receptors (Zhou et al., 1996). Perhaps ascorbic acid-induced increases in 
dopaminergic expression is also mediated in the same way since ascorbic acid would 
increase the amount o f dopamine by decreasing dopamine auto-oxidation and 
therefore allowing stimulation o f D1 and D2 receptors.
4.4.4 Rotational behaviour is not usefulfor a measure o f  graft size 
Determination o f  dopamine graft survival following pre-treatment with ascorbic acid 
was assessed by measuring rotational asymmetry in 6-OHDA lesioned rats. Prior to 
grafting, only rats displaying at least 600 ipsilateral turns following amphetamine 
stimulation over the 90-minute testing period were selected, which subsequently 
reflects near total depletion of striatal dopamine (Brundin et al., 1988). Even though 
grafts pre-treated with ascorbic acid contained more neurones than non-treated grafts, 
no difference in rotational bias between grafts groups was observed, with both groups 
showing attenuation o f rotational behaviour by 6 weeks (Fig. 4.5). This is consistent 
with an earlier report that showed grafts pre-treated with lazaroids contained more 
dopamine neurones but showed no significant difference in rotation to control grafts 6 
weeks post-transplantation (Nakao etal., 1994).
The reason why increased survival o f dopamine neurones in pre-treated grafts is not 
reflected in rotational behaviour tests is probably because the control grafts probably 
contained enough dopamine cells to reach saturation point (Bjorklund et al., 1980; 
Brundin et al., 1988). At this point, no further increases in dopamine cells within
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grafts will show any further effect on rotational behaviour (Brundin et a l., 1988). 
Since this saturation point occurs when as few as 300-500 dopamine neurones are 
present, and the number o f  dopamine neurones in non-treated and treated grafts in our 
study showed in the region o f 2000 dopamine neurones, it is unsurprising that no 
difference in rotational behaviour was observed. For this difference in graft size to be 
observed in vivo, less sensitive behavioural tasks should be employed such as the 
lateralised associative learning task recently used by Dowd & Dunnett., (2004).
In contrast to the data reported here, a recent report did show a significant difference 
in rotational behaviour between rats that received either grafts pre-treated with 
glutathione and ascorbic acid or non-treated grafts, even though both graft groups 
contained enough neurones to reach saturation point (Agrawal et al., 2004). 
Interestingly, this study also showed increased dopamine cells in the substantia nigra 
following grafts treated with antioxidants compared to non-treated grafts. No evidence 
of dopamine cells was observed in the substantia nigra in our study and its unlikely 
that grafts o f dopamine neurones in the striatum would cause neurogenesis of 
dopamine neurones in the substantia nigra. Instead this apparent neurogenesis of 
dopaminergic nigral neurones reported by Agrawal is probably a result o f insufficient 
lesioning o f the dopamine pathway rather than reflecting possible neurogenesis. This 
insufficient lesioning of the dopamine pathway may explain why a difference in 
rotational bias was observed between both graft groups.
In conclusion, the data reported in this study shows that pre-treatment of 
mesencephalic neurones with ascorbic acid increased the number o f dopamine 
neurones, both in culture and when transplanted into the brain. Although it is tempting 
to attribute the effects to the antioxidant properties of ascorbic acid, the possibility of 
ascorbic acid increasing dopaminergic expression via other mechanisms, for example, 
by enhancing dopaminergic differentiation, cannot be excluded. To be certain that 
antioxidant mechanism were involved, levels o f oxidative stress markers should be 
measured.
However, while the precise mechanisms o f remain elusive, increasing the yield of 
dopamine neurones by using ascorbic acid may improve the efficacy o f 
transplantation studies.
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‘Experiment Three — Neurogenic potentiaCof aduCt hvppocampaC 
neuraCprogenitor cells
Summary
This chapter investigates the potential of adult hippocampal neural progenitor cells to 
differentiate into neurones o f  dopaminergic phenotypes following short-term in vitro 
proliferation.
Neural progenitor cells were isolated from the hippocampus of 6-week-old rats and 
cultured in media supplemented with bFGF for 21 days. Following proliferation, cells 
underwent 7 days differentiation and the generation of astrocytes, neurones and 
dopaminergic neurones was assessed by examining cells immunopositive for GFAP, 
P-tubulin-III and TH respectively.
Results demonstrate that adult neural progenitor cells derived from the hippocampus 
generate neurones and astrocytes, thus displaying their multipotent properties. 
However, the level o f neurogenesis is extremely low and, more importantly, there was 
no evidence for the generation o f  dopamine neurones since no neurones were 
immunopositive for TH. In a second part o f this study, transplantation o f adult 
hippocampal progenitor cells into the developing ventral mesencephalon was planned, 
however, the proliferation of progenitors generated insufficient numbers o f cells for 
transplantation.
This study shows that generating large numbers of cells from adult hippocampal 
neural progenitor cells and their differentiation into neurones, in particular dopamine 
neurones, is proving difficult and may explain why research in this area has gone 
relatively quiet over the last few years.
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5.1 Introduction
The long-standing dogma that the brain is a structure incapable o f generating new 
neurones has now been proved wrong with the discovery of continued neurogenesis in 
specific areas o f  the adult brain. Neural stem cells have shown to exist predominantly 
in two distinct brain regions, namely the anterior regions of the subventricular zone 
(SVZa), and the dentate gyrus o f the hippocampus (Altman & Das., 1965; Gage et al., 
1995; Kuhn & Svendsen., 1999; Seaberg & van der Kooy., 2002). Cells originating 
from the SVZ migrate along the rostral migratory stream into the olfactory bulb where 
they differentiate into dopaminergic and GABAergic interneurones (Lois & Alvarez- 
Buylla., 1993), and cells o f the dentate gyrus migrate from the subgranular layer and 
into the granular cell layer where they differentiate into hippocampal granule cell 
neurones (Altman & Das., 1965; Kuhn et al., 1996).
Neurogenesis, albeit to a lesser extent, has also been reported to occur in several other 
brain areas. For instance, a stem cell population has been reported to reside in the 
rostral extension o f  the rostral migratory stream (Gritti et al,. 2002), evidence o f 
neurogenesis in the cortex has also been observed (Gould et al., 1999) and 
bromodeoxyuridine (BrdU) labelling studies have shown the existence of 
neurogenesis in the Ammon’s horn o f the hippocampus (Rietze et al., 2000). The 
medial-rostral part o f the substantia nigra pars compacta has also been reported to 
generate dopamine projection neurones (Zhao et al., 2003), however this remains 
debatable since multipotent progenitors from this region have only shown to generate 
mature glial cells in situ (Lie et al., 2002). Furthermore, the failure to show any nigral 
cells double labelled with BrdU & TH indicates that neurogenesis in the substantia 
nigra probably does not occur (Frielingsdorf et al., 2004).
The isolation, in vitro proliferation and differentiation o f adult neural stem cells has 
been achieved successfully, with cells from the rodent brain showing the capacity for 
in vitro neurogenesis when expanded in the presence of epidermal growth factor 
(EGF) (Reynolds & Weiss., 1992), or basic fibroblast growth factor (bFGF) (Richards 
et al., 1992; Gritti et al., 1996; Palmer et al., 1995; 1997). Interestingly, while the 
isolation and culturing o f cells from the SVZ have shown self-renewal and 
multipotent capacities (Gritti et al., 1996), which are characteristics for defining stem 
cells (Reynolds & Weiss., 1992; 1996; Gage et al., 1995; 2000), there is some debate 
about the identity o f the cells from the dentate gyrus of the hippocampus. Cells of the
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hippocampus have been shown to exhibit multipotentcy and self-renewal properties in 
vitro (Palmer et al., 1995; 1997), thus suggesting that the cells o f the dentate gyrus are 
stem cells. However, cells dissected specifically from the dentate gyrus show limited 
self-renewal capacities and unipotency, thus implying that these cells represent a 
population o f restricted progenitors rather than stem cells (Seaberg & van der Kooy,. 
2002). The multipotency demonstrated by hippocampal cells must therefore arise 
from another source, and it has been argued that gross dissection o f the hippocampus 
inevitably results in the removal o f the adjacent SVZ stem cells, which are the ones 
responsible for the apparent stem cell properties o f the hippocampus (Seaberg & van 
der Kooy,. 2002).
The isolation o f adult neural stem cells and their subsequent in vitro differentiation 
into neurones has now been successfully achieved from a number o f non-rodent 
species including monkeys (Gould et al., 2001), humans (Roy et al., 2000a; 2000b; 
Arsenijevic et al., 2001) and even from post-mortem human brain tissue (Palmer et 
al., 2001). Neurones and glia generated from human adult stem cells have also shown 
appropriate electrophysiological properties thus demonstrating their functionality 
(Westerlund et al., 2003). While no evidence for functional neurones has been 
demonstrated following transplantation o f adult neural stem cells into the adult brain, 
several reports clearly indicate that these cells can appropriately respond to 
environmental signals and differentiate into neural phenotypes following 
transplantation. For instance, expanded hippocampal progenitors transplanted into the 
hippocampus o f the adult brain have shown to differentiate into neurones when 
located in the neurogenic region o f the dentate gyrus, or into glia when residing 
outside this area (Gage et al., 1995b). Moreover, transplantation of hippocampus- 
derived adult progenitors into the rostral migratory stream of rats showed that the 
majority o f grafted cells behave like endogenous progenitors and migrate into the 
olfactory bulb where they differentiate into neurones (Suhonen et al., 1996).
The ability o f adult neural stem cells to generate neural phenotypes both in vitro and 
in vivo is o f  particular interest because o f their potential clinical use in transplantation 
therapies for neurodegenerative disease. However, for adult neural stem cells to be a 
potential source o f neurones in for Parkinson’s disease, cells must have the capacity to 
generate not only neurones, but also, dopaminergic neurones. Although the report by
106
Chapter Tive
Suhonen et al showed a small proportion of adult progenitor-derived neurones 
expressing TH, and therefore possibly being o f  dopaminergic phenotype, no other 
evidence for the generation o f dopamine neurones has been reported.
In this chapter we assessed the in vitro neural differentiation of hippocampal-derived 
adult neural stem cells following short-term expansion and examined the extent of 
dopamine differentiation. Since adult neural progenitor cells have previously been 
shown to respond to environment signals, we also wanted to examine whether these 
cells could respond to developmental signals and generate midbrain dopamine 
neurones when injected into the developing ventral mesencephalon of embryonic rats. 
However, due to inadequate number o f  cells, transplantation studies could not be 
undertaken.
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5.2 Experimental Procedure
For a detailed description on the protocols used see chapter two, section 2.3.1 & 2.5.1 
respectively.
The hippocampi from eight, 6-week-old female Sprague Dawley rats were dissected 
and enzymatically digested for 45 minutes at 37°C before being dissociated into single 
cells. Progenitor cells were isolated from the hippocampus using the Percoll buoyancy 
fraction method (Palmer et a l., 1999). Briefly, dissociated hippocampal cells were 
mixed with 35% Percoll solution and centrifuged for 10 minutes at 1000 x g. 
Following centrifugation, any white matter and floating debris were removed and the 
cell pellet was resuspended in 65% Percoll solution and centrifuged again for 10 
minutes at 1000 x g. Any remaining floating debris were removed and floating neural 
progenitors (~2ml above pellet of red blood cells) were collected and washed free of 
Percoll by centrifugation in DMEM/F12 + 10% fetal calf serum (FCS).
Cells were plated on poly-omithine and laminin coated Petri dishes at a density of
500,000 cells per dish in DMEM/F12 containing 10% FCS. After 24 hours, media 
was changed to growth media, which consisting of DMEM/F12, 1% N2 and 20ng/ml 
bFGF. 75% of growth media was replaced every other day. Initial cultures became 
confluent within 3-4 weeks at which point they were passaged (see chapter two, 
section 2.5.3). Cells were then differentiated on chamber slides coated with poly- 
omithine and laminin in media consisting o f DMEM/F12, 1% N2, 1% FCS & 
0.5pg/ml trans-retinoic acid, for 7 days. Following differentiation, cells were fixed in 
4% PFA and stained with P-tubulin-III (neuronal marker), GFAP (astrocyte marker) 
and TH (see chapter two, section 2.6.2).
All experiments were repeated three times and statistical tests o f analysis o f variance 
(ANOVA) were analysed using the statistical package Genstat v7.2.
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5,3 Results
5.3.1 Proliferation o f  adult neural progenitor cells
The number o f progenitor cells isolated from the hippocampi of 8 adult rats was 
relatively low and therefore all cells were pooled and plated onto a 100mm culture 
dish in media containing 20ng/ml bFGF. Unlike the study by Reynolds and Weiss 
where adult neural progenitor cells were expanded as free-floating aggregates, called 
neurospheres (Reynolds & Weiss et a l., 1992), adult hippocampal progenitors were 
proliferated as monolayer cultures that adhered to the culture dish as previously 
described (Palmer et a l., 1999). Initial cell cultures became confluent in 
approximately 3 weeks, and based on their morphological appearance, the cell culture 
contained a variety o f different cell types (Fig. 5.1 A). Following passaging, 
proliferation o f the progenitor cells was slower when compared to the cells in the 
starting culture, as cells were only 75% confluent by 4 weeks in vitro. The 
morphology o f these cells was also distinctly different to those observed in the initial 
cell culture, with the majority o f  the cultured cells appearing elongated and phase- 
bright (Fig. 5. IB).
Although the initial cell culture reached confluence, because of the small size of the 
cultures, and the progenitor-enrichment passaging protocol, which is used when 
dissociating adult neural progenitor cells (Palmer et al, 1995), only a small number of 
viable cells were available for re-plating. In this case, less then 100,000 viable cells 
were generated following passaging o f initial cell cultures. This insufficient number 
of cells meant that transplantation studies were abandoned since we estimate that at 
least 250,000 cells per host would be required for effective transplantation.
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Fig 5.1 Cell cultures o f adult hippocampal neural progenitor cells. Based on their 
morphological appearance, initial cell cultures contain a variety of different cell types 
(A). After passaging, the cells are phase bright and elongated and more characteristic 
of progenitor cells (B). Scale bar = 100pm.
5.3.2 Differentiation o f  adult neural progenitor cells
To assess whether adult neural progenitor cells had the in vitro capacity to generate 
neurones, primary (cells that were not proliferated) and expanded progenitor cells 
were differentiated for 7 days in media containing retinoic acid. Neurones were 
identified using the neuronal marker P-tubulin-III and astrocytes were identified using 
the marker GFAP. Figure 5.2 shows the appearance o f cells immunopositive for p- 
tubulin-III and GFAP.
Fig. 5.2 Fluorescent immunochemistry of neurones and astrocytes derived from adult 
hippocampal progenitor cells. Neurones are stained using P-tubulin (A) and astrocytes 
are stained using GFAP (B). Cells are visualised using green florescence. All cell 
bodies are stained blue with Hoechst. Scale bar = 100pm.
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The percentage o f neurones and astrocytes derived from adult hippocampal neural 
progenitor cells is shown in figure 5.3.
Both primary and expanded progenitor cells showed the generation of neurones and 
astrocytes as demonstrated by the expression of the neuronal marker P-tubulin-III and 
the astrocyte-specific marker glial fibrillary acidic protein (GFAP). The percentage of 
neurones derived from primary and expanded adult neural progenitor cells was 
relatively low, with approximately 5% o f primary cells and 3% of expanded cells 
expressing P-tubulin-III (Fig. 5.3). The percentage of astrocytes generated from 
primary and expanded adult progenitors was much higher than the yield o f neurones, 
with 20-25% o f both primary and expanded cells being immunopositive for GFAP 
(Fig. 5.3). Statistical analysis o f  the data showed no significant difference in the 
percentage o f neurones and astrocytes generated by primary and expanded progenitors 
(F(1.59)=2.01, n.s).
To examine the proportion of neurones that were of possible dopaminergic 
phenotypes, neurones from both primary and expanded cells were stained for tyrosine 
hydroxylase (TH), which is an enzyme involved in dopamine synthesis. No neurones 
immunopositive for TH were observed at any time, therefore indicating that neurones 
were not o f  dopaminergic phenotypes.
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Fig, 5.3 Percentage o f neurones and astrocytes derived from adult hippocampal neural 
progenitor cells. Both primary (P0) and expanded (PI) cell cultures yield relatively 
low percentages o f neurones (black bars), but high yields o f astrocytes (white bars). 
Data expressed as mean ± S.E.M. across three separate experiments.
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5.4 Discussion
In addition to the ability o f adult neural progenitor cells to generate neurones, the use 
of these cells in cell replacement strategies for Parkinson’s disease is a particularly 
attractive alternative to the use of foetal tissue for a number of reasons. Firstly, the use 
of adult cells is free from ethical issues that are currently surrounding the use of 
embryonic stem cells. Secondly, adult neural progenitors offer the possibility of 
autologous transplantation, thus avoiding the issues o f rejection which surround the 
use o f foreign tissue, and thirdly, since endogenous adult progenitor cells have shown 
to generate neurones in response to injury (Arvidsson et al., 2002; Nakatomi et al.,
2002) and infusions o f growth factors (Kuhn et al., 1997; Pencea et al., 2001 Fallon et 
al., 2000), the idea o f stimulating endogenous stem cells for the induction of self­
repair is a real possibility.
Since Parkinson’s disease is primarily characterised by a loss of midbrain dopamine 
neurones (Samii et al., 2004; Olanow & Tatton., 1999), the ability o f progenitor cells 
to differentiate into neurones o f dopaminergic phenotypes is essential. However, 
while adult neural progenitor cells have shown to generate neurones both in vitro 
(Gritti et al., 1996; Reynolds and Weiss., 1992; Palmer et al., 1995; 1997; 1999; 
2001) and following transplantation into the adult brain (Gage et al., 1995b; Suhonen 
et al., 1996), the extent o f dopaminergic differentiation has not been reported. By 
isolating adult hippocampal progenitor cells using the Percoll buoyancy faction 
method (Palmer et al., 1999) and differentiating cells in vitro, we have shown that 
adult progenitors can generate neurones, which is consistent with previous reports. 
However, the in vitro generation o f neurones is relatively low, and more importantly, 
adult progenitor cells fail to spontaneously differentiate into dopamine neurones as 
demonstrated by the lack o f neurones being immunopositive for TH.
5.4.1 Proliferation o f  adult neural progenitor cells
The proliferation o f  adult neural progenitor cells was successfully achieved following 
exposure to media containing 20ng/ml bFGF and unlike the neurosphere cultures that 
have been previously reported (Reynolds & Weiss., 1992), adult progenitor cells were 
influenced to grow as monolayer cultures by coating the culture dishes with poly- 
omithine and laminin. The initial cell culture contained a variety of different cell 
types as demonstrated by their distinct morphological characteristics. Although these
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cell types were not specifically identified, the initial cell culture has been shown 
previously to consist o f  oligodendrocytes, astrocytes, microglia, fibroblasts and 
immature neurones (Palmer et a l., 1995). After passaging, the appearance of cells was 
markedly different to primary cells. This vast contrast in cell morphologies is 
probably a result o f the absence o f glia and fibroblasts from the cell culture, due to the 
enrichment of progenitor cells during the passaging procedure. It is generally accepted 
that glia and fibroblasts are more adherent than immature progenitor cells, and 
therefore, brief treatment with trypsin during passaging can be used to selectively 
isolate the progenitor cells from the culture. Continued passaging therefore ‘filters 
out’ glial cells and in turn enriches the population o f adult-derived neural progenitors 
(Palmer et a l., 1995). The removal o f  glia from the culture following passage could 
also explain why progenitor-enriched cultures proliferate slower than initial cell 
cultures. It is possible that glial cells proliferate faster than progenitor cells and 
therefore, the removal o f glial cells during passaging will result in decreased 
proliferation rates o f passaged cultures. Alternatively, since glia are known to aid the 
maintenance and survival o f neurones by secreting trophic factors, their removal may 
result in the slower proliferation o f progenitor cells due to the lack o f trophic support.
5.4.2 Adult neural progenitor cells differentiate into neurones and glia in vitro 
Consistent with previous reports, which have shown the generation o f neural 
phenotypes from adult neural progenitor cells (Palmer et al., 1995; 1997), the results 
from this study have also shown that adult hippocampal neural progenitor cells have 
the capacity to differentiate into cells of neural phenotypes following periods of in 
vitro expansion. The neuronal yield from both primary and expanded progenitors was 
however relatively low (~5% and -3%  respectively, Fig. 5.3), whereas the percentage 
of adult progenitor cell-derived astrocytes was much higher (-25%  for primary cells 
and -22%  for expanded cells, Fig. 5.3). Although the remaining differentiated cells 
were not identified, a proportion of these cells are likely to be oligodendrocytes as 
previously shown (Palmer et al., 1995; 1997). It is also probable that some microglia, 
fibroblasts and undifferentiated progenitor cells remain in the cultures.
The levels o f neurogenesis observed in this study are consistent with the results 
reported by Palmer et al, who have also shown low yields of neurones following 
differentiation o f  adult progenitors (Palmer et al., 1999). However, while both studies
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have demonstrated low-levels o f neurogenesis, there are some differences between the 
data reported by Palmer and the results presented here. For instance, Palmer et al 
shows a neuronal yield o f 1% and 8% for primary and expanded progenitors (which 
have also been passaged once), respectively. Our results however, show that primary 
cells generate 5% neurones and expanded progenitors generate 3% neurones.
The reasons for these differences are unclear, but perhaps the difference in the 
neuronal yield for primary cells may be because o f the techniques used for cell 
preparation. In the study by Palmer et al. , dissected tissue was dissociated into single 
cells by filtering cells through a mesh, while we used gentle trituration. Our 
preparation technique may have been more favourable and may therefore explain why 
more neurones were observed following differentiation o f  primary cells. In turn, the 
higher neuronal yield reported by Palmer following differentiation o f expanded 
progenitors may have been because o f the different differentiation conditions used. 
Palmer and colleagues used differentiation media containing 0.1 p.g/ml of retinoic 
acid, while in our study we used a concentration o f 0.5/ig/mJ. Since retinoic acid is a 
factor important in promoting the neural differentiation o f adult neural progenitor 
cells (Takahashi et al., 1999), the difference in retinoic acid concentration may have 
contributed to the difference in neurogenesis observed.
Interestingly, it has been reported that adult neural progenitor cells may be a type of 
astrocyte since astrocytes have shown to generate neurones both in the subventricular 
zone (Doetsch et al., 1999) and in the hippocampus (Seri et al., 2001). Therefore, the 
abundant numbers of astrocytes observed in our cultures might reflect either 
differentiated astrocytes derived from progenitor cells or a proportion of these adult 
progenitor cells. I f  the astrocytes represent the former, then the multipotent potential 
of adult neural progenitor cells is demonstrated. However, if the astrocytes represent 
progenitor cells, then this suggests that the in vitro conditions were inadequate for the 
differentiation o f progenitor cells.
In addition, if  the astrocytes are progenitor cells, then the progenitor-enrichment 
passaging protocol, which eliminates glia, will reduce the number o f progenitors in 
the culture, and may explain why adult neural progenitor cells struggle to generate 
neurones. In an attempt to increase the number of progenitors in the culture, perhaps
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the progenitor-enrichment passaging protocol should be avoided, and all cells should 
be passaged to ensure that astrocytes are not removed from the culture.
5.4.3 Adult neural progenitor cells fa il to generate dopamine neurones 
The failure o f  expanded adult progenitors to differentiate into dopamine neurones was 
somewhat expected given the low yield o f (3-tubulin-positive cells. In addition, 
because embryonic ventral mesencephalic neural progenitor cells fail to generate 
dopaminergic neurones, or generate extremely low numbers o f dopaminergic 
neurones following expansion, the lack of dopaminergic differentiation following 
proliferation o f adult progenitor cells was not surprising. Because o f this detrimental 
effect o f proliferation on the generation o f dopamine neurones, we decided to 
differentiate primary cells (cells that were not proliferated) and assess their potential 
to generate into dopamine neurones. However, not even primary cells differentiated 
into dopamine neurones, again not overly surprising given of the low neuronal yield 
and the inability o f expanded progenitors to differentiate into dopaminergic 
phenotypes.
While evidence for the differentiation o f adult neural progenitor cells into 
mesencephalic dopamine neurones has not been reported, a small proportion o f these 
cells have been shown to differentiate into tyrosine hydroxylase-positive olfactory 
bulb neurones following transplantation (Suhonen et al., 1996). The lack o f in vitro 
dopamine differentiation is therefore likely to reflect the in vitro conditions, which 
might be missing essential factors/signals that influence dopaminergic differentiation, 
rather than an inability o f adult neural progenitor cells to differentiate into dopamine 
neurones. The identity o f these factors/signals are unknown, but to try and promote 
the in vitro dopaminergic differentiation o f adult neural progenitor cells, future studies 
should take known strategies that have been shown to enhance dopaminergic 
differentiation and apply these conditions to cultures of adult neural progenitors. For 
instance, the dopaminergic differentiation o f adult progenitors may require exposure 
to a cocktail o f different factors, similar to that reported for the dopaminergic 
differentiation o f embryonic neural progenitors (Ling et al., 1998; Carvey et a l, 
2001).
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5.4.4 Adult progenitor cells generate insufficient numbers o f  cells fo r  transplantation 
The isolation o f  adult neural progenitor cells using the Percoll buoyancy fraction 
method (Palmer et a l., 1999) generates a small number o f cells, which means only 
small-sized cultures can be established. Even when these cultures are confluent, there 
are still insufficient numbers o f progenitor cells available for transplantation. 
Interestingly, in a recent transplantation study using adult progenitor cells 
(Dziewczapolski et al., 2003), not only were cells at passage 11 used, but also, cells 
were isolated using a method other than the Percoll method, probably to generate 
larger starting cultures. The reason why passage 11 cells were used was not explained, 
but it suggests that this level o f  expansion is necessary to generate appropriate 
numbers o f cells. One possible explanation for using such cells may be because the 
neurogenic capacity o f adult neural progenitors has been reported to increase with 
increased proliferation, possibly because o f a result o f bFGF-induced recruitment of 
neurone-competent progenitors (Palmer et al., 1999). However, because 
Dziewczapolski et a l did not mention this in their report, it is unlikely that this was 
the reason why passage 11 cells were chosen.
The suggestion that neurogenesis increases with proliferation is quite interesting since 
the opposite has been shown with embryonic rat neural progenitors (see chapter three 
& Smith et al., 2003). Also, our results do not reflect this finding as we show that 
primary progenitors generate more neurones than expanded progenitors. The reasons 
for these conflicting results are unclear, but it is important to note that Palmer et al 
based their conclusion on the neurogenic potential of primary cells and cultures 
proliferated for 3, 7, 14 and 28 days. Our conclusion however, was only based on 
comparing the differentiation o f primary cells and cultures proliferated for 21 days. 
Since initial cell cultures and expanded cultures are distinctly different, direct 
comparisons between these cell types cannot be made. To confirm our findings we 
must compare the differentiation o f expanded progenitor cultures to cells that have 
been expanded for different periods o f time.
In summary, adult neural progenitor cells can differentiate into neural phenotypes in 
vitro, however, neurogenesis is low and dopamine differentiation is non-existent. The 
generation o f a large number o f cells is also proving difficult, therefore restricting
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transplantation studies. Over the past few years research into adult progenitor cells has 
gone relatively quiet, perhaps because o f the problems mentioned above. Substantial 
progress in this field is therefore required before adult neural stem cells can be 
considered as a potential source of neurones for transplantation.
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Experiment Tour- Evafuation o f nigrostriataf lesions in the 129 
OLJi mouse strain as a suita6(e modeCof (Parkinson’s disease.
Summary
This chapter discusses the use of the 129P2/OLA Hsd mouse strain as a suitable 
model for Parkinson’s disease.
Using the standard medial forebrain bundle (MFB) 6-OHDA lesion, and the induction 
of rotational behaviour following 5mg/kg amphetamine administration, it was 
apparent that the resultant rotations were variable and unreliable with no correlation 
between rotation and dopamine loss. It was therefore necessary to characterise the 
conditions that gave the optimal rotational response for the 129 OLA mouse strain. 
Both the unilateral 6-OHDA MFB lesion and the striatal terminal lesion protocols 
were compared, with mice analysed for appropriate rotational responses induced after 
the administration o f amphetamine and apomorphine at different concentrations. 
Neither the MFB nor striatal 6-OHDA lesioned mice produced high rotational 
responses following apomorphine stimulation at any dose. However, mice did respond 
to amphetamine, with peak rotation dose at 5mg/kg and lOmg/kg for MFB and striatal 
lesions respectively.
Although bundle lesioned mice responded to amphetamine and apomorphine, the
lesion was unreliable with there being no correlation between dopamine loss and
2 2 rotational asymmetry (r =0.007 amphetamine, r =0.005 apomorphine).
Striatal lesions provided more reliable lesions, with stronger correlations between
dopamine loss and rotational asymmetry being observed (r2=0.70 amphetamine,
r2=0.16 apomorphine).
From this assessment, it seems that the optimal conditions that produce maximum and 
reliable rotational behaviour recordings for the 129 OLA mouse strain were striatal 
terminal 6-OHDA lesion followed by rotation measurement after lOmg/kg 
amphetamine administration.
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6.1 Introduction
Parkinson's disease is a progressive neurological disorder that is characterised by a 
catalogue of movement impairments such as rigidity, tremor and bradykinesia 
(Olanow & Tatton., 1999; Samii et al., 2004). The disease is primarily caused by the 
loss of the nigrostriatal dopamine pathway (Olanow & Tatton., 1999), and therefore 
highlights the importance of striatal dopamine on motor function.
Experimental evidence for the role o f dopamine in the striatum, and its effects on 
motor function first came from dopaminergic stimulation o f the rat striatum, which 
resulted in marked changes in motor response (Ungerstedt et a l, 1969). The 
subsequent pioneering investigations on motor effects following unilateral dopamine 
depletion using 6-hydroxydopamine (6-OHDA) provided a unique way of analysing 
dopamine activity by measuring drug-induced motor function (Ungerstedt et a l, 
1970; Ungerstedt., 1971a; 1971b). Under these conditions rats displayed a turning 
behaviour referred to as ‘rotation’, with the degree of rotation being proportional to 
dopamine loss (Lee et al., 1996) and the direction of rotation being dependent on the 
rotation-inducing drug used (Ungerstedt., 1971a; 1971b).
The neurotoxin 1-methy 1-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can also be 
used to lesion the dopamine system because of its specific targeting and destruction of 
the nigrostriatal dopamine pathway. Its chance discovery following its Parkinsonism- 
inducing effects in humans (Langston et al., 1983 Ballard et al., 1985), has provided 
an alternative to the use o f 6-OHDA, and has been used to produce motor 
dysfunctions in a variety o f animals including monkeys (Burns et al., 1983; Jenner et 
al., 1984; Schneider et a l ,  1987), cats (Schneider & Markham., 1986; Williams & 
Schneider., 1989) and mice (Heikkila et al., 1984; Ricaurte et al., 1986).
The main advantage of MPTP is that it can be given systematically, unlike 6-OHDA, 
which requires accurate infusion in the desired brain area. This neurotoxin however 
causes bilateral dopamine depletion, so animals exhibit profound regulatory deficits 
in the absence of one normal system to maintain health. Moreover, reliable 
behavioural tests such as rotation, which are dependant on unilateral asymmetries, 
cannot be assessed. Furthermore, spontaneous recovery o f MPTP-induced deficits has 
been reported (Iancu et al., 2005 and references therein), which means long-term 
assessment o f behavioural deficits cannot be achieved. In addition, MPTP
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neurotoxicity varies in its effects (Giovanni et a l., 1994), with some mouse strains 
being more sensitive than others (Betarbet et al., 2002), and rats being resistant to 
MPTP toxic insults (Giovanni et al., 1994). It is currently unclear why rats are not 
susceptible to MPTP, but their inability to breakdown MPTP into the damaging toxic 
metabolite MPP is not the reason since intrastriatal infusion of MPP+ into the rat 
brain results in insignificant dopamine loss when compared to mice (Giovanni et al., 
1994). The temporary deficits caused by MPTP administration, and the variability o f 
its effects, both within and across species has therefore limited the use of MPTP in 
research.
Although a number o f models for Parkinson’s disease exist (see reviews by Betarbet 
et al., 2002; Shimohama et al., 2003), the 6-OHDA-lesion model of Parkinson’s 
disease is still well established and is probably the most widely used model in 
Parkinson’s disease research. This model has without doubt accelerated progress into 
Parkinson’s disease research by providing a powerful tool to assess the potential of 
curative treatments by examining the attenuation o f 6-OHDA-lesion-induced 
behavioural deficits. However, while this model has been well established in rats, it is 
surprising why the 6-OHDA-lesion model o f Parkinson’s disease is not more widely 
used in mice. With the advancements in mouse embryonic stem cell research, the 
requirement for a mouse 6-OHDA-lesion model of Parkinson’s disease is becoming 
essential in order to allow the therapeutic potential of mouse embryonic stem cells, 
and other mouse-derived cell lines to be assessed efficiently without the added 
complications o f immunosuppression.
Although rotational behaviour has been observed in dopamine-depleted mice 
(Brundin et al., 1986, Barberi et al., 2003; Iancu et al., 2005), the resultant rotational 
bias and the methods used to induce rotational behaviour in these studies vary 
considerably, with differences in lesion type, drug, and drug doses used. For instance, 
the unilateral, 6-OHDA intrastriatal lesions used by Brundin et al., (1986) produced 
low rotational asymmetry following 2.5mg/kg amphetamine stimulation. In contrast, 
much better rotations were reported by Barberi et al., (2003) following striatal lesions 
and stimulation by lOmg/kg amphetamine and apomorphine. However, while good 
rotations were observed by Barberi and colleagues, the drug doses used seem
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excessive, particularly with respect to apomorphine. This high-dose apomorphine- 
induced rotation suggests that no supersensitivity o f post-synaptic dopamine receptors 
occurred, even though increased receptor binding has been previously reported 
following striatal 6-OHDA lesions in mice (Bensadoun et a l., 2000). In addition, 
while MFB lesions used by Iancu et a l., (2005) have been shown to produce good 
rotational behaviour following 2.5mg/kg amphetamine challenge, lesions were 
inconsistent and are therefore unreliable.
It is clear from these studies that a standard protocol for developing good rotational 
bias following the unilateral 6-OHDA lesions in mice has yet to be established.
This chapter aims to evaluate the 129 OLA mouse strain for its suitability to produce 
rotational behaviour following 6-OHDA lesioning, and to establish the conditions that 
are necessary to produce optimal rotational bias that reflect dopamine depletion. Both 
medial forebrain bundle (MFB) and striatal terminal 6-OHDA lesions have been 
compared for rotation after amphetamine and apomorphine stimulation. Drug dose 
giving peak rotational behaviour has also been calculated for amphetamine and 
apomorphine.
This chapter provides a comprehensive, detailed assessment o f lesion type, drug and 
drug dose required to produce a standard, reproducible model where rotational bias 
reflects dopamine loss in the 129 OLA mouse strain.
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6.2 Experimental Procedure
A full, detailed description o f the experimental procedures can be found in chapter 
two, section 2.7.1 & 2.8.2 and will only be briefly described here.
Prior to commencing behavioural testing, all mice underwent ten minutes of 
habituation to their testing environment. This eliminated any novel environmental 
stimuli that might have interfered with rotational recordings.
When testing amphetamine-induced rotations, d-amphetamine was used rather than 
the more potent methamphetamine. Behavioural testing lasted 90 minutes, with each 
mouse having its rotational behaviour recorded for one minute at each interval, for a 
total o f fifteen intervals, with each interval lasting six minutes.
Due to the faster metabolism and clearence of apomorphine compared to 
amphetamine, apomorphine-induced rotations lasted for 48 minutes with each mouse 
having its rotational behaviour recorded for one minute at each interval, for a total of 
eight intervals, with each interval lasting six minutes.
Both amphetamine and apomorphine were dissolved in 0.01% ascorbic saline to 
prevent the oxidation of the drugs, and were administered via intraperitoneal and 
subcutaneous injection respectively. Mice were given at least 7 days to recover 
between each amphetamine dose and at least 4 days between each apomorphine dose, 
to ensure that drugs had been eliminated from the system.
Stimulation of lesioned mice by amphetamine results in rotations ipsilateral to the side 
of the lesion. Apomorphine stimulation o f the lesioned mice results in rotations 
contralateral to the side o f the lesion. For this reason, when plotting rotational data, 
ipsilateral rotations were given positive values whereas contralateral rotations were 
given negative values, thus reflecting the direction of rotation.
Statistical tests of analysis of variance (ANOVA) were analysed using the statistical 
package Genstat v7.2, with further analysis o f the results being achieved by using the 
Neuman Keuls t-test.
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6.3 Results
6.3.1 Effect o f  ascorbic acid on amphetamine-induced rotations 
Mice (n=5) with 6-OHDA, medial forebrain bundle lesions were tested for rotational 
bias following stimulation with 2.5mg/kg amphetamine, supplemented with or 
without 0.01% ascorbic acid. Mice were also observed for rotational asymmetry 
following 0.01% ascorbic saline injection (Omg/kg -  control group).
The addition o f ascorbic acid to amphetamine had no effect on rotational behaviour, 
with both amphetamine groups (with and without ascorbic acid) rotating an average of
3.3 times per minute. As expected, the control group displayed little rotational 
behaviour (Fig. 6.1).
Statistical analysis of data confirmed these observations. Although a significant 
difference in rotations across groups was shown (F(2,24>=111.21, p<0.001), further 
analysis showed no significant difference between the amphetamine groups (NK: 
t(2,2f=0.223, n.s). However, 2.5mg/kg amphetamine-induced rotations (with and 
without ascorbic acid) showed significantly higher rotational bias compared to the 
control group (NK: t<3,2)= 18.436, p<0.01 amphetamine) & (NK: t<2,2)= 18.212, p<0.01 
amphetamine + ascorbic acid).
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Fig. 6.1 Effect of ascorbic acid on rotational behaviour following 2.5mg/kg 
amphetamine stimulation. Statistical analysis shows no effect of ascorbic acid on 
rotational behaviour.
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6.3.2 Amphetamine-induced rotations on medial forebrain bundle (MFB) 6-OHDA 
lesioned mice
24 mice were tested for their rotational behaviour over time after the administration of 
amphetamine at Omg/kg (0.01% ascorbic saline injection) 2.5mg/kg, 5mg/kg and 
lOmg/kg.
Mice injected with Omg/kg amphetamine showed little rotational behaviour. At 
2.5mg/kg, mice showed good rotation, with peak rotation ( 6  rotations/minute) at 
interval 3 (18 minutes) which stabilised over the following three intervals. After the 
sixth interval (36minutes), rotational behaviour decreased to  1.71 rotations/minute 
(Fig. 6 .2 ).
Rotations at 5mg/kg were similar to  the rotational behaviour observed at 2.5mg/kg 
with peak rotation at around 6  rotations/minute. However, rotation was more stable at 
this dose with a reduction in drug-induced response occurring after interval ten 
(60minutes), compared to interval six (36 minutes) at a dose o f 2.5mg/kg (Fig. 6.2).
At a dose o f 1 Omg/kg, the induced rotational behaviour was notably lower than the 
rotation induced at both 2.5mg/kg and 5mg/kg. After the sixth interval, there was an 
increase in rotational response that remained stable until a small drop at the final two 
intervals (Fig. 6.2).
Results show a significant effect o f amphetamine dose on rotational response 
(F(3.1380)=40.31, p<0.001), with further analysis indicating that 5mg/kg amphetamine 
induces rotational responses that were significantly higher than rotations produced by 
lOmg/kg and Omg/kg amphetamine (NK. t<3,3>-13.85, p<0.01) & (NK. t(4,3>=8.624, 
p<0.01) respectively, but not than 2.5mg/kg (NK: t<273)= 1.957, n.s). Rotation induced 
by 2.5 mg/kg was significantly higher than the rotation produced from both 1 Omg/kg 
and Omg/kg (NK. t(2,3)=6.667, p<0.05) & (NK. t(3,3)=l 1.896, p<0.01) respectively. 
Rotations induced by 1 Omg/kg were also significantly higher than Omg/kg (NK: 
t(2,3)=5.229, p<0.05) (Fig. 6.2).
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Fig. 6.2 Amphetamine induced rotations at different sample intervals on bundle 
lesioned mice. Amphetamine dose has a significant effect on the induction of 
rotational response (p<0 .0 0 1 ).
6.3.3 Amphetamine-induced rotations on striatal 6-OHDA lesioned mice 
7 mice were tested for their rotational behaviour over time after the administration o f 
amphetamine at Omg/kg (0.01% ascorbic saline injection) 2.5mg/kg, 5mg/kg, 
1 Omg/kg and 15mg/kg.
Mice injected with Omg/kg amphetamine showed little rotational behaviour (Fig. 6.3). 
At 2.5mg/kg, mice showed good rotations during the early intervals with rotations 
reaching over 6  rotations/minute. However, after interval 5 (30minutes) the effects on 
rotation rapidly decreased with rotation at the final interval being 1.43 
rotations/minute (Fig. 6.3). At 5mg/kg, rotational behaviour was, in general, higher 
than that produced from 2.5mg/kg. By interval 6  (30 minutes), notation had reached its 
peak (over 8  rotations/minute) with rotation stabilising over the next few intervals. 
After 72 minutes (interval 12) rotation rate decreases sharply ending at 3.57 
rotations/minute at the final interval (Fig. 6.3). 1 Omg/kg amphetamine produced a 
high rotation rate with rotations o f 9.71 per minute by the third interval (18 minutes). 
Rotation rate was stable for a long period of time, reaching values of 11.29 
rotations/minute. After the thirteenth interval (78 minutes) rotation rate reduced but
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was still relatively high with rotations of 8.14 rotations/minute at the final interval 
(Fig. 6.3). At 15mg/kg, there was a steady increase in rotational behaviour with time, 
with a peak rotation rate o f 8.29 rotations/minute occurring in the final interval (Fig. 
6.3).
Analysis o f variance (ANOVA) indicated a significant effect of amphetamine dose on 
rotational response (F(4,450)=l80.07, p<0.001). Further analysis shows that 1 Omg/kg 
amphetamine-induced rotation was significantly higher than rotations produced by 
15mg/kg, 5mg/kg, 2.5mg/kg and Omg/kg amphetamine (NK: t(3,4)=16.68, p<0.01), 
(NK: t(4j4)=14.324, p<0.01), (NK: t(2,4)=14.324, p<0.01) & (NK: t(5,4)=36.865, p<0.01) 
respectively. 5mg/kg amphetamine-induced rotations were significantly higher than 
rotations induced by 2.5mg/kg (NK: t^ 3,4)=8 .5 3 3 , p<0.01) and Omg/kg (NK: 
t(4,4)=2 2 .5 4 ), p<0.01) but not significantly different than the rotations induced by 
15mg/kg amphetamine (NK: t<2,4)=2 .3 5 5 , n.s). 15mg/kg amphetamine rotations were 
significantly higher than the rotations induced by 2.5mg/kg amphetamine (NK. 
t(2,4>=6 .178, p<0.05), with rotations induced by 2.5mg/kg being significantly higher 
than behavioural rotation at Omg/kg (NK. t(2,4)=l4.008, p<0.01) (Fig. 6.3).
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Fig. 6.3 Amphetamine induced rotations at different sample intervals on striatal 
lesioned mice. Amphetamine dose has a significant effect on the induction of 
rotational response (p<0 .0 0 1 ).
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6.3.4 Amphetamine-induced rotations on non- lesioned (control) mice 
Non-lesioned mice were tested for amphetamine-induced rotation at all doses 
(Omg/kg-15mg/kg). This was necessary to confirm that rotations observed in the mice 
were due to the lesioning o f the dopamine system and not any other factor (Fig. 6.4). 
Following amphetamine simulation, the activity o f mice was amplified and slight 
rotational behaviour was seen, this rotation was however insignificant at all doses 
(F(4,525)= l 88, n.s).
The rotational response after amphetamine stimulation on control mice across time 
can be seen in Fig. 6.4 with Fig. 6.5 showing individual dose-response graphs.
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Fig. 6.4 Amphetamine induced rotations at different sample intervals on non lesioned 
(control) mice. Statistical analysis shows that there is no significant effect of 
amphetamine on the rotational behaviour o f non-lesioned (control) mice at any dose.
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Fig. 6.5 Individual dose-response graphs for amphetamine-induced rotations on non- 
lesioned (control) mice at 2.5mg/kg (a), 5mg/kg (b), 1 Omg/kg (c) & 15mg/kg (d).
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6.3.5 Apomorphine-induced rotations on medial fore brain bundle 6-OHDA lesioned 
mice
As well as mice being tested for their rotational behaviour after the administration of 
amphetamine, rotation was also assessed after apomorphine stimulation. 8 mice with 
unilateral MFB 6-OHDA lesions received doses of apomorphine at Omg/kg (0.01% 
ascorbic saline injection), O.Olmg/kg, 0.05mg/kg, 2.5mg/kg, 5mg/kg and lOmg/kg, 
with rotation lasting 48 minutes (8 intervals).
Mice injected with Omg/kg, O.Olmg/kg and 0.05mg/kg showed little rotational 
response across the whole eight intervals (average rotations o f 0.19, 0.08 and 0.05 
rotations/minute respectively, Fig. 6.6). Doses o f  2.5mg/kg produced better rotation 
compared to Omg/kg, O.Olmg/kg and 0.05 mg/kg, with an average rotation rate of 2.76 
rotations/minute. Rotation rate was stable for a short period, with rotation at intervals 
2-4 (12-24 minutes) being around 3 rotations/minute. Over time, rotation slowly 
decreased, with rotation at the final interval being 2.12 rotations/min (Fig. 6.6).
At a dose of 5mg/kg, rotation was more stable for a longer period of time, with 
rotation rates o f  around 3 rotations/minute being established and maintained from the 
second interval (12 minutes) until the final interval (Fig. 6.6). At lOmg/kg 
apomorphine produced rotations that were stabile throughout the 48 minute testing 
session but with rotations being relatively low (less than 2 rotations/minute) compared 
to the rotations produced by 2.5mg/kg & 5mg/kg apomorphine (Fig. 6.6).
Analysis o f variance (ANOVA) indicated a significant effect o f apomorphine dose on 
rotational response (F(5336)=31.43, p<0.001).
Further analysis showed that rotations at 5mg/kg apomorphine were significantly 
higher than rotations produced by 1 Omg/kg, 0.05mg/kg, O.Olmg/kg and Omg/kg 
apomorphine (NK. t(3,5)=6519, p<0.05), (NK: t(6,5)= l l  704, p<0.01), (NK: 
t(5.5)=l 1.593, p<0.01) & (NK: t(4,5)=l 1.185, p<0.01) respectively, but not than 
2.5mg/kg (NK: t<2,5)=1.667, n.s). 2.5mg/kg apomorphine-induced rotations were 
significantly higher than rotations induced by 1 Omg/kg (NK: t(2,5)=4 852, p<0.05), 
0.05mg/kg (NK: t<5,5)=10.037), p<0.01), O.Olmg/kg (NK: t<4,5)=9.926, p<0.01) and 
Omg/kg (NK. t(3,5)=9.519, p<0.01).
Apomorphine doses of 0.05mg/kg, O.Olmg/kg and Omg/kg did not produce rotations 
that were significantly different to each other (NK: t(2,5)==0.407, n.s), (NK. t(3,5)=0.519, 
n.s) & (NK: t(4,5)=0.Ill, n.s) respectively (Fig. 6.6).
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Fig. 6.6 Apomorphine-induced rotations at different sample intervals on medial 
forebrain bundle lesioned mice. Statistical analysis shows that there is a significant 
effect of apomorphine dose on the rotational behaviour of lesioned mice (p<0.001). 
Negative values = contralateral rotations.
6.3.6 Apomorphine-induced rotations on striatal 6-OHDA lesioned mice 
7 mice with unilateral striatal 6-OHDA lesions, received subcutaneous injections of 
apomorphine at doses of 15mg/kg, 1 Omg/kg, 5mg/kg, 2.5mg/kg, 0.05mg/kg and 
Omg/kg (0.01%ascorbic saline injection).
Neither Omg/kg nor 0.05mg/kg apomorphine produced any behavioural rotation. 
There was little rotational behaviour with 2.5mg/kg apomorphine, with rotations 
fluctuating at 1 rotations/minutes or below across the whole 8 intervals, with the 
average rotation being 0.588 rotations/minute (Fig. 6.7).
Rotation after 5mg/kg apomorphine administration produced a small rotational 
response that reduced slowly over the second to fifth interval (12-30 minutes) before 
stabilising. Peak rotation occurred at interval two (1.29 rotations/minute) but by the 
final interval rotation had reduced to 0.57 rotations/minutes. The average rotation over 
the entire eight intervals (48 minutes) was 0.69 rotations/minute (Fig. 6.7).
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Rotations at 1 Omg/kg apomorphine produced the best rotations of the group with the 
first four intervals having rotations o f  nearly 3 rotations/minute. After the fourth 
interval, rotation decreased sharply with rotation falling below 1 rotations/minute after 
the fifth interval (30 minutes). Average rotation over the entire eight intervals was 
1.89 rotations/minute (Fig. 6.7).
15mg/kg apomorphine-induced rotations were relatively low, with no rotations above 
1 rotations/minute after the first interval. The average rotation over the entire eight 
intervals was 0.73 rotations/minute (Fig. 6.7).
Analysis o f  variance (ANOVA) indicated a significant effect of apomorphine dose on 
rotational response (F(55288)=36.21, p<0.001).
Further analysis o f results showed that 1 Omg/kg apomorphine produced rotations that 
were significantly higher than the rotations produced at 15mg/kg, 5mg/kg, 2.5mg/kg, 
0.05mg/kg and Omg/kg (NK: t(2,5)=6902, p<0.01), (NK: t(3,5)=8.754, p<0.01), (NK: 
t<4,5) = l l H I ,  p<0.01), (NK. t(5,5)=13.847, p<0.01) and (NK: t(6,5)= 15.001, p<0.01) 
respectively. Doses o f 15mg/kg apomorphine produced rotations that were 
significantly higher than the rotations produced at 0.05mg/kg (NK: t<4.5>=6.944, 
p<0.05), and Omg/kg (NK: t(5 5)=8.098, p<0.05), but not significantly different to 
5mg/kg (NK. t(2,5)= l .852, n.s) and 2.5mg/kg (NK. t(3,5)=4.209, n.s).
5mg/kg also produced rotations that were significantly higher than the rotations after 
0.05mg/kg and Omg/kg apomorphine administration (NK: t(3,5>=5.093, p<0.05) & 
(NK: t(4,5>=6.247, p<0.05) respectively. This dose however, did not produce rotations 
that were significantly different to the rotations corresponding to dose 2.5mg/kg (NK. 
t(2.5)=2.357, n.s).
Rotations at 2.5mg/kg, 0.05g/k and Omg/kg apomorphine were not significantly 
different to each other (Fig. 6.7).
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Fig. 6.7 Apomorphine-induced rotations at different sample intervals on striatal 
lesioned mice. Statistical analysis shows that there is a significant effect of 
apomorphine dose on the rotational behaviour of lesioned mice (p<0.001). Negative 
values = contralateral rotations
6.3.7 Apomorphine-induced rotations on non- lesioned (control) mice 
Non-lesioned mice were tested for apomorphine-induced rotation at all doses 
(Omg/kg-15mg/kg). This was necessary to confirm that rotations observed in the mice 
were due to the lesioning of the dopamine system and not any other factor (Fig. 6.8). 
There was no significant rotational behaviour at any dose. The rotational response 
after apomorphine stimulation on control mice across time can be seen in Fig. 6.8 
with Fig. 6.9 showing individual dose-response graphs.
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Fig. 6.8 Apomorphine-induced rotations at different sample intervals on non-lesioned 
(control) mice. Statistical analysis shows that there is no significant effect of 
apomorphine on the rotational behaviour of non-lesioned (control) mice at any dose.
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Fig. 6.9 Individual dose-response graphs for apomorphine-induced rotations on non- 
lesioned (control) mice at 0.01 mg/kg (a), 0.05 mg/kg (b), 2.5mg/kg (c), 5mg/kg (d), 
1 Omg/kg (e) & 15mg/kg (f).
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6.3.8 Comparison o f MFB and striatal 6-OHDA lesioned mice
6.3.8.1 Dose-response curves o f  amphetamine and apomorphine
The average rotational response for MFB and striatal lesioned mice at each dose of
amphetamine and apomorphine is shown in Fig. 6.10.
Mice with MFB lesions show dose-dependent rotational behaviour after the 
stimulation by either amphetamine (F(395)=3.20, p<0.05) or apomorphine (F(5,42)=5.13, 
p<0.001). At Omg/kg amphetamine (control), rotation is negligible. Doses of 
2.5mg/kg and 5mg/kg amphetamine induce rotations that are higher than rotations at 
Omg/kg, with mean rotations reaching at least 4 rotations/minute. There is a decrease 
o f  rotational behaviour at 1 Omg/kg amphetamine where mean rotation decreases to 
less than 2 rotations/minute. Doses o f Omg/kg and 0.05mg/kg apomorphine result in 
little or no rotation, whereas mean rotations o f 2.78 and 3.18 rotations/minutes are 
observed at doses o f 2.5mg/kg and 5mg/kg apomorphine respectively. At 1 Omg/kg 
there is a reduction in mean rotational response to 1.47 rotations/minute (Fig. 6.10a).
Striatal 6-OHDA lesioned mice also show a significant dose-dependent effect 
following either amphetamine (F(43o>=22.30, p<0.001) or apomorphine challenge 
(F(5,36)~ 11.10, pco.ooi). Amphetamine dose of lOmg/kg produced peak rotation of 
9.69 rotations/minute, with doses o f 2.5mg/kg, 5mg/kg and 15mg/kg giving rotations 
o f 3.9, 6 and 5.39 rotations/minute respectively. There was little rotation at Omg/kg 
(control) with average rotations o f 0.3 per minute. Closer analysis o f  the results show 
the rotational response at 1 Omg/kg being significantly higher than at 5mg/kg, 
15mg/kg, 2.5mg/kg & Omg/kg (NK: t(2,4)=5.118, p<0.05), (NK: t(3,4)=5 964, p<0.05), 
(NK: t(4,4)=8.031, p<0.05) & (NK: t<5,4)= 13.024, p<0.01) respectively.
Doses of 5mg/kg, 15mg/kg and 2.5mg/kg produced rotations that were not 
sienificantlv different from each other, but were sienificantlv different when 
compared to Omg/kg (NK: t<4,4)=7.906, p<0.05), (NK: t(3,4>=7.060, p<0.05) & (NK: 
t(2,4)=4.993, p<0.05). Apomorphine-induced rotations on striatal lesioned mice 
produced relatively low rotation rates. All doses induced rotations o f less than 2 
rotations/minute, with 1 Omg/kg apomorphine producing peak rotation of 1.74 
rotations/minute. Analysis o f the results show that the rotations induced after 1 Omg/kg 
apomorphine administration were significantly higher than the rotations at all other 
doses (NK. t(2,5)=4.998, p<0.05), (NK: ^>=5.047, p<0.05), (NK: t<4,5)=5.344, p<0.05)
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& (NK: t(5,5)=7.917, P<0.05) for doses 15mg/kg, 5mg/kg, 2.5mg/kg, Omg/kg & 
0.05mg/kg respectively.
Rotations induced by 15mg/kg, 5mg/kg, 2.5mg/kg, 0.05mg/kg & Omg/kg 
apomorphine were not significantly different from each other (Fig. 6.10b).
a. Medial forebrain bundle lesion
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Fig. 6.10 Dose-response curves for amphetamine and apomorphine-induced rotations 
show the average rotational response at each drug dose for MFB (a) and Striatal (b) 
lesioned mice. Positive values indicate ipsilateral rotations and negative values 
indicate contralateral rotations.
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6.3.8.2 Comparison o f  amphetamine and apomorphine-induced rotations 
Although amphetamine stimulation in the MFB lesion model induces slightly higher 
rotations than those produced by apomorphine (Fig. 6.11a), statistical analysis shows 
no significant difference in the rotational behaviour induced following amphetamine 
and apomorphine stimulation at 2.5mg/kg, 5mg/kg and lOmg/kg (NK. t(2,3)=1.353, 
n.s), (NK. t<2,3)= l-623, n.s) & (NK. t(23)=0.487, n.s) respectively (Fig. 6.11a).
The striatal lesion model however, shows a significant difference in drug effect with 
amphetamine proving a better pharmacological stimulant in inducing rotational bias at 
all doses except for Omg/kg (p<0.01) (Fig. 6.11b). Interestingly peak effects of both 
amphetamine and apomorphine are different for the two lesion models, with peak 
dose o f amphetamine and apomorphine occurring a 5mg/kg for the MFB lesion group 
and at 1 Omg/kg for the striatal lesion group (Fig. 6.1 la  & b).
b . Striatal lesionsa. Bundle lesions
Amphetamine 
1 1 Apomorphine
0 2 .5  5 10 0 2 .5  5 10
Drug dose (mg/kg) Drug dose (mg/kg)
Fig. 6.11 Comparison o f amphetamine and apomorphine-induced rotations on 6- 
OHDA lesioned mice. Effects o f amphetamine and apomorphine are similar on MFB 
lesioned mice (a), however amphetamine was more successful at inducing rotations in 
the striatal lesion group (b). Peak drug effects occurred at 5mg/kg for both drugs in 
the MFB lesion group compared to 1 Omg/kg for both drugs in the striatal lesion 
group. **p<0.01
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6.3.9 Bundle vs. Striatal lesions
6.3.9.1 Am phetamine-induced rotations
Fig 6.12 and 6.13 show the comparison between the effects of amphetamine-induced 
rotations at different doses on both striatal and medial forebrain bundle lesioned mice. 
At a dose o f 2.5 mg/kg amphetamine, the rotational behaviour for both lesion models 
is very similar (Fig. 6.12a). There is no significant difference between lesion groups at 
this dose (NK: t(2,3>=0.214, n.s), with the average rotation rate at this dose for striatal 
and bundle lesioned mice being 3.77 and 4.13 rotations/minute respectively.
At 5mg/kg amphetamine, the rotational behaviour for both lesion models are also 
similar to each another (Fig. 6 .12b), with no significant difference o f  rotation between 
the two (NK: t<2,3)=l .189, n.s).
1 Omg/kg amphetamine reveals a large rotational difference between the two groups 
(Fig. 6.12c), with striatal lesions rotating significantly higher than bundle lesioned 
animals (NK. t(2,3>=7.544, p<0.05).
Statistical analysis o f  the results confirm a difference in rotations after amphetamine 
stimulation on different lesion groups (F(3,i22>=3.04, p<0.05).
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Fig. 6.12 There is a significant difference of lesion group after amphetamine-induced 
rotations (p<0.05), with lOmg/kg amphetamine being more effective on striatal than 
bundle lesioned (p<0.05).
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Fig. 6.13 Effect of amphetamine on lesion groups is similar at doses of 2.5mg/kg and 
5mg/kg. At lOmg/kg, amphetamine is more effective at producing rotations on striatal 
lesion models than bundle lesions. *p<0.05.
6.3.9.2 Apomorphine-induced rotations
Fig 6.14 and 6.15 show the comparison between the effects o f  apomorphine-induced 
rotations at different doses on both striatal and medial forebrain bundle lesioned mice. 
At a dose of 0.05mg/kg apomorphine, there is negligible rotation of mice with both 
bundle and striatal lesions, with rotations averaging -0.04 and 0.01 rotations/minute 
respectively (Fig. 6.14a).
At 2.5mg/kg and 5mg/kg, apomorphine-induced rotations appear to be more effective 
on the bundle lesioned animals compared to the striatal lesioned mice, with rotations 
of -2.78 and -3.18 compared to -0.66 and -0.72 rotations/minute (Fig. 6.14 b & c). 
Statistical analysis o f  these results indicate a significant differences in rotation (NK; 
t(2,4)= 4 -198, p<0.05) & (NK; t(2,4>= 4 -8 7 1 , p<0.05).
lOmg/kg apomorphine rotations are similar, with average rotations of -1.47 
rotations/minute for bundle lesion animals, and -1.78 rotations/minute for striatal 
lesioned mice (Fig 6.14d). There is no significant difference between these two 
groups at this dose (NK; t(2,4>=0.614, n.s)
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The difference in rotational behaviour after apomorphine stimulation on the two 
lesioned groups is confirmed by statistical analysis of variance (F(4,78)=3.24, p<0.05).
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Fig. 6.14 There is a significant difference of 
lesion group after apomorphine-induced 
rotations (p<0.05). Bundle lesion group at doses 
of 2.5mg/kg & 5mg/kg induce significantly 
higher rotations compared to striatal lesion 
groups (p<0.05)
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Fig. 6.15 Effects o f apomorphine on lesion groups are similar at lOmg/kg but not at 
2.5mg/kg and 5mg/kg where bundle lesions are more responsive. *p<0.05.
6.3.9.3 Comparison o f dose-response
The dose-response curves in Fig. 6.10 for bundle and striatal lesioned mice have been 
superimposed for direct comparison, as shown in Fig. 6.16a.
It appears that the striatal lesioned animals require higher doses of amphetamine and 
apomorphine to produce peak rotations compared to bundle lesion animals. For 
example, with bundle lesions 5mg/kg amphetamine and apomorphine induce the peak 
rotational response. However in striatal lesioned mice, peak rotation occurs at 
lOmg/kg for both amphetamine and apomorphine.
Another observation is that striatal lesioned animals respond better to amphetamine 
with greater rotations rates compared to bundle lesions (Fig. 6 .16b).
Although apomorphine produces relatively low rotations, it is more effective on 
bundle lesions than on striatal lesions, with doses of 2.5mg/kg and 5mg/kg inducing 
the best rotations (Fig. 6.16c)
With the aid of statistical regression, it is possible to calculate statistically the doses of 
amphetamine and apomorphine that give peak rotations for both bundle and striatal
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lesioned animals (Fig. 6.17). Regression analysis on amphetamine-induced rotations 
on bundle and striatal lesioned animals calculated peak rotations of 5.1 and 8.8 per 
minute at doses of 5.46mg/kg and 9.43 mg/kg amphetamine respectively (Fig. 6.17a). 
Regression analysis on apomorphine-induced rotations on bundle and striatal lesioned 
animals calculated peak rotations of 3.5 and 1.4 per minute at doses of 5.66mg/kg and 
9.25 mg/kg apomorphine respectively (Fig. 6.17b).
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Fig. 6.16 Dose-response curves of amphetamine and apomorphine for both lesion 
groups (a). Dose-response curves for amphetamine (b) and apomorphine (c) are also 
shown separately for both lesion groups.
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Fig. 6.17 Regression analysis of dose-response curves for amphetamine (a) and 
apomorphine (b) for both lesion groups.
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6.3.10 Rotation vs. dopamine cell loss
The extent of dopamine cell loss was analysed in both lesion models (Fig. 6.18) by 
counting and comparing the number o f TH positive cells in the substantia nigra, on 
both the lesioned and non-lesioned side of the brain (Table 6.1). Counts were obtained 
from at least three 60pm brain sections, and the average percentage dopamine cell 
loss was calculated. The mean cell loss for MFB and striatal 6-OHDA lesions were 
68.5% and 69.3% respectively, however MFB lesions were significantly more 
variable than the striatal lesions (F(2o,5)=63.66, p<0.001).
Fig 6.19 shows the correlation between dopamine cell loss and peak drug-induced 
rotations for each animal with either a MFB 6-OHDA lesion or a striatal 6-OHDA 
lesion. Medial forebrain bundle lesioned animals show sporadic results with no 
pattern between dopamine cell loss and rotation following amphetamine and 
apomorphine-induced rotations. Linear regression analysis for MFB lesioned animals 
following amphetamine and apomorphine-induced rotations are r2=0.007 & r^=0.005 
respectively. Striatal lesions however, show stronger correlations between dopamine 
cell loss and rotation following amphetamine and apomorphine stimulation with r2 
values of 0.70 and 0.16 respectively.
Fig. 6.18 TH immunohistochemical staining in brain sections moving rostral-caudal 
from left to right through the levels o f the striatum and the substantia nigra. MFB 
lesions show clear depletion o f TH staining on right hand side, in both the striatum 
and the substantia nigra (A). Striatal lesions show partial depletion of TH staining on 
right hand side in the striatum and the substantia nigra (B). Scale bar = 1.5mm
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Table 6.1. Comparison o f the percentage dopamine cell loss and peak drug-induced 
rotation scores for MFB and striatal lesioned animals.
MFB Lesions*
Animal number % Dopamine neurone loss Rotation score
1 77.0
Amp
5.5
Apo (5mg/kg)
-5.9
2 84.0 17.9 -8.5
3 95.0 12.2 -1.4
4 99.0 11.3 -1.8
5 65.0 13.9 -2.6
6 88.0 9.5 -4.0
7 97.0 11.0 -2.9
8 77.0 -9.8 1.3
9 73.0 10.5
10 31.0 9.6
11 95.0 10.1
12 98.0 9.5
13 -8.0 6.9
14 12.0 1.7
15 81.0 -11.9
16 81.0 -12.2
17 62.0 0.1
18 79.0 3.1
19 50.0 -6.5
20 79.0 9.0
21 0.0 7.4
22 24.0 5.9
Striatal Lesions *
Animal number % Dopamine neurone loss Rotation score
1 70.0
Amp
11.9
Apo (lOmg/kg)
-2.1
2 68.0 8.6 -3.6
3 75.0 12.7 -1.3
4 65.0 9.1 -2.1
5 66.0 9.1 -1.6
6 72.0 10.5 -1.6
* 2 mice with MFB lesions and 1 mouse with a striatal lesion died before the time o f histological
examination. Therefore table only shows the results from 22 MFB lesioned and 6 striatal lesioned 
animals.
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Fig. 6.19 Comparison of dopamine cell loss and rotation for each animal. Linear 
regression indicated that there was a stronger correlation between dopamine cell loss 
and rotations with the Striatal lesion group compared to MFB lesion group after 
amphetamine and apomorphine stimulation (i^= 0.70 & 0.16 vs. 0.007 & 0.005) 
respectively.
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6.4 Discussion
The data reported in this chapter show that unilateral 6-OHDA lesions o f either the 
medial forebrain bundle or the striatum produce marked and significant rotational bias 
following pharmacological stimulation. The frequency of rotational asymmetry 
however, showed substantial variability with lesion type, drug, and drug dose used.
Rotational behaviour was initiated following the administration of the stimulants 
amphetamine and apomoiphine. Amphetamine is an indirect agonist causing the 
release of dopamine from dopamine terminals (Ungerstedt., 1971a; Kelly et a l., 
1975), whereas apomorphine is a direct agonist, and stimulates post-synaptic 
dopamine receptors (Ungerstedt., 1971b; Kelly et al., 1975).
Unilateral destruction of the nigrostriatal dopamine pathway results in the 
removal/loss of pre-synaptic dopamine terminals, decreased innervation of post- 
synaptic striatal neurones and up-regulation and hypersensitivity o f post-synaptic 
dopamine receptors (compensation for the loss o f dopamine input). Consequently the 
two drugs have opposing effects on the direction o f rotational bias.
Amphetamine causes greater dopamine release and striatal stimulation on the intact 
side compared to the lesioned side (due to the loss of dopamine neurones on the lesion 
side), an imbalance that results in marked motor impairments and net ipsilateral 
rotations (towards the lesioned side) (Ungerstedt., 1971a). In contrast, apomorphine 
produces contralateral rotations (away from the lesioned side) due to higher 
dopaminergic excitation of the lesioned striatum because o f the up-regulation and 
hypersensitivity of post-synaptic dopamine receptors (Ungerstedt., 1971b).
In addition to the different mechanisms o f actions of the two drugs, amphetamine and 
apomorphine also differ in their stability, with apomorphine being rapidly oxidised 
into an inactive form. Supplementing apomorphine with the antioxidant, ascorbic acid 
prolongs apomorphine activity, however, apomorphine is still cleared and metabolised 
relatively quickly compared to amphetamine, hence reflecting the difference in 
rotation trial times.
Since ascorbic acid had no influence on the rotational behaviour induced in 
dopamine-depleted mice, it was decided that amphetamine as well as apomorphine 
would be supplemented with 0.01% ascorbic acid to standardise all conditions.
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6.4.1 Drug-induced rotations
A short period o f time was taken for the effects o f the drugs to induce rotations, but 
once established a clear pattern emerged with amphetamine and apomorphine-induced 
rotations declining with time, presumably because of metabolism of the drugs. 
However, at high doses of amphetamine (lOmg/kg and 15mg/kg for bundle and 
striatal lesions respectively), the reverse was observed, with rotations increasing with 
time. The reason for this increased rotational activity is unclear, but perhaps these 
high doses o f amphetamine stimulated not only the denervated dorsal striatum, but 
also, other intact dopaminergic regions, including the ventral striatum. Since this 
striatal region is involved in the initiation o f stereotypical behaviour, such as 
repetitive limb and head movements, sniffing, and oro-facial stereotypies (Iancu et a l., 
2005), and because stereotypy is dopamine dependent (Creese & Iversen., 1973), it is 
likely that stereotypy would have been induced at these high amphetamine doses. 
Such stereotypic behaviour would have decreased rotational bias, in a similar fashion 
to the way that high-dose amphetamine-induced stereotypy has been reported to 
decrease locomotor activity in non-lesioned rats (Gentry et a l., 2004). As time elapsed 
and amphetamine is metabolised, stereotypy would decrease and rotational behaviour 
would be enhanced, thus explaining why rotational behaviour at high drug doses is 
delayed and increases with time.
The possible reasons why this phenomenon occur at different doses for the different 
lesion groups in discussed in section 6.4.3.
6.4.2 Amphetamine and apomorphine stimulation o f non-lesioned (control) animals 
Amphetamine and apomorphine stimulation o f non-lesioned mice was necessary to 
confirm that the drug-induced rotations seen in lesioned animals were due to the 
depletion of the dopamine pathway and not other external factors.
Interestingly, although mice did show increased rotational behaviour after 
amphetamine and not saline injections, this increase was not significant and therefore 
we were confident that the rotations that were observed in lesioned mice was a 
reflection of dopamine loss. Similar increased rotational activity has been previously 
reported (Jerussi & Glick., 1974), however, in this particular case, non-lesioned rats 
showed significantly higher rotations following amphetamine stimulation compared to
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saline injection, suggesting that rats had an innate imbalance of the nigrostriatal 
dopamine system (Jerussi & Glick., 1974).
The increase in rotational activity observed in the non-lesioned 129 OLA mice could 
also reflect an inherent asymmetry o f the nigrostriatal pathway. Alternatively, the 
increased rotations could be simply a result of amphetamine-induced enhanced 
locomotor activity. Regardless of the cause of these rotations, to be confident that 
rotations seen in lesioned animals are reflecting dopamine loss, either pre-lesion 
rotations as well as post-lesion rotations should be carried out, with the difference in 
rotation used as the final rotation score. Alternatively, one could lesion against 
spontaneous bias (i.e if  non-lesioned mice rotated to the right, then lesioning the left 
nigrostriatal pathway would result in rotations towards the left following 
amphetamine challenge. Any rotations to the left would then provide a more reliable 
index of the loss o f dopamine).
6.4.3 M FB vs. Striatal lesions
The two different lesion models used in this study produced either near total (MFB) or 
partial (striatal) unilateral lesions o f the nigro-striatal dopamine pathway. As a result 
there was a marked difference in rotations between the two groups, with MFB lesion 
animals responding to both amphetamine and apomorphine stimulation, while striatal 
lesion mice responded significantly more to amphetamine than apomorphine. When 
the two lesion groups were directly compared, the degree o f amphetamine-induced 
rotations was generally higher for the partial lesion group, and significantly higher at 
lOmg/kg. In contrast, apomorphine-induced rotations were more pronounced in the 
MFB group compared to the striatal lesion group with doses o f  2.5mg/kg and 5mg/kg 
producing significantly higher rotations.
Since at least 50% dopamine loss is necessary for amphetamine-induced rotations to 
be observed (Hefti et al., 1980a, 1980b, Hudson et al., 1993), it is unsurprising that 
both lesion groups showed rotations following amphetamine stimulation. It is 
somewhat surprising however, that amphetamine was more effective at producing 
rotations in the striatal lesion group when compared to the MFB lesion group. MFB 
lesions produce extensive and maximal dopamine depletions, and therefore it would 
seem logical that these lesions would result animals displaying better rotations than 
animals receiving striatal lesions. The reason why this does not occur is explained by
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the severity o f the MFB lesion. In addition to depleting the nigrostriatal dopamine 
pathway, MFB lesions also deplete the dopaminergic neurones o f the ventral 
tegmental area (VTA), which project to the nucleus accumbens. Although the role of 
the nucleus accumbens is not involved in the direction of rotation, it is involved in 
locomotor activity (Kelly et al., 1983) and therefore influences the speed of rotations. 
This was clearly demonstrated by Brundin and colleagues who showed significant 
reduction in amphetamine-induced locomotor activity and rotational behaviour 
following bilateral 6-OHDA lesions o f the nucleus accumbens. In addition, dopamine 
grafts into the lesioned accumbens significantly increased both of these motor 
behaviours (Brundin et al., 1987).
The decrease in locomotor activity following the lesioning o f the VTA by MFB 
lesions may therefore explain why amphetamine causes greater rotational bias in 
striatal lesion animals when compared to MFB lesion animals.
The difference in apomorphine-induced rotational behaviour between the two lesion 
groups is explained by whether or not up-regulation and hypersensitivity o f post- 
synaptic dopaminergic receptors occurs (Hefti et al., 1980a; 1980b; Hudson et al., 
1993).
Since MFB 6-OHDA lesions produce near complete unilateral destruction of the 
nigrostriatal pathway, striatal post-synaptic dopamine receptors are up-regulated and 
become highly sensitive as a compensatory mechanism for dopamine loss. Since this 
global receptor hypersensitivity only occurs when more than 90% of the nigrostriatal 
system is destroyed (Hefti et al., 1980a; 1980b), global hypersensitivity will not occur 
in the lesioned striatum o f  the partial lesion model. Instead, only localised areas of 
post-synaptic receptor hypersensitivity will occur, with the majority o f compensation 
being provided by increased dopamine synthesis from the remaining neurones (Hefti 
et al., 1980a). Because o f this global hypersensitivity in the MFB lesion group, not 
only are low doses of apomorphine sufficient to induce rotations, but also, this lesion 
model is more responsive to apomorphine than the striatal lesion model.
While this would explain why the MFB model produced better rotations than the 
striatal model following apomorphine stimulation, hypersensitivity of receptors 
probably did not occur to a great extent, since low doses o f apomorphine (0.01- 
0.05mg/kg) did not result in any rotational behaviour. In addition, most of the MFB 
lesions resulted in less than 90% dopamine cell loss. Therefore, the rotations observed
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in MFB lesion mice were probably a combined result of increased numbers of post- 
synaptic dopamine receptor and increased receptor sensitivity. Similar to 
hypersensitivity, receptor up-regulation would be global in the striatum o f the MFB 
model, but localised in the striatum of the partial lesion model. This combination of 
global receptor hypersensitivity and up-regulation would explain why significantly 
higher apomorphine-induced rotations were observed in the MFB lesion group 
compared to the striatal lesion group at relatively high drug doses (2.5 & 5mg/kg).
In addition, post-synaptic receptor up-regulation probably also occurred in the nucleus 
accumbens o f MFB lesion mice, as previously shown following dopamine depletion 
o f the nucleus accumbens (Brundin et al., 1987). Therefore the rotations observed in 
the MFB lesion group following apomorphine challenge was probably a collective 
result o f increased excitation o f the lesioned striatum and increased rotational drive 
initiated by the activation o f the nucleus accumbens.
The combination o f striatal rotational bias and the locomotor activity or ‘drive’ 
initiated by the accumbens probably explains why a shift in the dose-response curve 
for striatal lesions is observed. For example, at 2.5 & 5mg/kg amphetamine, MFB 
lesioned animals rotate less than striatal lesioned animals because although MFB 
lesions have larger rotational bias, they have less drive than striatal lesioned animals 
because of the lesioned accumbens. At lOmg/kg amphetamine, increased stimulation 
of all dopaminergic areas result in stereotypy in MFB lesioned animals and low levels 
o f rotation. This does not occur in striatal lesioned animals because at this dose, 
although other dopaminergic regions are stimulated, there is maximal stimulation of 
the accumbens on both sides o f the brain. This results in excessive drive which 
overshadows the other responses resulting in larger rotational responses than those 
observed at 5mg/kg, and a shift in the dose-response curve. However at 15mg/kg, 
although accumbens stimulation is still maximal, stimulation of regions outside the 
accumbens and lesioned dorsal striatum is excessive, and therefore stereotypy is 
induced and rotations decrease.
With apomorphine-induced rotations, at low doses (0.05mg/kg), no rotational 
behaviour was observed because hypersensitivity and up-regulation o f post-synaptic 
dopamine receptors was insufficient. At 2.5 & 5mg/kg apomorphine however, 
because of the larger rotational bias and the larger drive (because of supersensitivity 
and up-regulation o f dopamine receptors in the lesioned accumbens), rotations are
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higher in the MFB lesion model than the striatal lesion model. At lOmg/kg 
apomorphine, although drive is high in the MFB lesion group, rotations are lower 
compared to 5mg/kg because there is lower rotational bias due to high-dose 
apomorphine stimulation o f intact striata. However, in the striatal lesion model, 
although rotational bias will be smaller because o f stimulation of the intact striata, 
apomorphine rotations are higher than those observed at 5mg/kg because the drive is 
increased due to high-dose apomorphine stimulation of the nucleus accumbens. This 
therefore causes a shift in the striatal lesion dose-response curve for apomorphine. At 
15 mg/kg apomorphine, striatal lesioned animals show decreased rotations because of 
increased stimulation o f  the intact striata which reduces rotational bias.
An alternative explanation for the reduced rotational behaviour at lOmg/kg 
apomorphine for MFB lesioned mice could be because of stereotypy. However, this 
probably did not occur since if  stereotypical behaviour is induced at this dose, then 
one would expect stereotypy to be induced in the striatal model also, and this clearly 
does not occur.
6.4.4 Dopamine loss vs. Rotations
Unilateral 6-OHDA MFB lesions in mice have recently been used to produce a model 
of PD which shows good rotational asymmetry in response to amphetamine and 
apomorphine challenge (Iancu et a l., 2005). However, while this model shows good 
rotational behaviour, less than 50% of the total number o f animals that were lesioned 
in the study by Iancu et a l., (2005) were selected to participate in behavioural tests. 
The reason why only a small proportion of animals were used was because the MFB 
lesion was variable, which meant that some animals had good lesions, whereas others 
did not. Consequently, only the animals with good lesions were chosen.
Histological examination of the MFB lesioned animals in our study also shows that 
MFB lesions are variable. In contrast, the striatal lesions show more reliable and 
consistent dopamine loss. This difference in lesion reliability is reflected in rotational 
behaviour, where striatal lesion animals rotate better (following amphetamine 
challenge) than MFB lesion animals. Like the study by Iancu, we could also have 
selected a proportion o f MFB lesion mice that showed good rotational behaviour, and 
only used these animals in the rotation tests. However, while this would have 
certainly increased the average rotational bias o f this lesion group, it would not have
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reflected the significant inconsistentcies o f dopamine loss produced by the MFB 
lesion. The level o f  inconsistency o f  the MFB lesions is extremely relevant when 
attempting to reproduce this model since it would mean that more animals than 
required would need to be lesioned, so that sufficient numbers of animals would 
display good lesions. The level of inconsistency of the MFB lesions is therefore 
unacceptable, and whenever possible striatal lesions should be used to produce a 
model o f PD in mice.
Since only 7 mice received striatal lesions compared to 24 mice which received MFB 
lesions, it can be argued that striatal lesions do not show much lesion variability 
because o f  the few animals lesioned. Although this is a valid argument, the reason 
why MFB lesions are so variable is because the MFB is relatively small and is 
therefore difficult to target. The striatum on the other hand, is easier to target and 
therefore it is unlikely that such variability would result from striatal lesions.
In summary, the 129 OLA mouse strain exhibits rotational bias following unilateral 6- 
OHDA lesioning o f  either the medial fbrebrain bundle (MFB) or the striatum. 
Lesions of the MFB model produced rotations that are responsive to both 
amphetamine and apomorphine with peak rotations occurring at a drug dose of 
5 mg/kg for both drugs. The striatal lesion model however, is more responsive to 
amphetamine than apomorphine-induced rotations with peak rotations being induced 
at a dose of 1 Omg/kg for both drugs.
There was little correlation between dopamine loss and rotations following 
amphetamine and apomorphine stimulation in MFB lesioned animals. Striatal 
lesioned animals were more reliable since more consistent lesions, more consistent 
rotation, and stronger correlations were observed especially with amphetamine 
rotations. Striatal lesions also showed less variability in rotations particularly 
following amphetamine stimulation confirming the reliability o f the striatal lesion 
model.
The data reported here suggest that the optimal model for Parkinson’s disease in the 
129 OLA mouse strain is produced following striatal lesions, which can be measured 
most effectively using drug-induced rotation with an optimal dose of 1 Omg/kg 
amphetamine. Although the striatal 6-OHDA lesion model is not novel, the model
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established here is fundamentally different and better than previous mouse models 
since the conditions which produce optimal rotational behaviour have been defined.
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(Experiment Tive - TunctionaCrecovery o f rotationaCasymmetry 
in uniCateraC6-OJf(DJ%-(esionecfmice
Summary
This chapter examines whether the recently developed 6-OHDA-lesion mouse model 
o f Parkinson’s disease (see chapter six), is reliable in assessing the functional capacity 
of transplanted dopamine neurones.
Mice with partial, unilateral lesions o f the nigrostriatal pathway, which showed good 
rotational behaviour following 1 Omg/kg amphetamine challenge, received intrastriatal 
grafts of E l 3 mouse mesencephalic dopamine neurones. Rotational behaviour of these 
mice was then assessed at 2, 4 and 6 weeks post-transplantation. Results showed no 
substantial difference in rotation at 2 weeks post-transplantation, however a 
significant reduction in ipsilateral rotational bias was observed at 4 & 6 weeks post­
transplantation when compared to pre-graft scores. Histological examination o f the 
dopamine grafts showed that transplanted cells formed large grafts which contained in 
excess o f 1200 dopamine neurones. The absence o f any attenuation o f rotational 
asymmetry in non-transplanted lesioned mice over the 6 week testing interval 
confirmed that the behavioural recovery seen in grafted group was attributable to 
striatal reinnervation by grafted dopamine neurones and not by spontaneous recovery 
of the lesioned striatum.
These results show that stable, unilateral 6-OHDA lesions can be well established in 
mice, and that this model is suitable for assessing the functional ability o f mouse- 
derived ES and other mouse-derived cell lines without the need for 
immunosuppression.
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7.1 Introduction
Intrastriatal transplantation o f  embryonic dopamine neurones into the dopamine- 
depleted striatum has provided strong evidence that neurotransplantation strategies are 
effective at reinnervating the lesioned striatum. This evidence has not only come from 
animal models where improvements in lesion-induced behavioural deficits such as 
rotational asymmetry have been observed (Perlow et al., 1979; Bjorklund & Stenevi., 
1979; Dunnett e ta l., 1983), but also from clinical trials where improvements in motor 
control have been demonstrated following transplantation of human foetal 
mesencephalic tissue in Parkinson’s disease (PD) patients (Wenning et al., 1997; 
Lindvall e ta l., 1990; 1992; Kordower et al., 1995; Kopyov eta l., 1997).
However, while cell replacement therapies are clearly effective, the clinical 
application o f this procedure is limited by the nature of the tissue used. Alternative 
tissue sources that can form dopamine neurones and are capable of integrating with 
the brain are therefore required if  neurotransplantation strategies are going to succeed 
in providing treatments for PD. To date, most success has come from using 
embryonic stem cells (ES cells). These cells have not only shown the generation of 
dopamine neurones in vitro (Lee et al., 2000; Perrier et al., 2004), but they have also 
shown to alleviate rotational bias when transplanted into rat models of PD (Kim et al., 
2002; Bjorklund et al., 2002). Assessing the potential o f human or mouse-derived ES 
cells to develop into functional dopamine neurones via transplantation into rats 
models of PD, is however, far from ideal since rats receiving the xenografts require 
immunosuppression to avoid graft rejection. This immunosuppression is normally 
achieved by the administration o f the drug Cyclosporin A (CsA), which suppresses 
the immune response by inhibiting T-cell activation (Kadereit et al., 2001). While 
CsA promotes xenograft survival (Brundin et al., 1985), its use is problematic 
because not only is prevention from cell rejection not absolute (Pedersen et al., 1997), 
but also, CsA treatment is associated with toxic side effects such as hepatotoxicity 
(Deters et al., 1997). Rats treated with CsA also have increased health risks, 
presumably because o f the suppression o f the immune system, and show a decline in 
their general health with notable weight loss and reduced life span. These effects of 
this immunosuppressant can be fatal as illustrated in many studies, for example, 
where a number o f  CsA-treated rats receiving grafts o f human-derived neural
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progenitor cells have died due to side effects of CsA treatment (Svendsen et al., 
1997a).
Interestingly, continued injections o f CsA into unilateral 6-OHDA-lesioned rodents 
have also been shown to elevate striatal dopamine levels, perhaps by having 
neuroprotective effects or by promoting regeneration of nigral-striatal dopamine 
neurones (Matsuura et al., 1996; 1997). This property of CsA is extremely relevant 
when assessing the functional capacity of cells to restore behavioural deficits, since 
any recovery o f grafted cells will be a result o f the combination o f the cells’ potential 
to generate functional dopamine neurones and the effect of CsA-induced increase in 
striatal dopamine. These problems associated with the use o f CsA means that if  
possible, treatment with CsA should be avoided, which could readily be achieved if 
the species of the donor and recipient are the same. The most obvious choice would 
be to transplant rat-derived ES cells into the well established rat model o f  PD. 
However, the generation of ES cells from rats is itself proving problematic. The other 
alternative for exploring the differentiation potential o f embryonic stem cells, without 
immunosuppression, is to graft mouse embryonic stem cells into the mouse brain. 
Measuring rotational bias in mice is however difficult because in spite o f a couple of 
brief reports (Brundin et al., 1986; Iancu et al., 2005) the 6-OHDA lesion model has 
not been fully characterised in mice.
The recently developed 6-OHDA-lesion mouse model of PD shows appropriate 
rotational bias following amphetamine stimulation (see chapter six). As a first step to 
validating the reliability of this model to assess the functional capacity o f mouse- 
derived ES and other cell lines (such as the Nurrl-overexpressing neural stem cells), 
we have assessed behavioural recovery following intrastriatal transplantation of 
primary VM neurones. Grafts of E13 mouse VM tissue were transplanted into the 
lesioned striatum of mice and amphetamine-induced rotational behaviour was 
assessed at 2, 4 and 6 weeks post-transplantation. A significant reduction in rotations 
was observed at 4 & 6 weeks post-transplantation indicating reinnervation of the 
striatum.
This chapter demonstrates that our mouse model of PD is a reliable animal model, 
which shows appropriate behavioural recovery following transplantation of functional 
dopamine neurones. This model provides a tool to efficiently assess the potential of 
mouse-derived ES cells and other mouse-derived cell lines to provide functional 
recovery without the need for immunosuppression.
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7.2 Experimental Procedure
Adult female 1290LA mice (~25g) received unilateral 6-OHDA lesions o f the right 
midstriatum (see chapter two, section 2.7.1). After full recovery from surgery, mice 
were habituated to experimental conditions for 10 minutes before 1 Omg/kg d- 
amphetamine-induced rotational testing commenced. Rotations lasted 90 minutes and 
were assessed in a closed room to avoid any environmental disturbance (see chapter 
two, section 2.8.2.1). Only mice showing good rotational behaviour (at least 6 net 
ipsilateral turns per minute) were selected for this experiment. Lesioned mice were 
split into 2 equal groups (2 x n=8), with one group receiving transplants of E13 mouse 
VM cells into the right striatum (see chapter two, section 2.7.2), and the other group 
remaining as the non-transplanted lesion group. As a control, non-lesioned mice were 
also tested for rotation bias (n=10). The grafted group, non-transplanted lesion group 
and non-lesion groups underwent amphetamine-induced rotation at 2, 4 & 6 weeks 
post-transplantation. After behavioural testing, animals were sacrificed, brains were 
isolated and the striatal dopaminergic grafts were analysed (see chapter two, section 
2.9.4).
Statistical tests of analysis o f variance (ANOVA) were analysed using the statistical 
package Genstat v7.2, with further analysis of the results being achieved by using the 
Neuman Keuls t-test.
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7.3 Results
7.3.1 Amphetamine-induced rotations
The effect o f E l3 mouse VM grafts on unilateral 6-OHDA lesion-induced rotational 
asymmetry can be seen in figure 7.1, along with the rotational behaviour o f  lesioned 
and non-lesioned mice over a 6-week period. Rotational behaviour was only assessed 
for 6 weeks since this time period was sufficient for grafts to reverse 6-O H D A  lesion- 
induced rotational deficits.
Mice receiving grafts o f VM tissue (n=8), showed a significant decline in rotational 
bias at 4 (NK. t(3,3)=13.125, p<0.01) and 6 weeks (NK: t(4,3)=13.546, p<0.01) post­
transplantation when compared to pre-graft scores (Fig. 7.1). No difference was 
observed however between pre-graft rotations and rotations 2 w eek s post­
transplantation (NK: t(2,3)=0.937, n.s).
Lesion only mice (n=8) showed good, stable rotational behaviour with no difference 
in rotational scores throughout 6 weeks o f testing. When compared to rotations in 
mice receiving grafts, a significant difference was observed at 2 (NK. t<2»2)= 7.707, 
p<0.05), 4 (NK: t<2,2)= 17.099, p<0.01) and 6 weeks (NK: t<2,2y=17.892, p< 0 .O l) post- 
transplantation (Fig. 7.1).
As expected, non-lesioned mice (n=10) showed no significant rotational behaviour 
(Fig. 7.1). Statistical analysis of the data confirms a significant difference in  rotational 
behaviour with groups ( F (2j o 3>= 83 .92, p<0.001).
TH immunohistochemistry o f all three groups is shown in Fig. 7.2, w ith grafts of 
dopamine neurones clearly visible (Fig. 7.2D) Using the Abercrombie correction 
formula, grafts were calculated to contain in excess of 1200 dopamine neurones.
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Figure 7.1 Amphetamine-induced rotational behaviour. A significant difference in 
rotational bias with groups is observed (p<0.001), with VM grafted groups showing a 
reduction in rotation at 4 and 6 weeks post-transplantation when compared to pre­
graft rotation scores. Lesion only mice show stable rotations throughout the 6-week 
testing period and non-lesioned rats show no significant rotational bias. **a p<0.01 
vs. pre-graft; scores, **b p<0.01 vs. lesion only group, *b p<0.05 vs. lesion only group. 
Data expressed as mean ± S.E.M.
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Figure 7.2 TH immunohistochemical staining in brain sections moving rostral-caudal 
from left to right through the levels of the striatum and the substantia nigra.
Lesion groups show partial depletion of TH staining on right hand side, in both the 
striatum and the substantia nigra (A). Control groups show equal staining for TH in 
the striatum and substantia nigra on both sides of the brain (B). VM Graft can be 
clearly seen in the striatum (C). Scale bar represents 2 mm. Higher magnification of 
graft (in C) shows the presence of TH neurones (D).
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7,4 Discussion
Rotational asymmetry caused by unilateral depletion o f striatal dopamine, and its 
subsequent behavioural recovery following intrastriatal transplantation of dopamine 
neurones is a model that has been well characterised in rats, but not so well 
established in mice. With the successful in vitro generation o f mouse-derived 
dopamine neurones (Lee et a l., 2000; Kim et al., 2003), we believe the requirement 
for a reliable mouse model is essential so that the functional potential o f  these cells 
can be efficiently assessed without the added complications of immunosuppression. 
The need for a mouse model o f Parkinson’s disease has also recently been addressed 
elsewhere and unilateral 6-OHDA lesioned mice showing appropriate behaviour have 
been established (Iancu et al., 2005). However, while this study shows that drug- 
induced rotations, cylinder and rotarod tests are the most sensitive tests for reflecting 
dopamine loss, functional recovery o f these tests following transplantation of 
dopamine neurones was not assessed. This chapter examined whether our recently 
developed 6-OHDA-lesion mouse model o f  Parkinson’s disease, which shows good 
rotational bias as a result o f significant dopamine loss, can show behavioural recovery 
following intrastriatal transplantation o f mouse dopamine neurones.
Prior to transplantation, unilateral 6-OHDA lesioned mice showed good rotational 
behaviour following 1 Omg/kg amphetamine stimulation with an average pre- 
transplantation score of 12-13 ipsilateral turns per minute. Little change in rotational 
bias was observed at 2 weeks following grafting, however a significant reduction in 
rotations was observed at 4 & 6 weeks post-transplantation, indicating reinnervation 
o f the lesioned striatum by grafted dopamine neurones (Bjorklund et al., 1980; 
Dunnett., 1992). Although overcompensation of motor response was not observed 
when looking at the average rotation scores of the whole group, two animals did show 
complete reversal of rotational bias and contralateral rotations. Why this was not 
demonstrated for all animals is unclear, but perhaps dopamine grafts required longer 
than 6 weeks to mature.
Analysis o f striatal transplants revealed large surviving grafts containing over 1200 
dopamine neurones. Since 500,000 cells were transplanted and approximately 10% of 
cells stained immunopositive for TH in vitro (data not shown), the survival rate of 
grafted dopamine neurones is equivalent to approximately 2-3%, which is consistent
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with the typically low survival rates of grafted rat dopamine neurones previously 
reported (Brundin e ta l., 2000).
The rotational behaviour o f non-transplanted mice was also measured and showed 
consistently high ipsilateral turns throughout the 6-week testing period. This 
confirmed that the attenuation of rotational asymmetry was solely because of 
dopamine graft-induced reinnervation of the dopamine-depleted striatum and not 
because of spontaneous recovery o f the striatum, which has been previously reported 
in mice, albeit following MPTP-induced lesions (Iancu et al.y 2005 and references 
therein). The absence o f any spontaneous recovery also demonstrates that 6-OHDA 
lesions o f the striatum show long-term stability, which is an essential requirement for 
a reliable animal model o f PD.
As expected, non-lesioned mice showed no substantial rotational bias throughout the 
6-week testing period, although a gradual increase in rotations o f non-lesioned 
animals was observed at 4 & 6 weeks post-transplantation. This increase may reflect a 
conditioned response to amphetamine administration resulting in hyperactivity of 
mice, however, this increase in rotational behaviour was not significantly different 
from pre-graft levels and therefore is not of great concern.
In summary, we provide evidence that functional recovery o f lesion-induced 
behavioural deficits can be achieved in unilateral 6-OHDA-lesioned mice following 
intrastriatal transplantation o f mouse dopamine neurones. This model is therefore 
suitable for assessing the functional potential o f mouse-derived cell lines without the 
need for immunosuppression.
This mouse model was initially established to assess the potential o f  mouse-derived 
ES cells to generate functional dopamine neurones in vivo. These cells are currently 
being generated by Professor Austin Smith’s laboratory at Edinburgh University, but 
due to technical and practical difficulties in cell production, this study has been 
delayed. However, when these cells become available, we have a reliable, efficient 
model in place which is ready to assess the potential of these cells.
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generaf Discussion
Neurotransplantation is an effective strategy for treating neurodegenerative disorders 
such as Parkinson’s disease, however, its clinical application is limited by the absence 
of a suitable donor source of neurones. The ability o f stem cells to generate neurones 
may provide a solution to this problem, and has consequently been the focus of this 
research. This thesis attempted to assess the potential of embryonic, foetal and adult 
neural stem cells to provide a source o f neurones suitable for transplantation for 
Parkinson’s disease. Unfortunately, embryonic stem cells could not be obtained, and 
therefore the results described here only reflect the neurogenic capacity of foetal and 
adult neural progenitor cells.
This chapter outlines the important parameters which affect neuronal differentiation 
of progenitor cells, discusses the importance o f increasing dopamine survival 
following transplantation, and reviews the current status o f embryonic, foetal and 
adult stem cell research in terms o f providing a treatment for Parkinson’s disease. In 
addition, the case for a 6-OHDA-lesion mouse model of Parkinson’s disease is 
evaluated, and finally, based on the results from this thesis, the chapter ends with a 
discussion concerning the directions that future research studies must concentrate on 
if foetal and adult progenitor cells are going to be considered for clinical 
transplantation programmes.
8.1 Factors affecting neuronal differentiation o f  neural stem cells
8.1.1 Donor age
Over the past decade, an enormous amount of research has focused on generating 
sufficient numbers o f neurones o f appropriate phenotypes from neural stem cells. 
While this research has clearly accelerated our knowledge on the fundamental aspects 
of neural stem cell behaviour, the field of stem cell research remains inconsistent, 
with huge variability in the protocols used between different laboratories to dissect, 
prepare, culture and/or transplant stem/progenitor cells (Gage., 2000). Such variability
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means that comparing studies from different laboratories is difficult, and those 
comparisons that are made are often based on the assumption that neural 
stem/progenitor cells behave identically. Since one common variable is the donor age 
from which neural stem/progenitor cells are isolated, the in vitro neurogenic potentials 
of cells isolated from different donor ages were examined in order to determine 
whether this factor had any effect on progenitor cell behaviour. The results from this 
study were conclusive and showed that neural progenitor cells from different donor 
ages had distinct neurogenic potentials, a finding which is o f particular importance in 
terms o f research studies since it means that direct comparisons between different 
studies cannot be made unless donor age are the same. In addition, some o f the other 
variables such as the type o f enzyme used in cell dissociation and the growth media 
used in progenitor cell proliferation may also have pronounced effects on progenitor 
cell behaviour, particularly since these factors have been previously shown to affect 
the properties of other cells (Barker et a l., 1995, Brundin et a l., 2000). The 
experimental variations used to investigate stem cells are therefore causing 
unnecessary complications, and for this reason, research would perhaps benefit from 
standardising all experimental conditions so that comparisons between studies can be 
easily achieved.
The effect of donor age is, o f course, also relevant in terms o f the clinical application 
of these cells in the treatment o f neurodegenerative disorders. In this case, selecting 
the age o f  donor tissue which gives optimal differentiation o f specific neuronal 
phenotypes, is imperative for treating diseases such as Parkinson’s and Huntington’s 
disease. Interestingly, the optimal age for the generation o f dopamine neurones from 
rat VM tissue has been reported to correspond to approximately embryonic day 13-15 
(Barker et al., 1995; Brundin et a l., 2000), resulting in the majority of transplantation 
studies using E 14 VM tissue. However, results from a study presented in this thesis 
are in contrast to these findings and suggest that optimal numbers of dopamine 
neurones are generated when using E12 VM tissue.
8.1.2 Cell proliferation
One of the properties of neural stem cells is their potential to undergo long-term 
proliferation whilst retaining the ability to generate neurones. In theory, this property 
is very appealing since it would provide a continuous supply o f neurones, which could 
potentially be used for transplantation. However, based on the results in this thesis,
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and from data published elsewhere (Smith et a l., 2003), it is clear that even short 
periods o f  in vitro proliferation result in rat progenitor cells losing their ability to 
differentiate into neurones. Since there is little data comparing the effects of 
prolonged proliferation on the differentiation o f progenitor cells, and evidence of 
species-specific properties exist (Svendsen et al., 1997), it is currently unclear 
whether this finding is a general characteristic of progenitor cells, or a species-specific 
property o f rat progenitor cells. The generation of neurones from long-term expanded 
human progenitor cells (Carpenter et al., 1999) suggests that the loss of the 
neurogenic potential o f  rat progenitor cells is a species-specific characteristic, or 
alternatively, a result o f  the culture conditions being inadequate to support neuronal 
differentiation following cell expansion. However, on closer inspection, the data by 
Carpenter et al, also shows a reduction in the neurogenic potential of human 
progenitor cells after proliferation, albeit following much longer periods in culture, 
thus indicating that the loss o f neurogenic potential could be a general property of 
progenitor cells. The capacity o f expanded progenitor cells to generate neurones 
therefore merits further investigation since this property is crucial to the success of 
these cells in providing an alternative to the use of foetal tissue in 
neurotransplantation.
8.2 Increasing the survival o f  transplanted dopamine neurones is imperative fo r  the 
success o f  cell replacem ent strategies fo r  P arkinson’s disease 
One of the problems associated with cell replacement strategies for Parkinson’s 
disease is the inadequate survival o f dopamine neurones following transplantation. In 
experimental models and clinical trials, only 5-10% of transplanted embryonic 
dopamine neurones have been reported to survive (Dunnett., 1992, Bjorklund., 1992). 
Similarly, the survival rate o f functional dopamine neurones derived from expanded 
neural progenitor cells have also been shown to be typically low (Brundin & 
Bjorklund., 1998). This insufficient survival is partly the reason why dopamine grafts 
are unable to completely reverse all behavioural deficits, and is consequently a major 
limiting factor for the use o f these cells in clinical trials o f Parkinson’s disease.
In an attempt to increase dopamine cell survival, embryonic dopamine neurones were 
transplanted into unilateral 6-OHDA lesioned rats in a solution containing the 
antioxidant ascorbic acid. Although no difference in the recovery of rotational 
behaviour was observed in these animals when compared to animals receiving
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standard dopamine grafts, analysis of the transplants 6 weeks post-transplantation 
revealed that neurones treated with ascorbic acid formed grafts containing 
significantly more dopamine neurones compared to grafts of standard dopamine cells. 
While the increased presence o f dopamine neurones is likely to reflect enhanced 
dopaminergic survival, it is also possible that ascorbic acid increased dopaminergic 
expression via other mechanisms i.e. by increasing dopaminergic differentiation. 
Although the precise mechanisms involved in this increase of dopamine neurones 
remain elusive, it is clear that reducing dopamine death following transplantation, 
perhaps by the administration ascorbic acid, alternative antioxidants or even growth 
factors (Zawada et a l., 1998), is an absolute prerequisite if  dopamine replacement 
therapies are going to provide an efficient treatment for Parkinson’s disease. Only 
when this is achieved will the use o f  neural progenitor cell-derived dopamine 
neurones be o f any value in clinical trials.
8.3 Embryonic, foetal and adult stem cells — which cells are best?
The capacity o f  embiyonic, foetal and adult neural stem cells to generate neurones has 
been discussed extensively throughout this thesis. It is clear that while the use o f adult 
neural stem cells might be the preferred cell type, embryonic stem cells have a far 
greater potential for generating functional dopamine neurones, and are therefore 
currently the strongest candidate for providing a source of neurones in cell 
replacement therapies for Parkinson’s disease.
The use o f adult neural stem cells is particularly favourable because their use is not 
associated with the ethical concerns that surround the use o f embryonic and foetal 
tissue. It is also possible that these cells can be taken for autologous transplantation, a 
procedure that will avoid the complications associated with immunosuppression and 
tissue rejection. In contrast, embryonic stem cells are probably the least favoured cell 
type because not only is the use o f these cells seen by some as ethically unacceptable, 
but also, their use is associated with serious safety concerns since they have the 
potential to generate tumours following transplantation. Unfortunately however, the 
generation o f functional dopamine neurones from adult neural progenitor cells has not 
been reported and therefore the use o f these cells is currently unfeasible in 
transplantation strategies. Foetal neural progenitor cells have fared little better with 
only a few studies reporting the generation o f functional dopamine neurones. The 
most encouraging results o f  functional dopamine generation have come from
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embryonic stem cells, however considering their ethical and safety concerns can these 
cells be truly successful in transplantation strategies for Parkinson’s disease? The 
safety issues associated with the use o f embryonic stem cells will be removed if the 
potentially dangerous tumour-forming undifferentiated cells can be efficiently 
eliminated. This is an area that has been the focus o f much research and methods have 
been developed which can efficiently select and destroy such cells (Schuldiner et a l, 
2003; Fareed & Moolten., 2002). However, while the safety element surrounding the 
use o f embryonic stem cells can be solved, the ethical debate that is related to their 
use will always be present and is an issue for social consensus rather than scientific 
determination. Embryonic stem cell research is currently in a position similar to what 
was seen with the emergence o f in vitro fertilisation (IVF) techniques in the late 70’s. 
IVF treatment was seen as unethical since the procedure generates more embryos than 
are required, and therefore results in some embryos being destroyed. However, since 
this procedure enables children to be bom to infertile couples, it is a technique that is 
now widely accepted. Similarly, destroying embryos left over from IVF procedures to 
provide a treatment for Parkinson’s disease will hopefully become ethically 
acceptable.
8.4 Do we need a 6-OHDA-lesion mouse model o f  Parkinson’s disease?
The unilateral 6-OHDA-lesion model of Parkinson’s disease is an efficient model for 
assessing the functional potential o f  dopamine neurones. However, while this model 
has been extensively used in the rat, it is surprising that this model has not been more 
extensively used in mice, especially when considering the advances made in mouse 
embryonic stem cell research and developments o f genetic mouse experimental 
models. One possible reason for the absence of this model in mice might simply be 
because the rat model is more than sufficient to assess the functionality o f cells, and 
therefore the requirement for a mouse model is not necessary. In addition, lesioning of 
the dopaminergic nigrostriatal pathway in mice is more difficult when compared to 
rats, since the medial forebrain bundle (MFB) is relatively small in size. Therefore 
accurately targeting and destroying this structure is difficult and consequently results 
in mice often showing variable levels o f  dopamine cell loss. Considering the success 
o f the rat model and the unreliable lesions in mice, would a 6-OHDA-lesion mouse 
model o f Parkinson’s disease be o f any benefit in stem cell research?
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In this thesis, a novel 6-OHDA-lesion mouse model based on targeting lesions in the 
area o f the striatal terminals rather than in the MFB has been established, which 
accurately reflect dopamine loss and show appropriate behaviour following 
reinnervation o f the denervated striatum. We believe that the requirement for this 
model is highly warranted so that the potential of mouse-derived dopamine neurones 
can be efficiently assessed without the complications of immunosuppression that are 
currently associated with the use of the rat model. This mouse model of PD will 
undoubtedly be a valuable tool in measuring the functional capacity of mouse-derived 
cell lines.
8.5 Conclusions and further considerations
The results presented in this thesis have addressed some of the important parameters 
which affect the differentiation potential o f neural progenitor cells, and while it is 
apparent that both foetal and adult progenitor cells have the capacity to generate 
neurones, it is clear that future studies must focus on a number o f issues if these cells 
are going to provide a source o f dopamine neurones for cell replacement therapies in 
Parkinson’s disease. These issues mainly centre around increasing both dopamine 
differentiation and dopamine cell survival following transplantation, two factors 
which are o f equal importance and will ultimately dictate the successful clinical use of 
any potential cell replacement-based therapy.
With foetal neural progenitor cells increasing dopamine differentiation is imperative, 
since even following relative short periods of expansion these cells fail to generate 
dopamine neurones. Although progress in this area is currently being made with a 
number o f studies reporting the generation o f dopamine neurones following cell 
expansion, these studies are limited and cell expansion has not been extensive. The 
focus of research must therefore be to increase dopamine differentiation following 
long-term progenitor cell proliferation. O f course, dopamine differentiation will not 
be beneficial if the survival of dopamine cells following transplantation is poor, and 
for this reason dopamine cell survival must also be enhanced. Although ascorbic acid 
treatment was successful in promoting dopamine graft survival in a study reported in 
this thesis, perhaps ascorbic acid in combination with other antioxidants (Love et a l., 
2002), growth factors (Zawada et al., 1998) or even different cell preparation 
techniques (Barker et a l., 1995) could reduce the death of dopamine cells even further
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following transplantation. If  these two goals are met, foetal neural progenitor cells 
will be an excellent source o f neurones for transplantation, since fewer cells need to 
be transplanted and larger surviving grafts would be observed, which would perhaps 
result in improved recovery o f function.
With adult neural progenitor cells, it is evident from the results in this thesis and from 
the literature that neuronal differentiation is low and dopamine differentiation is non­
existent. The main priority o f research is therefore to increase neuronal yield of these 
cells and determine whether or not adult progenitors can generate dopamine neurones. 
Achieving these goals will be a major step forward in adult neural progenitor cell 
research, and only when this is done can the use o f these cells be considered in 
clinical transplantation programmes for Parkinson’s disease.
The results discussed in this thesis have highlighted a number o f important parameters 
which affect the differentiation potential of neural stem cells, and will accelerate the 
progress of further studies researching stem cell behaviour. From the current research 
it is clear that the factors which govern the behaviour o f these cells are still not fully 
understood, and therefore a wealth o f research has yet to be done before the clinical 
application o f neural progenitor cells can be considered.
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Appendix 1: Recipes for solutions and culture media
General Buffers
Phosphate-buffered saline (PBS)
Basic 0.1M solution used as an isotonic buffer in immunocytochemistry. One litre 
PBS is composed of: 9g sodium chloride, 11.46g disodium hydrogen orthophosphate 
and 7.96g sodium dihydrogen orthophosphate. Make up to one litre with distilled 
water. Adjusted to pH 7.4 with hydrochloric acid.
TRIS-buffered saline (TBS)
Used as a basic histological buffer. To one litre of distilled water is added. 12g 
Trizma base and 9g sodium chloride. Adjusted to pH 7.4 with concentrated 
hydrochloric acid.
Triton X  TBS (TXTBS)
To 250ml TBS add 500pi Triton X-100. Adjusted to pH 7.4 with concentrated 
hydrochloric acid.
IRIS non-saline solution (IN S)
To one litre of distilled water, 6g Trizma base is added. Adjusted to pH 7.4 with 
concentrated hydrochloric acid.
TRIS-buffered saline + sodium azide (TBZ)
This solution prevents microbial growth and allows long-term storage o f histological 
specimens. To 500ml of TBS add 2.5ml o f 20% sodium azide.
Solutions used in perfusion and fixative protocols
Pre-wash
For one litre o f pre-wash add: 18g disodium hydrogen phosphate (dehydrate), 9g 
sodium chloride and make up to one litre with distilled water. Adjust to pH 7.4 with 
orthophosphoric acid.
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4% Paraformaldehyde (PFA)
The basic fixative for tans-cardial perfusion of animals. For five litres add. 90g 
disodium hydrogen phosphate, 45g sodium chloride, and one litre of 20% PFA (1kg 
PFA + 5 litres distilled water). Make up to five litres with distilled water and adjust to 
pH 7.4 with orthophosphoric acid.
Culture media
The recipes for the growth and differentiation media used for embryonic and adult 
tissue can be found in chapter two, sections 2.4.2 and 2.5.2. All media is filter 
sterilised and stored at and store at 4°C.
Dissection media
For 45ml dissection media add. 43ml DMEM/F12, 1ml 30% glucose (30g glucose in 
100ml distilled water), 0.75ml 7.5% NaHC03 (Gibco) and 0.25ml 1M HEPES 
(Gibco). Filter sterilise and store at 4°C.
0.05% DNase solution
To 5mg DNase (Sigma), add 10ml dissection medium. Filter sterilise and store at -
0.1% Trypsin solution
To lOmg trypsin (Worthington Biochemical Corporation), add 10ml DNase solution. 
Filter sterilise and store at -20°C.
20°C.
Appendix 2: Suppliers
Sigma
Gibco
R & D Systems
Worthington Biochemical Corporation
DAKO
Poole, Dorset, UK 
Paisley, Scotland, UK 
Abingdon, Oxon, UK 
Freehold, New Jersey, U S A 
Glostrup, Denmark
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